University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2016

Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape
From Cellular And Humoral Immunity
Edward Kreider
University of Pennsylvania, fkreider@upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Microbiology Commons

Recommended Citation
Kreider, Edward, "Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape From Cellular And
Humoral Immunity" (2016). Publicly Accessible Penn Dissertations. 2406.
https://repository.upenn.edu/edissertations/2406

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2406
For more information, please contact repository@pobox.upenn.edu.

Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape From Cellular
And Humoral Immunity
Abstract
Longitudinal HIV-1 single genome sequencing (SGS), which permits unambiguous genetic
characterization of circulating viral strains without introduction of PCR error, can be used to identify sites
in the viral genome that are under selective pressure. Following transmission, the earliest sites under
positive selection often fall in cytotoxic T lymphocyte (CTL) epitopes. During escape from CTL immune
pressure, viral sequences typically exhibit nonsynonymous mutations within the span of the cognate T
cell epitope. I applied SGS to study sequence evolution in the HIV-1 5’ leader sequence, which is thought
to be translationally silent. I observed mutational patterns consistent with CTL escape and demonstrated
that the HIV-1 5’ leader expresses T cell antigens from non-canonical one-off AUG codons (e.g. CUG).
While these non-canonical start codons can be mutated during CTL escape, a reverse transcriptase
overextension error periodically restores a one-off AUG within the 5’ leader. As infection ensues, sites
under selection within the gene encoding the viral envelope glycoprotein (Env) often fall within autologous
neutralizing antibody epitopes. In a subset of individuals, the strain-specific neutralizing antibody
response develops into a broadly cross-reactive neutralizing antibody (bnAb) response. To understand
what factors influence bnAb ontogeny, I used SGS to study Env evolution both during natural infection and
immunotherapy. I found viral diversification in bnAb contact residues and divergence of the virus
population into multiple persistent lineages to precede bnAb development. Taken together, these data
demonstrate that longitudinal HIV-1 SGS can be used to discover novel aspects of virus biology and hostpathogen interactions.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Beatrice H. Hahn

Subject Categories
Microbiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2406

WITHIN-HOST EVOLUTION OF HIV-1: NOVEL PATHWAYS OF VIRUS ESCAPE
FROM CELLULAR AND HUMORAL IMMUNITY
Edward F. Kreider
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2016

Supervisor of Dissertation
________________________
Dr. Beatrice H. Hahn, MD
Professor, Departments of Medicine and Microbiology
Graduate Group Chairperson
________________________
Dr. Daniel S. Kessler, PhD
Associate Professor of Cell and Developmental Biology

Dissertation Committee
James A. Hoxie, MD (Chair), Professor, Department of Medicine
Robert W. Doms, MD, PhD, Professor, Department of Pathology and Laboratory Medicine
Scott E. Hensley, PhD, Associate Professor, The Wistar Institute
Rahul M. Kohli, MD, PhD, Assistant Professor, Department of Medicine

ACKNOWLEDGMENTS
I would first and foremost like to thank my mentor, Dr. Beatrice Hahn. She has helped me flourish
as a scientist and provided me with unbelievable opportunities. Her mentorship over the past four years has
molded me as a both a person and an investigator. I cannot thank her enough.
Dr. George Shaw has also played an integral role both in my training and mentorship. His
insistence that we understand every stripe in every highlighter plot forced me to think critically about every
datum and even led to unexpected discoveries.
My thesis committee members Dr. James Hoxie, Dr. Robert Doms, Dr. Rahul Kohli, and Dr. Scott
Hensley have all provided me with guidance and mentorship on personal, academic, and scientific matters.
Dr. Doms is a major reason why I am here today and I am so thankful for the guidance and opportunities he
has provided me.
Dr. Yingying Li welcomed me to the lab, taught me everything that I know about sequencing, and
cared for me every day of my PhD training. Dr. Hui Li is an incredible collaborator and friend whose door
was always open. Dr. Gerald Learn provided me with a foundation in sequence analysis and is a treasured
colleague. Dr. Katherine Bar was a mentor and, to my great pleasure, a collaborator. To the Hahn lab
graduate students who have been a family throughout these past four years, in particular Hannah Barbian
and Shilpa Iyer, thank you so much for being there. And Ranjit Warrier, whose calming presence got me
through tough days. Additionally, many thanks are due to all of the collaborators who welcomed me into
their labs: Dr. Persephone Borrow, Dr. Andrew McMichael, and Dr. Bette Korber. As well to the CHAVI
Duke family, particularly Dr. Barton Haynes and Dr. Mattia Bonsignori
I also need to thank my social support network: Liz, Sarah, Andrew, Alice, Justin, and my entire
MSTP class, and Skip, Maggie, and Maureen. Finally, to my family and Fraz, thank you for putting up with
me.

ii

ABSTRACT

WITHIN-HOST EVOLUTION OF HIV-1: NOVEL PATHWAYS OF VIRUS ESCAPE
FROM CELLULAR AND HUMORAL IMMUNITY
Edward F. Kreider
Beatrice H. Hahn, MD

Longitudinal

HIV-1

single

genome sequencing (SGS), which

permits

unambiguous genetic characterization of circulating viral strains without introduction of
PCR error, can be used to identify sites in the viral genome that are under selective
pressure. Following transmission, the earliest sites under positive selection often fall in
cytotoxic T lymphocyte (CTL) epitopes. During escape from CTL immune pressure, viral
sequences typically exhibit nonsynonymous mutations within the span of the cognate T
cell epitope. I applied SGS to study sequence evolution in the HIV-1 5’ leader sequence,
which is thought to be translationally silent. I observed mutational patterns consistent
with CTL escape and demonstrated that the HIV-1 5’ leader expresses T cell antigens
from non-canonical one-off AUG codons (e.g. CUG). While these non-canonical start
codons can be mutated during CTL escape, a reverse transcriptase overextension error
periodically restores a one-off AUG within the 5’ leader. As infection ensues, sites under
selection within the gene encoding the viral envelope glycoprotein (Env) often fall within
autologous neutralizing antibody epitopes. In a subset of individuals, the strain-specific
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neutralizing antibody response develops into a broadly cross-reactive neutralizing
antibody (bnAb) response. To understand what factors influence bnAb ontogeny, I used
SGS to study Env evolution both during natural infection and immunotherapy. I found
viral diversification in bnAb contact residues and divergence of the virus population into
multiple persistent lineages to precede bnAb development. Taken together, these data
demonstrate that longitudinal HIV-1 SGS can be used to discover novel aspects of virus
biology and host-pathogen interactions.
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CHAPTER 1

INTRODUCTION

Edward F. Kreider

Departments of Medicine and Microbiology, Perelman School of Medicine at the
University of Pennsylvania

All figures appear at the end of this chapter
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Section 1.1 – AIDS and HIV-1
In 1981, the Centers for Disease Control published a Morbidity and Mortality
Weekly Report describing five cases P. jiroveci pneumonia (formerly known as P. carinii
pneumonia) in young, otherwise healthy gay men (www.cdc.gov/mmwr). This MMWR
would mark the first official reporting of Acquired Immunodeficiency Syndrome (AIDS)
in the United States (1). Since 1981, over 35 million people have died from AIDS-related
illnesses worldwide (www.UNAIDS.org). The causative agent is a lentivirus called
human immunodeficiency virus type 1 (HIV-1, Figures 1.1 and 1.2). HIV-1 primarily
infects CD4+ T cells (2, 3). Viral entry into a new target cell is mediated by the Env
glycoprotein, which engages the host cell receptor (CD4) and a coreceptor (e.g. CCR5,
CXCR4) (3). These events trigger a series of Env conformational changes that ultimately
result in fusion of the viral and host membranes and delivery of the vial payload into the
host cell cytoplasm (3). After entry, HIV-1 undergoes reverse transcription and
integration (4). During reverse transcription, the single stranded RNA genome is
converted into a double stranded DNA provirus (5). This DNA provirus is then trafficked
to the nucleus where it is integrated into the host genome (4).
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Section 1.2 – Biology of the 5’ leader sequence
The HIV-1 5’ leader is a conserved RNA element that lies at the 5’ end of every
HIV-1 RNA transcript and performs multiple essential replicative functions. It extends
from nucleotide 1 of R through the gag AUG, approximately 336 nucleotides in most
subtype B and C viruses (Figure 1.3). Given its placement upstream of all coding
sequences, the 5’ leader has the alternative designation of the 5’ untranslated region. The
various functions of this region depend on proper folding of mRNA secondary structure
(6, 7) and/or exact sequence identity (5).

R elements
The first two RNA features of the 5’ leader – TAR and the polyA signal – fall in
the retroviral Repeat element (R). As shown in Figure 1.1, the DNA provirus is flanked
by two long terminal repeats (LTRs). Promoter and enhancer elements within the Unique
3 (U3) element of the 5’ LTR are bound by a variety of host transcription factors, like
NF-κB (8), that regulate transcription of viral RNA (9). Early studies of the HIV-1 LTR
revealed that an additional regulatory element fell downstream of the transcription start
site and required expression of a factor in trans for efficient transcription (the
transactivator of transcription, Tat). This additional cis acting regulatory domain called
TAR is encoded by the first 59 nucleotides (nts) of R (9). It was found that TAR RNA,
not DNA, is bound by a viral protein called Tat via a bulge in the stem loop structure
(10). If the TAR RNA element is properly folded and Tat is expressed, viral RNA is
3

efficiently transcribed (11, 12). If Tat is not expressed, HIV-1 elongation is potently
restricted by a host factor called negative elongation factor (9). As a result, Tat acts in a
positive feedback loop in which Tat expression drives higher levels of transcription and
more Tat expression. The next R element, the polyA signal, is silenced at the 5’ end of
the genome such that premature polyadenylation does not occur (13-15).

Primer binding site and reverse transcription
The next 5’ leader element, the primer binding site (PBS), plays multiple essential
roles in virus reverse transcription. Retrovirus reverse transcription is primed by a host
tRNA(Lys,3), which is incorporated into budding virions during assembly (Figure 1.4 A)
(16-18). The tRNA anneals to the viral PBS via the 18 nucleotides (nts) at its 3’ end
(Figure 1.4, bent cyan arrow). As minus strand DNA is polymerized, the RNase H
domain of RT cleaves RNA in RNA:DNA hybrids (5). Once RT reaches the 5’ RNA cap
(Figure 1.4 B), the newly synthesized DNA undergoes the first strand transfer (19). In
this reaction, the R element of the minus strand DNA is annealed to the complementary R
element at the 3’ end of the genome (Figure 1.4 C). Post-strand transfer, minus strand
synthesis commences once again along with concomitant digestion of the RNA template
by RNase H (5). Stretches of the plus strand RNA that are rich in purines (called
polypurine tracts) are RNase-resistant (Figure 1.4 D) and can serve as the primers for
plus strand DNA synthesis (20). RT extends plus strand synthesis past the 5’ end of the
negative strand DNA, transcribing 18 nts of the host tRNA and generating the PBS in the
4

plus strand intermediate (Figure 1.4 E) (5, 21, 22). It is hypothesized that RT reverse
transcribes the host tRNA until it encounters a modified base, which is a methyladenosine at position 58 of the tRNA, 19 bases from the 3’ end (22-24). Subsequently RT
performs the second strand transfer reaction (Figure 1.4 F) and completes synthesis a full
length, 2-LTR DNA provirus is generated (Figure 1.4 G).

Ψ Stem Loops
The final set of RNA elements in the 5’ leader are collectively referred to as the Ψ
packaging stem loops and are involved in mRNA splicing and virion assembly. 3 Ψ stem
loops fall within the 5’ leader and have been named stem loop 1, 2, and 3 (25). Within the
loop of Stem loop 1, HIV-1 encodes a palindromic 6-8 nt sequence called the
dimerization initiation site (DIS). During virion assembly, two HIV-1 genomes base pair
via the DIS and initiate the genomic dimerization reaction (25-27). Co-packaging of
HIV-1 genomes is a requirement for virus particle infectivity (28) and can result in
recombination if two genetically distinct viruses infect the same cell (29). Stem loop 2
encodes the first, or major, splice donor (SD1), which is used as the splice donor in every
HIV-1 splicing reaction (30). Although this secondary structure has only been recently
been directly detected using nuclear magnetic resonance methods (31), the proper folding
of this motif is crucial to viral fitness (32). Collectively, these three stem loops (plus one
that falls downstream of the gag AUG) play an important role in accurate genomic
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packaging. When the Ψ signal is removed, cellular RNAs are nonspecifically packaged
into budding virions (33).

HIV-1 translation
In addition to the conserved functions discussed above, the 5’ leader plays an
important role in regulation of virus translation. Because all HIV-1 RNAs are 5’ 7methylguanosine capped, it has been proposed that translation initiation should be
mediated by typical, cap-dependent ribosomal scanning (34). When ligated to a reporter,
however, regions of the HIV-1 5’ leader inhibit ribosomal scanning and downstream
translation initiation (35, 36). Thus, many alternative mechanisms of HIV-1 translation
regulation have been proposed (reviewed in (37)). Multiple groups have identified
Internal Ribosomal Entry Sites (IRESs) in various regions of the HIV-1 genome (38-40),
however assays used to characterize these elements are subject to false positive results
(37). Thus, new methods of assessing the mechanism HIV-1 translation initiation are
needed.
Additionally, a growing body of literature concerning eukaryotic and viral
translation has suggested that “untranslated regions,” like the HIV-1 5’ leader, may
actually be translated. While AUG codons are heavily disfavored in the 5’ leader, one-off
AUGs (e.g. CUG) have been shown to mediate translation initiation (41, 42). Further,
ribosomal profiling in the presence of lactimidomycin or harringtonine – two drugs that
that lead to the accumulation of ribosomes at translation initiation sites – has supported
6

the notion that upstream, one-off AUGs initiate translation. For example, 96 of 506
mapped initiation sites in the human cytomegalovirus genome were one-off AUGs (43).
These findings, while further removed from HIV-1 itself, shed light on the complexities
of eukaryotic translation and may inform our ultimate understanding of HIV-1 translation
regulation.
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Section 1.3 –HIV-1 evolution and the T cell response
Acute HIV-1 infection
For 7-21 days following transmission, newly infected individuals generally show
no signs or symptoms of HIV-1 infection (44). During this eclipse phase, the virus
undergoes an initial local expansion, infecting CD4+ T cells in the genital mucosa,
submucosa and draining lymphoid tissue (45). When local infection disseminates into the
bloodstream, the first clinical markers of HIV-1 infection are detected (44). These include
viral RNA (Fiebig stage I), Gag p24 antigen (Fiebig stage II), and, in some cases, a “flulike” acute retroviral syndrome (46, 47). Once viral RNA is detected in the blood, the
virus population increases in size exponentially with a median doubling time of ~16
hours and a Ro of 8 (48). Infection spreads from the local site of infection to the gut
associated lymphoid tissue (GALT), leading to a massive depletion of mucosal CD4+ T
cells (45, 47, 49). During this viral ramp up, viral loads frequently reach >1 million
copies/mL (44, 47). Analysis of viral sequences taken at this time reveals random
mutation with no evidence of positive selection. If these sequences demonstrate both a
star-like phylogeny with coalescence to a single ancestral sequence and Poisson
distribution of Hamming Distances (50, 51), it can be inferred that infection was
established by a single transmitted founder virus. In 2008, Keele and colleagues studied
this process using single genome sequencing. Single genome amplification of end-point
diluted plasma followed by direct amplicon sequencing (single genome sequencing or
SGS) eliminates Taq-induced errors, Taq-mediated recombination, and cloning bias (5153). Using this model, paired with single genome sequencing, it has been determined that
8

70-80% of sexually transmitted HIV-1 infections are established by a single transmitted
founder (TF) virus (47, 50, 54).
Around 22 days post-infection, viral load peaks and begins to decline. This drop
in viral load is accompanied by the appearance of HIV-1 specific, non-neutralizing
antibodies (44, 55) and the first detectable T cell response (56, 57). As an HIV-infected
person transitions into chronic infection, viral load reaches a quasi-stable set point
(usually between 100-100,000 copies/mL) that is maintained for years (46).

Factors affecting within patient HIV-1 evolution
Longitudinal HIV-1 sequence analysis has revealed that the genetically
homogeneous population present during acute infection accumulates remarkable genetic
diversity over time (46, 58, 59). Two parameters contribute to this feature of the virus:
the mutation rate and the turnover rate. While estimates of the substitution rate vary
slightly based on method, it is generally agreed that the HIV-1 substitution rate ranges
between 1.4-3.4 x 10-5 mutations/base pair/cycle (5, 51, 60, 61). With a genome size of
approximately 10 kilobases, it can be conservatively estimated that 1 in 10 progeny
genomes will harbor a base substitution relative to the parental virus per generation. The
next parameter, the virus turnover rate, has been estimated using data from monotherapy
trials. Mathematical modeling has demonstrated that infected cells and virions have a
short half-life of 1-2 days and <6 hours, respectively (46, 62-65). Based on this clearance
rate, ~1010 new virions must be produced each day in an infected individual (65). The
9

combined effect of the HIV-1 error and turnover rates is staggering – every substitution at
every position of the viral genome is sampled hundreds to thousands of times per day
(64).
Another hallmark of HIV-1 evolution within a host is the iterative fixation of
immune escape mutations over time (59, 66). Longitudinally collected sequences taken
during chronic infection exhibit a time-ordered phylogenetic structure, characteristic of a
pathogen evolving under positive selection (66, 67). When single genome sequencing is
used to generate these data, the molecular pathway of virus evolution can be ascertained
(51, 52, 68). An important consequence of SGS is the maintenance of genetic linkage
across the entire amplicon. The application of this tool is best illustrated through an
example. Figure 1.5 depicts longitudinally collected single genome sequences from
subject CH40 in a synonymous/nonsynonymous highlighter plot (68). In this plot,
horizontal lines represent sequences generated using plasma from days 45-412 post-trial
enrollment, with the genomic map shown at the bottom. Tick marks represent nucleotide
changes relative to inferred transmitted founder virus, with green ticks representing
synonymous changes, red ticks nonsynonymous, and blue ticks changes outside of viral
ORFs. Concentrated non-random mutations away from the TF (positive selection) are
observed in nearly all day 45 sequences in five regions throughout the viral genome.
Figure 1.6 zooms in on such region in Nef that demonstrates a pattern of mutation called
toggling. As shown in Figure 1.6, sequences from days 45-412 exhibited toggling of one
of three nonsynonymous changes in Nef: S188N, R192H, and R196Q. These three
mutations are embedded in a peptide – SLAFRHVAR – that was encoded by the
10

autologous TF virus. Multiple studies have shown that this pattern of mutation is
consistent with escape from an autologous T cell response (68-71), which can be
measured using interferon-γ ELISPOT assays (Figure 1.7). As subjects are followed for
longer durations of time, more shared mutations away from the TF are observed – in
CH40 at least 14 sites within the viral genome exhibit concentrated, non-random
mutations at day 412. In this way, virus evolutionary patterns found in SGS datasets can
be used to precisely characterize host-pathogen interactions and directly measure positive
selection. Similar analysis has revealed that this technique can also be applied to study
escape from the neutralizing antibody response (53, 72-74).
In summary, acute and chronic HIV-1 infection are characterized by different
evolutionary processes. During acute infection, the virus exhibits random diversification
and exponential population growth (50). During chronic infection, the population
demonstrates continuous, strong positive selection (66). As demonstrated by the Nef-SR9
example, mutations can serve as footprints of selection that provide insight into immune
pressure in vivo (68, 71).
However, certain selected mutations in longitudinal SGS datasets represet
synonymous changes or fall outside of canonical HIV-1 ORFs. As shown in Figure 1.3,
CH40 sequences taken at day 412 have shared synonymous mutations in viral ORFs
(green tick marks, in pol and env, Figure 1.5) and shared mutations outside of canonical
coding regions (blue tick marks). These selected mutations, while less commonly
observed than their nonsynonymous counterparts, could potentially represent a number of
processes. They may represent escape from immune responses directed at alternative
11

reading frame peptides (75, 76); alterations to functional RNA elements and secondary
structures (7); or genetic “hitchhikers” that are linked to neighboring CTL escape
mutations (77). A subset of these selected changes fall in the 5’ leader sequence (blue tick
marks, Figure 1.3), which has the alternative designation of “5’ untranslated region.” In
Chapters 2 and 3, I will investigate two such patterns of non-random mutation within
longitudinally collected HIV-1 5’ leader sequences. The first pattern is a set of nonrandom mutations, similar to T cell escape mutations observed within canonical HIV-1
epitopes like Nef-SR9 described above. The second pattern of mutation falls in a short 5’
leader motif called the primer overextension sequence.
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Section 1.4 – HIV-1 and the neutralizing antibody response
Following the initial T cell response, neutralizing antibodies (nAbs) against the
Env glycoprotein rise. The fully folded mature Env protein is a trimer of non-covalently
bound heterodimers (78, 79). The protein is expressed as a gp160 polyprotein that is
cleaved by the host protease furin into gp120 and gp41 subunits (3). gp120 is partitioned
into constant regions (C1-5) and variable loops (V1-5), which harbor hypervariable
regions that are not readily aligned when comparing strains (3). gp41 consists of an
extracellular region, a transmembrane domain, and a long cytoplasmic tail. Like the
cytotoxic T lymphocyte response, the neutralizing antibody (nAb) response potently
drives selection for virus escape mutations (53, 72, 74, 80).
In a subset of individuals, the autologous strain-specific antibody response
matures into a broadly cross-reactive one (81, 82). A cross-sectional analysis of plasma
neutralization breadth from 205 individuals using a heterologous panel of 219 viruses
revealed that neutralization breadth exists on a spectrum from narrowly strain-specific to
broadly cross-reactive during chronic infection (83). Advances in B cell cloning and Ig
locus amplification have permitted the rapid isolation and cloning of broadly neutralizing
monoclonal antibodies (bnAbs) from subjects who exhibit broad plasma neutralization
(84, 85). These monoclonal bnAbs recapitulate the neutralization patterns observed in
plasma and exhibit atypical properties such as: unusually long heavy chain
complementarity determining region 3s (HCDR3s), high levels of somatic hypermutation
(upwards of 30% mutated relative to the germline), and autoreactivity (84, 86).
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Monoclonal bnAbs bind at multiple sites of vulnerability on the Env trimer
(Figure 1.8). The three most commonly targeted sites are (1) the high mannose patch at
the base of V3, (2) the CD4 binding site (CD4bs), and (3) V2 at the apex of the trimer
(79). V3 glycan bnAbs that target the high mannose patch often engage Env at different
angles relative to the viral membrane (87). These antibodies all contact a short motif in
the descending arm of V3 (324GDIR327) and an N-linked glycan at position 332 (87, 88).
CD4bs bnAbs come in multiple flavors: VRC01-like bnAbs are restricted in which VH
gene is used (1-2 and 1-46), while others converge on a common mode of Env-binding
via their HCDR3s (73, 89, 90). V2 apex bnAbs typically have long HCDR3s that interact
with strand C of the V2 loop and a set of adjacent glycans at N156 and N160 (91). The
remaining bnAb classes target additional sites on the Env trimer, but may be elicited less
frequently during natural HIV-1 infection (79, 84). These include gp120-gp41 interface,
membrane proximal external region, and fusion peptide-directed bnAbs (84, 92).

bnAb/virus co-evolution
It has been proposed that molecular characterization of virus/antibody coevolution during bnAb development may inform HIV vaccine design (92, 93). Through
genetic and phenotypic characterization of both B cell and virus evolution, these types of
studies identify crucial steps along the path of bnAb development and the viral antigens
that drove this maturation. Here, I will introduce the first and most well characterized
individuals studied with this technique, CH0505 (72-74). CH0505 is an African man who
14

was infected with a single Subtype C virus and sampled regularly over more than six
years of infection, prior to initiation of antiretroviral therapy (ART, Haynes, B.,
unpublished). An CD4 binding site bnAb lineage designated CH103 was isolated from
CH0505 and extensively characterized for its autologous and heterologous binding and
neutralization properties (72). Interestingly, the unmutated common ancestor (UCA) of
the CH103 lineage bound, but did not neutralize, the autologous transmitted founder (TF)
virus (72). Evaluation of virus sequence evolution during the first 4 weeks of infection
revealed that a small subset of Envs harbored changes in Loop D of the CD4 binding site.
Interestingly, the sampled Loop D mutations sensitized autologous Envs to neutralization
by the CH103 lineage (72, 74). A second, strain-specific CD4bs antibody, called CH235,
was then isolated from CH0505. Loop D variants were neutralization resistant when
assayed with CH235 antibodies, suggesting that these mutations were driven by immune
pressure from CH235 nAbs in vivo. In other words, the CH235 antibody lineage
cooperated with the CH103 lineage, sensitizing Envs to CH103 binding and
neutralization (74). Env sequences subsequently showed significantly increased
diversification within CD4 binding site contact residues, prior to the development of
heterologous neutralization breadth when compared to subject who did not develop
bnAbs (72). A recent follow up study revealed that the CH235 lineage, which was
initially a strain-specific nAb, underwent continued affinity maturation for five years of
infection and developed into an even broader bnAb than CH103 (73). Thus, in CH0505,
the development of bnAb lineages involved bnAb precursor engagement of the TF Env,
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cooperation between multiple nAb lineages to maintain Env neutralization sensitivity,
diversification in bnAb contacts, and extended affinity maturation over many years.
Antibody/virus coevolution in other subjects has supported the findings in
CH0505. For example, human subjects CAP177 and CAP331 both developed broadly
cross-reactive neutralizing serum that was dependent on the glycan at 332 for
neutralization (V3 glycan bnAbs). The transmitted founder viruses from both of these
individuals lacked this glycan, raising the question of what stimulated these N332-glycan
dependent bnAbs (94). Likely as a result of autologous immune escape from another nAb
lineage, the plasma virus acquired the glycan at 332 ~6 months into infection and
heterologous neutralization breadth subsequently developed. While monoclonal
antibodies were not isolated from these individuals, this pattern in plasma neutralization
is consistent with the idea of cooperating nAb lineages. In fact, findings consistent with
cooperating antibody lineages were seen in CAP256 (95, 96), PC76 (97), and CAP257
(98). Together, these data suggest that, perhaps unsurprisingly, bnAb lineages do not
develop in isolation during natural HIV-1 infection.
Unfortunately, comprehensive Env sequencing is not available for all of these
subjects for direct comparison to virus evolution in CH0505. In one subject, CAP256,
deep sequencing of V2 (the target of the bnAb response) revealed that, like CH0505, the
plasma quasispecies exhibited diversification prior to neutralization breadth development
(95). Future studies in more subjects will be needed to explore whether similar patterns of
Env diversification precede breadth. In Chapter 4, I will present one such study, the
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virus-antibody co-evolution in a human subject, CH0848, who developed V3-glycan
specific bnAbs.
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Section 1.5 – Monoclonal bnAbs in prevention and therapy
The recent explosion in the number of cloned monoclonal bnAbs has led to the
development of exciting prevention and therapeutic modalities. Non-human primate
studies have demonstrated that passive immunization of rhesus macaques with
monoclonal bnAbs prevents simian/human immunodeficiency virus (SHIV) infection
(99). These and other findings have led to the hypothesis that bnAb expression at the time
of transmission may prevent infection in humans (92). To test this hypothesis, ~4,200
HIV-negative adults will be infused with a CD4bs bnAb called VRC01 and monitored for
HIV-1 acquisition. This study’s findings will be important for the HIV vaccine field, no
matter the outcome.
bnAbs have also been tested as possible therapeutics. Monoclonal antibodies may
provide benefit over small molecule inhibitors based on their ability to engage the host
innate immune response (100). Initial studies in humanized mice demonstrated that
treatment with 3-5 bnAbs were required to completely suppress viremia (101). This
finding was followed up by two non-human primate trials in which suppression of
simian/human immunodeficiency viruses (SHIV) replication in macaques was achieved
with one or a combination of bnAbs (102, 103). Given the success of these non-human
studies, monoclonal bnAb infusions have now been tested in humans in two settings:
viremic individuals (104, 105) and antiretroviral therapy (ART)-suppressed individuals
(106). In these trials, bnAb treatment was safe and, in some cases, may have offered
therapeutic benefit in the form of a delay in rebound viremia and a restriction in the
number of rebounding viruses (106). In all cases, however, bnAb treatment led to the
18

emergence of resistant viral strains. Future studies will be needed to test if combination
bnAb treatment can fully suppress viremia and prevent the development of resistance.
Further, comparisons must be made to small molecule inhibitors to determine whether
bnAb infusion has added benefit over combination ART. In Chapter 5, I will present a
study that monitored bnAb and virus evolution after bnAb immunotherapy.
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Section 1.7 – Figures

Figure 1.0-1 HIV-1 RNA and DNA Genomic Organization
(A) During the HIV-1 lifecycle, the viral genome is converted between a single stranded,
positive-sense RNA molecule and a double stranded DNA molecule (top and bottom,
respectively). All transcripts begin with the 5’ leader sequence. It harbors the retroviral
repeat (R) element, the unique 5 (U5) element, and the gag leader sequence (GLS).
Following are the nine canonical HIV-1 open reading frames (ORFs): gag, pol, vif, vpr,
tat, rev, vpu, env, and nef. The viral group specific antigen (gag) encodes structural
proteins including matrix, capsid, and nucleocapsid (3, 25, 107). The pol gene encodes
the enzymes protease, reverse transcriptase, and integrase (4, 5, 25). rev and tat encode
the two essential viral regulatory factors that mediate viral RNA nuclear export and
transactivation, respectively (9, 108). env encodes the Envelope glycoprotein, which
mediates viral entry (3). The remainder of the viral ORFs encode so-called accessory
proteins: Nef, Vif, Vpu, and Vpr (109). These proteins perform functions that are
sometimes dispensable for replication in vitro, but affect pathogenesis in vivo (109).
Finally, the RNA genome ends with a retroviral unique 3 element (U3) and the 3’ R
element. (B) Upon reverse transcription into a DNA provirus, the HIV-1 genome is
flanked by two complete long terminal repeats (LTRs), each consisting of U3, R, and U5
elements. The spans of these elements are depicted. Abbreviations: R – repeat element,
U5 – unique 5 element, GLS – gag leader sequence, U3 – unique 3 element, 3’ UTR – 3’
untranslated region, LTR – long terminal repeat. Adapted from www.hiv.lanl.gov.
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Figure 1.0-2 HIV-1 Group M env diversity.
HIV-1 strains can be categorized into four lineages, which are referred to as Groups M,
N, O, and P. Group M strains, which cause the vast majority of HIV-1 infections, have
been further classified as one of nine subtypes (A-D, F-H, J, K) or recombinants
thereof. Depicted is a maximum likelihood env phylogenetic tree with 208 representative
sequences from major Group M subtypes and circulating recombinant forms (CRFs).
Adapted from Bonsignori, et al., submitted.
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Figure 1.0-3 Secondary structure of the 5’ leader sequence.
Depicted is a graphical representation of the RNA secondary structure of the 5’ leader.
Adapted from Lu, et al., 2011. Abbreviations – transactivation response element (TAR),
poly-adenylation signal (polyA), primer binding site (PBS), dimerization initiation site
(DIS), major splice donor (SD), psi packaking signal stem loop 3 (Ψ).
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Figure 1.0-4 Reverse trascription
As described in the text, depicted are the steps of reverse transcription. tRNA(Lys,3) is
represented as a bent cyan arrow, plus strand RNA in cyan (digested RNA dotted), and
DNA in dark blue. (A) Priming from tRNA(Lys,3). (B) reverse transcription of U5 and R
and digestion of viral RNA in RNA:DNA duplex until the minus strand strong stop. (B)
to (C) First strand transfer. (D) Continued minus strand synthesis and RNA digestion
(except for the polypurine tracts, ppt). (E) plus strand synthesis using the ppt as a primer
until plus strand strong stop, typically after 18 nts of the tRNA are copied. (E) to (F)
Second strand transfer. (G) full extension of both plus and minus strands. Adapted from
Hu and Hughes, 2011.
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Figure 1.0-5 HIV01 sequence evolution in CH40
CH40 is a human subject who was identified during acute infection and sampled
longitudinally. Depicted is a nucleotide highlighter plot in which horizontal lines
represent single genome sequences derived at screening (S), day 6, day 45, day 11, day
181, and day 412 post-screening. Tick marks denote sequence changes relative to the
transmitted founder (TF) virus. Red ticks are nonsynonymous, green are synonymous,
and blue fall outside of known ORFs. Selected mutations are embedded in cytotoxic T
lymphocyte (CTL) epitopes (grey squares) and neutralizing antibody (Nab) epitopes
(orange triangles) and confer escape from these immune responses in ex vivo assays.
Viral load (vL) is indicated to the left. Adapted from Salazar-Gonzalez, et al., 2009,
Goonetilleke, et al., 2009, and Bar, et al., 2012.
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Figure 1.0-6 Amino acid toggling in Nef.
Depicted is an amino acid alignment of Nef positions 185-202 from CH40 (far right,
figure 1.3). The inferred transmitted founder sequence is depicted at the top. Mutations
relative to this sequence are highlighted in red. 15, 12, 6, and 12 single genome
sequences were generated at days 45, 111, 181, and 412, respectively. The number of
SGS matching each amino acid variant is indicated to the left. 100% of sequences from
day 45 onward harbored a nonsynonymous mutation relative to the TF within a 9 amino
acid span, SLAFRHVAR. Sequences that did not encode a full length, gross nondefective nef reading frame were excluded.
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Figure 1.0-7 CH40 immune recognuition of Nef-SR9.
CH40 PBMCs taken at day 45 were stimulated with the autologous TF Nef peptide
SLAFRHVAR or one of two Nef peptide variants (NLAFRHVAR and SLAFRHVAQ,
see Figure 1.4) and assayed with an interferon-γ ELISPOT. Stimulation with the TF
peptide resulted in more than 75 spot forming units/million PBMCs (SFU/million).
Stimulation with Nef peptide variants that were selected observed day 45 and after
yielded fewer than 20 SFU/million PBMCs. Adapted from Goonetilleke, et al., 2009.
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Figure 1.0-8 Broadly neutralizing antibody sites of vulnerability on the Env trimer.
Adapted from Haynes, et al., 2016
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Section 2.1 – Abstract
Introduction: The lentiviral 5’ leader is a conserved RNA structure that lies upstream of
canonical coding regions and is conventionally considered “untranslated.” Nonetheless,
we recently observed concentrated, non-random mutations within the 5’ leader of
SIVmac strains sequenced longitudinally from Mamu-B*29+ macaques. Follow up
studies revealed that this sequence evolution represented virus escape from a MamuB*29-restricted cytotoxic T lymphocyte (CTL) response targeting a 5’ leader-encoded
peptide called KA9 (KGAGRYQTA). We hypothesized that the HIV-1 5’ leader also
expressed peptides that were recognized by host T cells during infection.
Methods: Longitudinal plasma viral single genome sequences were generated from 27
human subjects who were acutely infected with HIV-1. Ex vivo interferon-γ ELISPOT
assays were performed on human PBMCs stimulated with autologous transmitted founder
virus peptides or putative escape variants encoded by the viral 5’ leader and proteome.
Mass spectrometry analysis of major histocompatibility complex (MHC)-presented
epitopes was conducted on peptides purified using MHC immunoprecipitation, acid
elution, and reverse phase liquid chromatography of lysates from HIV-infected CD4+ T
cells.
Results: Longitudinal 5’ leader sequencing from 13 out of 27 HIV-1-infected human
subjects revealed mutational patterns consistent with escape from CTLs. Interferon-γ
ELISPOT assays using PBMCs from three of these subjects (infected with subtype A or
C HIV-1) demonstrated autologous T cell recognition of five HIV-1 5’ leader peptides
(5’L-ER10, 5’L-LL9, 5’L-IA9, 5’L-RS9, and 5’L-AA10). These peptides were encoded
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by reading frames +1 and +3 within R or around Stem Loop 1. Mutations selected in vivo
either conferred nonsynonymous changes that abrogated host CTL recognition or altered
the 5’ leader reading frame by through start codon deletion, nonsense mutation, or
frameshifts. Morevoer, these putative escape mutations spared known functional RNA
stems and loops and were predicted to not alter stem base-pairing. A sixth 5’ leader
peptide encoded by reading frame +2 within the R element of a subtype B virus was
detected using mass spectrometry.
Conclusions: These data collectively demonstrate that 5’ leader sequences from subtype
A, B, and C HIV-1s express peptides from all three forward reading frames. During
natural infection, these peptides elicit robust T cell responses that potently drive virus
escape. These findings provide new insight into mechanisms of viral translation and will
inform future vaccine efforts that target this region of the genome.
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Section 2.2 – Introduction
The lentiviral 5’ leader sequence is polyfunctional RNA structure that lies
upstream of the canonical coding regions in every viral transcript. It spans from the first
nucleotide of the long terminal repeat (LTR) R element to either the gag AUG or the first
splice donor. Within its primary and secondary RNA structure, the HIV-1 5’ leader
encodes a series of functional domains that perform essential replicative functions
throughout the viral lifecycle (1). These include the transactivation response element
(TAR) (2,3), the poly-adenylation signal (polyA) (4,5), the tRNA primer binding site
(PBS) (6,7), the genomic dimerization initiation site (DIS) (8), the major splice donor
(SD1) (9), and the Ψ packaging signal (10). Proper RNA hairpin folding is required for
many 5’ leader functions (9,11-13) and is evolutionarily conserved among primate
lentiviruses (14). Because the leader falls upstream of the canonical viral open reading
frames (ORFs), it has the alternative designation of 5’ “untranslated” region.
Based on this conserved structure and function, we became interested in
evaluating whether the 5’ leader sequence evolved over time during infection. We have
previously developed an experimental strategy based on single viral template
amplification followed by direct amplicon sequencing (single genome sequencing, SGS)
that has permitted the genetic inference of transmitted HIV-1 strains (15,16) and
molecular characterization of immune escape pathways (17-20). Application of this
method to canonical viral ORFs has demonstrated that concentrated nonsynonymous
mutations within a 30-45-nucleotide window (10-15 amino acids, toggling) serves as a
strong indicator of an embedded cytotoxic T lymphocyte (CTL) epitope (18,19,21). Thus,
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we applied this method to study virus evolution of the simian immunodeficiency virus
(SIV) challenge strains SIVmac239/SIVmac766 during infection of Indian rhesus
macaques. Strikingly, viruses from 14 of 14 Mamu-B*29:01+ macaques demonstrated
rapid and complete selection confined to a 27-nucleotide (nt) span within Ψ Stem Loop 1
of the 5’ leader (Figure 2.1A). 100% of mutations conferred nonsynonymous or nonsense
changes within a predicted 9-amino acid span (9-mer), KGAGRYQTA (5’L-KA9). Thus,
we hypothesized that 5’L-KA9 was expressed from the SIVmac 5’ leader and targeted by
a host CTL response.
To test this hypothesis, we performed interferon-γ (IFN-γ) ELISPOT assays,
stimulating macaque PBMCs with predicted peptides from all 6 5’ leader reading frames
(3 forward and 3 reverse). Autologous CTLs demonstrated reactivity to the 5’L-KA9
peptide (Figure 2.1B) that was later confirmed with tetramer staining (Li, H., Shaw, G.,
unpublished). Ribosomal profiling of SIVmac766 demonstrated that the translation of
5’L-KA9 was initiated at two tandem one-off AUG codons (ACGACG) at positions 388390 and 391-393, immediately upstream of 5’L-KA9 (Figure 2.1C, Warrier, R., Shaw,
G., unpublished). Thus, our studies in SIV-infected macaques demonstrated that 5’LKA9 is a novel Defective Ribosomal Product (DRiP) that is expressed from an ACG
codon within the 5’ leader and elicits a robust CTL response during natural infection.
Given this surprising discovery, we hypothesized that the 5’ leader of HIV-1 also
expressed DRiPs that would elicit host CTL responses. Here, we tested this hypothesis
using longitudinal SGS, ex vivo immunophenotypic assays, and a mass spectrometric
analysis of MHC-loaded peptides.
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Section 2.3 – Results
Prevalence of 5’ leader mutation during infection
To determine whether mutational selection within the 5’ leader is common during
HIV-1 infection, we evaluated longitudinally collected HIV-1 single genome sequences
from 27 subjects (17-19,21). Sequences from 19 of these subjects were available from
previous studies of viral evolution (17-19,21) (Li, H., Hahn, B., Shaw, G., unpublished)
and we performed 5’ leader-specific sequencing on the remaining eight subjects
(CH0236, CH0694, R463F, R880F, CH0470, CH0256, CH0042, CH0850). Table 2.1
summarizes the sites and frequency of selection for longitudinal virus sequences from all
27 subjects, who were infected with either a subtype A, B, or C virus. Viruses from 13/27
subjects exhibited selection within the 5’ leader over time, suggesting that 5’ leader
sequence evolution is common during HIV-1 infection.

HIV-1 Whole Genome Evolution in 3 Subjects
We selected three subjects, CH0236, CH0694, and R463F, for more in-depth
study. These individuals were prospectively followed from acute HIV-1 infection for 1-4
years and exhibited diverse human leukocyte antigen (HLA) genotypes (Table 2.2).
CH0236 and CH0694 were identified during acute HIV-1 infection, enrolled in a Center
for HIV/AIDS Vaccine Immunology (CHAVI) acute infection cohort (CHAVI 001), and
followed for 1.5 and 4 years of infection, respectively. R463F was identified as the acute
recipient in a heterosexual transmission pair, enrolled into an International AIDS Vaccine
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Initiative (IAVI) Protocol C acute infection cohort, and followed for 1 year of infection
(22). Viral setpoint for all three subjects fell between 105-106 copies/mL and CD4+ T cell
counts steadily declined over the course of follow up in all subjects (Figure 2.2). To
compare patterns of 5’ leader sequence evolution to that seen throughout other regions of
the viral genome, we collected either half genome or near-full genome single genome
sequences (SGSs) on human subject plasma. For CH0236 and CH0694, 3’ and 5’ half
genome SGSs were generated at 6 and 4 time points, respectively (Figures 2.3 and 2.4).
Near-full length SGSs from six R463F plasma samples had been previously published
(Figure 2.5, GenBank accession numbers KJ190253-62; KP223729-75) (22).
Studies of virus sequence evolution are facilitated by genetic inference of the
transmitted HIV-1 strain because it provides a reference point of comparison for all
sequences obtained at later time points. 70-80% of mucosally transmitted HIV-1
infections are established by a single transmitted founder (TF) virus (23-25). To test if
this was the case in CH0236, CH0694, and R463F, we applied the Poisson Fitter v2 tool.
Poisson Fitter measures A) if sequences exhibit a star-like phylogeny with coalescence
back to a single transmitted founder virus, B) if Hamming Distances between sequences
exhibit a Poisson Distribution (nonsignificant p-value indicates a Poisson Distribution
consistent with random diversification), and C) estimates time since infection. Using this
tool, sequences from all three subjects coalesced to a single transmitted founder virus (TF
virus, Table 2.2) (15,26). A note on the CH0236 TF inference is discussed in the Methods
section.
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We have previously shown that sites within the viral proteome that exhibit
positive selection often overlap with cytotoxic T lymphocyte (CTL) epitopes (17-19).
Therefore, we evaluated longitudinal sequences from these three subjects for regions
under selection (mutually exclusive mutations relative to the TF in >67% of sequences in
a 45-nt sliding window) (18,21). As expected, plasma virus SGSs from all three subjects
accumulated an increasing number of sequence changes relative to the TF virus
throughout the viral genome over time. Six months post trial enrollment, concentrated,
nonrandom mutations relative to the TF were observed in 7-19 regions of the HIV-1
genome (Table 2.3), including the 5’ leader. 17/44 (38%) of these selected sites fell
within Env, which is consistent with previous studies that have linked to Env evolution to
escape from either CTL responses (18,21,27) or neutralizing antibodies (19,20,27). Thus,
these subjects exhibited typical HIV-1 sequence evolution throughout the proteome along
side potent, early selection within the 5’ leader.

5’ leader evolution and immune recognition in CH0236
To further evaluate sequence evolution within the CH0236 viral 5’ leader, we
performed additional 5’ leader SGS on eight longitudinally collected plasma samples. 5’
leader sequences from CH0236 exhibited selection for non-TF variants at multiple sites
during follow up (Figure 2.6A). At RNA position 169 in U5 (HXB2 position 624), a Tto-A substitution was observed in 16/36 (44%) week 24 sequences, 24/24 (100%) week
36 sequences, and 47/47 (100%) week 60 sequences. Additionally, toggling of mutually
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exclusive mutations was observed in a 61-nt span (RNA 352-412, HXB2 680-740) in
11/15 (73%) week 1 sequences, 16/18 (89%) week 2 sequences, and >90% of sequences
thereafter. 44/47 (94%) week 60 sequences shared an insertion mutation immediately
following RNA position 255 (HXB2 710). Thus, CH0236 5’ leader sequences exhibited
mutational selection at two sites within the 5’ leader.
To test if either of these patterns of 5’ leader mutation correlated with immune
escape from a CTL response, we performed autologous interferon-γ ELISPOT assays
(18,21,22). Overlapping 18-mer peptides (OLPs) encoded by all six reading frames of the
CH0236 TF 5’ leader and the canonical viral proteome were synthesized (Sigma-Genosys
or MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine). 5’
leader peptides were pooled by reading frame and proteome peptides were pooled using a
previously described matrix approach (18,21,28). CH0236 enrollment and week 12 cells
reacted with pooled peptides encoded by the +1 reading frame (RF) of the 5’ leader
(Figure 2.6B). Deconvolution of this peptide pool revealed that this reactivity could be
mapped to the 18-mer RRRTRLAEVHSARGEGRR (RR18). Stimulation of CH0236
PBMCs with 8-11-mers within this 18-mer span demonstrated host recognition of the
autologous 11-mer AEVHSARGEGR (Figure 2.6C). To conserve cells, we then
generated an RR18-specific, short-term CD8+ T cell line (29). Stimulation of this T cell
line with the 11-mer AR11 and a shorter 10-mer (EVHSARGEGR, ER10) at a range of
peptide concentrations revealed that ER10 was recognized by CH0236 PBMCs and was
the minimal epitope (Figure 2.6C).
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We next evaluated whether mutations observed in longitudinal 5’ leader
sequencing data overlapped with ER10. ER10 is encoded by a potential 5’ leader open
reading frame (ORF) that spans RNA positions 178-312, surrounding Stem Loop 1 of the
Ψ packaging signal (Figure2.6D, HXB2 positions 633-765). While the ER10 ORF does
not encode AUG codons, we have previously shown that SIVmac766 5’L-KA9 was
expressed from a one-off AUG (e.g. CUG, ACG). Therefore, all one-off AUGs in the
ER10 ORF are highlighted in green. Two observed mutations upstream of ER10
eliminated a one-off AUG codon (AUC) at RNA positions 226-228 (HXB2 681-683).
Substitutions at 232 and 263 each incorporated a stop codon in the ER10 reading frame.
Six additional substitutions were embedded in ER10. An insertion immediately
downstream of RNA position 255 resulted in a frameshift within ER10. The five
remaining mutations within in ER10 conferred a nonsynonymous changes at the first,
fourth, or tenth residue. Autologous CH0236 T cells did not recognize any of these five
ER10

variants

(Figure

2.6E,

GVHSARGER,

KVHSARGER,

EVHLARGER,

EVHSARGEQ, or EVHSARGEW), demonstrating that these mutations conferred CTL
escape. And finally, the substitution at RNA position 287 (HXB2 742) confers a
nonsynonymous change downstream of ER10. NetChop 3 analysis revealed that this
mutation removes a predicted proteasomal cleavage site, and thus may affect peptide
processing (30-32). In sum, toggling mutations either A) deleted a one-off AUG, B)
incorporated a stop codon, C) shifted ER10 into another reading frame, or D) conferred a
nonsynonymous change within or downstream of ER10.
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Finally, we compared the kinetics of the ER10 response to T cell responses
against the canonical viral proteome. CH0236 T cells recognized 19 autologous TF
proteome peptides: Gag-QQ28, Gag-DI8, Pol-FL9, Pol-NNY9, Pol-NPY-9, Pol-KY9,
Vif-KY9, Vif-SY9, Vif-DR9, Tat-KY9, Rev-AY9, Env-DL13, Env-DF9, Env-RY9, EnvGR9, Nef-WM8, Nef-QY9, Nef-LF9, and Nef-DW9 (Fig. 2.7). Concentrated,
nonsynonymous mutations were embedded within 11/19 of these peptides (Figure 2.3).
The 5’L-ER10 response in CH0236 was detected at trial enrollment but was smaller in
magnitude when compared to the early Vif-KY9 (green) and Nef-QY9/NefLF9 (blue)
responses (Fig. 2.7). Thus, the 5’L-ER10 CTL response was among the earliest CTL
responses and potently drove virus escape.

5’ leader evolution and immune recognition in CH0694
Similar to CH0236, 5’ leader sequencing over three years of CH0694 infection
revealed multiple, complex patterns of selection (Figure 2.8A). At week 24, 26/30 (87%)
SGSs demonstrated toggling mutations between RNA positions 44-59 (HXB2 497-513).
At subsequent time points, a base substitution at position 50 was observed in all variants.
All week 24 variants also encoded a substitution at RNA position 179 (HXB2 633),
which was observed for the remainder of follow up. Complex toggling was observed
between positions 200-264 (HXB2 654-718). This toggling, which resembled that seen in
CH0236 both in span and location, involved single and double mutations at RNA
positions 200 and 201 (HXB2 654-655), a substitution at position 228 (HXB2 682), an
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insertion downstream of position 238 (HXB2 692), an insertion downstream of position
254 (HXB2 708), and a substitution at position 263 (HXB2 717). One of these mutations
was present in 30/34 (88%) week 96 sequences and 23/23 (100%) week 140 sequences.
Screening ELISPOT assays revealed that CH0694 PBMCs taken from week 16
and 48 reacted with pooled 5’ leader peptides from +3 RF and +1 RF, respectively
(Figure 2.8B). Deconvolution of the reading frame +3 pool response demonstrated that
the reactive peptide was a 9-mer LAIWGTHCL, encoded by RNA positions 40-58 of the
TAR stem loop (5’-LL9, Figure 2.8C). 5/6 toggling mutations fell within 5’L-LL9 and
conferred nonsynonymous changes to the epitope, whereas the selected variant encoded a
stop codon at the fourth amino acid (Figure 2.8D). Due to restrictions on cell availability,
we were unable to test 5’L-LL9 variant peptides in IFN-γ ELISPOT assays.
Deconvolution of the RF+1 pool response revealed immune recognition of two
partially overlapping peptides, ISRRRTRLA (5’L-IA9) and RTRLAEVHS (5’L-RS9,
Figure 2.8E). 5’L-IA9, 5’L-RS9, and 5’L-ER10 were all encoded by the same open
reading frame; that is, they shared upstream one-off AUG codons. Consistent with this
finding, mutations in the CH0694 5’L-IA9/5’L-RS9 reading frame closely resembled
those observed in CH0236 5’L-ER10 (Figure 2.8F). In the CH0236 TF virus, one-off
AUGs upstream of 5’L-ER10 were observed at positions 193, 223, 226, and 238 (HXB2
positions 648, 678, 681, and 693). In the CH0694 TF virus, upstream one-off AUGs were
found at 179, 194, 200, 227, and 239 (HXB2 positions 633, 648, 654, 681, and 693).
Variants that deleted the one-off AUG at HXB2 position 681 were observed in both
subjects (AUC, bolded residue mutated). Additional variants in CH0694 harbored
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mutations in one-off AUGs at HXB2 positions 633 (RNA 179, AAG) and 654 (RNA 199,
UUG), which were not present in the CH0236 TF virus. Thus, even though these two
subjects mounted immune responses to different peptides in this 5’ leader reading frame,
virus variants from both subjects exhibited similar patterns of mutation, including
deletion of the same one-off AUG.
Finally, we compared the kinetics of the anti-5’ leader T cell responses against
those targeting peptides derived from the viral proteome. CH0694 PBMCs from the first
year of infection recognized 13 peptides from the proteome: Gag-YL9, Gag-TE18, GagTA18, Gag-GL9, Pol-Tl9, Vif-WI9, Vpr-CL9, Rev-IL9, Rev-DN18, Env-VL18, EnvRR11,

Nef-KM9,

and

Nef-TL10

(Figure

2.9).

Concentrated

non-random,

nonsynonymous changes were embedded in 10/13 (77%) of these epitopes during follow
up. Interestingly, 43/52 (83%) week 24 sequences harbored a single nucleotide insertion
in Env-RR11, throwing the cytoplasmic tail of this protein out of frame (Figure 2.4,
orange tick marks). The resulting Env protein had a 19-amino acid cytoplasmic tail
truncation that was later replaced by one of two other variants that restored the reading
frame. Similar to CH0236, 5’ leader responses were detected throughout CH0694
infection, albeit at lower magnitude than responses against canonical proteome epitopes:
T cells specific for 5’L-LL9 were detectable at enrollment and quickly waned, whereas T
cells specific for other 5’ leader peptides arose later.

5’ leader evolution and immune recognition in R463F
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A previous study of subject R463F mapped autologous T cell responses against
the entire viral proteome, but did not investigate 5’ leader sequence evolution or T cell
responses (22). We, therefore, performed 5’ leader sequencing on three time points of
infection (Figure 2.10A, plasma availability restricted analysis). Of note, the R463F TF
virus harbors a 20-nt insertion downstream of the PBS that is seen ~20% of subtype A
viruses and most CRF_01 subtype AE viruses (M group alignment, www.hiv.lanl.gov).
Sequences derived from week 24 plasma demonstrated toggling of mutations between
RNA positions 274-287 (HXB2 717-723). These included an insertion downstream of
nucleotide 274 (HXB2 709), a single nucleotide deletion at RNA position 281 (HXB2
717), a substitution at 283 (HXB2 719), and a two-nt deletion at 286-287 (HXB2 722723). Previously published sequences harbored two more sequences changes – an
insertion at 257 (HXB2 692) and a substitution at 259 (HXB2 694) (22).
Screening ELISPOT assays demonstrated that R463F PBMCs reacted with pooled
peptides from the +3 RF and deconvolution of this pooled mapped the minimal epitope to
AECTQQEARA, which was encoded by Stem Loop 1 of the Ψ packaging signal (RNA
positions 270-299, HXB2 726-757, Figure 2.10B and C, 5’L-AA10). Similar to CH0236
and CH0694, R463F viral variants observed during infection harbored a mutation in an
upstream one-off AUG, a substitution within 5’L-AA10, and frameshift mutations. Week
46 PBMCs reacted with the TF 5’L-AA10 variant, but not the week 24 variant
(AECTRQERA, Figure 2.10D). Thus, all three subjects mounted CTL responses against
5’ leader encoded peptides that potently drove viral turnover and escape.
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Escape mutation location on stem loop structure
Previous studies have shown that the RNA sequence and secondary structure of
the HIV-1 5’ leader play crucial roles in the leader’s function (9,12,33). We, therefore,
mapped the mutations observed during 5’ leader sequence evolution in CH0236,
CH0694, and R463F onto a previously published 5’ leader secondary structure (14) to
determine if any of these mutations fell in functional stem loops. This structure, which
was determined using selective 2’-hydroxyl acylation analyzed by primer extension
(SHAPE), was used as a scaffold that we threaded each TF virus sequence into (Figure
2.11 and Figure 2.12) (14). Because the R463F encoded a 20-nt insertion in this region
downstream of the primer binding sequence (PBS), it could not be aligned to the
sequence used to build the SHAPE structure (NL4.3), and we omitted this part of the
structure in Figure 2.11. 5’L-ER10, 5’L-IA9, 5’L-RS9 and 5’L-AA10 (bracketed) all
overlapped with Ψ stem loop 1, which contains the palindromic dimerization initiation
site (DIS). While this palindromic sequence can differ between subtypes, all three TF
viruses encoded GUGCAC (Figure 2.11). Mutations observed in longitudinal sequence
datasets all spared the DIS and, in CH0694 and CH0236, spared the residues in the stem.
5’L-LL9 was encoded by the TAR stem loop of R (Figure 2.12). The sites of mutations in
CH0694 viruses are shown relative to the functional TAR loops/bulges, which have
known functions in directly engaging both Tat and Cyclin T1 during transactivation (3436). The G-to-A substitution at RNA position 50 (starred) was selected for during
CH0694 follow up and alters a G-U base pair to a Watson-Crick A-U base pair. Thus,
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escape mutations spared functional sequences like the DIS or Tat binding bulge and were
predicted to maintain stem base-pairing.

Mass Spectrometry Detection of a 5’ Leader Peptide
We next attempted to directly detect 5’ leader DRiPs during in vitro infection.
Ternette and colleagues recently developed a mass spectrometry-based approach for the
identification of peptides loaded onto MHC complexes from cells infected with HIV-1
(37). We applied this technique HIV-1 IIIB-infected CD4+ T cells from a donor who
expressed HLA-A*01:01, HLA-A*02:01, HLA-B*07:02, HLA-B*08:01, HLA-C*07:01,
and HLA-C*07:02 to screen for 5’ leader peptides. Mass spectrometry analysis identified
four HIV-1 peptides: two overlapping 5’ leader peptides (LSLGALWLAREPTA and
LSLGALWL, Figure 2.13) and two overlapping Gag peptides (FLGKIWPSY and
FLGKIWPS, data not shown). To verify peak assignments, we synthesized
LSLGALWLAREPTA (5’L-LA14) and collected spectra on this synthetic standard
(Figure 2.13 bottom). Spectral matching between the infected-cell derived and synthetic
peptide suggested that peak assignment was correct. Consistent with the HLA of this
donor, both 5’L-LA14 and Gag-FS8 were predicted HLA-A*02:01 epitopes (NetMHC
predicted affinity <500nM) (38). 5’L-LA14 was encoded by RNA positions 23-64
(HXB2 477-518) in a distinct reading frame from 5’L-LL9, but also overlapping with the
TAR stem loop. Thus, mass spectrometry of in vitro infection can be readily used to
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detect 5’ leader DRiPs and facilitated the identification of a protein encoded by the first
~60 nts of the HIV-1 RNA.
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Section 2.4 – Conclusions
We recently demonstrated that the 5’ leader of SIVmac766 expresses an
immunogenic peptide called 5’L-KA9. In this study, we investigated whether diverse
HIV-1 strains expressed peptides from their 5’ leader sequences by correlating virus and
CTL evolution and developing a mass spectrometry-based approach for the identification
of MHC-loaded peptides. We provided evidence that at least six 5’ leader peptides are
expressed from four different subtype A, B, and C HIV-1 strains. Further, we reported
indirect evidence of 5’ leader peptide immune pressure and viral escape in 13/27 subjects.
Our findings, while rooted in the observation of immune escape variants that arise
during infection, have implications for models of lentivirus translation regulation. During
typical cap-dependent eukaryotic translation, the 43S preinitiation complex (comprised of
the 40S ribosome and ternary complex) binds to the 7-methylguanylate 5’ RNA cap and
scans 5’ to 3’ through the RNA leader sequence until it reaches a translation initiation
codon (39). Unlike most other eukaryotic 5’ “untranslated” regions, the HIV-1 5’ leader
is long (~336 nts in unspliced transcripts) and exhibits extensive secondary structure, two
features that impede cap-dependent ribosomal scanning in vitro (40-42). Whether HIV-1
translation initiation occurs via 5’ RNA cap-dependent (43) or cap-independent (44-47)
mechanisms is a matter of controversy within the field. The identification of 5’ leader
DRiPs in all three forward reading frames, however, suggests that cap-dependent
ribosomal scanning is a major contributor to HIV-1 translation initiation. Moreover, these
data provide direct evidence that ribosomes frequently initiate translation at one-off
AUGs while scanning through this region (48-51). Future studies will be needed to
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investigate the factors that impact translation initiation efficiency at these one-off AUGs,
including Kozak context and RNA secondary structure (52-54).
This study also expands upon our previous observation of 5’ leader DRiP
expression from SIVmac766. Here, we identified 5’ leader peptides encoded by all three
forward reading frames of Subtype A, B, and C viruses using multiple different methods.
Collectively, these findings suggest that 5’ leader DRiP expression is a general feature of
lentivirus infection. Further, mutations during escape from peptides derived from the
same 5’ leader ORF (5’L-ER10, 5’LIA9/5’L-RS9) often overlapped with one another and
have help identify candidate ORF start codons. We have recently proposed that lentiviral
5’ leader DRiPs offer an exciting new vaccine target and are in the process of testing 5’
leader peptide vaccine efficacy using the RhCMV68.1 platform (55-57). Translation of
these rhesus/SIV vaccines into an HIV-1 vaccine would require an understanding of
which 5’ leader ORFs are expressed and how often these ORFs are present in circulating
HIV-1s. This study sheds light on both of these considerations and, along with future
studies, will help define the rules underlying 5’ leader DRiP expression.
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Section 2.5 – Methods
Viral sequencing
Single genome amplification followed by direct amplicon sequencing (SGS) was
performed for 3’ half and 5’ half genomes as previously described (17-19,21).
CH0236 TF Inference
CH0236 sequences exhibited shared differences from the first time point consensus
within the rev1-tat1 overlap, changes that could confound TF inference. Despite these
shared changes, Poisson fitter analysis of both the 5’ and 3’ half genomes yielded a
Poisson distribution of Hamming Distances (p=0.515 for the 3’ half genome) and a starlike phylogeny. This pattern is consistent with one of two scenarios: recent infection by
multiple viruses that differed from one another at one nucleotide or infection by a single
TF virus that developed early escape mutations from an early autologous T cell response.
26 of 36 screening time point sequences harbored a single nucleotide difference when
compared to the most recent common ancestor (MRCA) of these sequences. Of these 26
changes, 26 were nonsynonymous in a Rev peptide (MRCA variant AVRTKILLY,
AY9). CH0236 PBMCs reacted with Rev-AY9 (data not shown), therefore, we concluded
that CH0236 was infected with a single TF virus, whose genetic identity was the
coalescent of the screening time point sequences. CH0694 and CH0236 were each
infected with a subtype C virus and R463F was infected with a subtype A virus.

Interferon-γ ELISPOT assays
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ELISPOT assays were performed as previously described (18,21). Short term cell lines
were generated as previously described (29)

HIV IIIB infection
Primary CD4+ T cells were isolated from Donor 97 (HLA type: A*01:01, A*02:01,
B*07:02, B*08:01, C*07:01, C*07:02) with the CD4+ T cell isolation kit (Miltenyi
Biotec) according to the manufacturer’s instructions. Cells were infected the lab-adapted
strain HIV-1 IIIB at an MOI of 0.1 then cultured in RPMI 1640 medium containing 20%
FBS and 20 U/ml IL-2 at 2 x 106/ml. Purification of MHC class I-bound peptides was
performed as described previously (Ternette et al 2015 EJI). Briefly, peptide-MHC class I
complexes were captured from cleared cell lysates by protein A resin coupled to W6/32
antibody. Complexes were washed with 50 mM Tris buffer pH 8.0 first with 150 mM
NaCl, then 450 mM NaCl then without salt. Complexes were then eluted in 10% acetic
acid, dried then loaded onto a 4.6 x 50 mm ProSwift RP-1S column (ThermoFisher
Scientific) and eluted using a 500 ul/min flow rate over 10 minutes from 2-35% Buffer B
(0.1% formic acid in acetonitrile) in Buffer A (0.1% formic acid in water) using an
Ultimate 3000 HPLC system (ThermoFisher Scientific).

LC-MS/MS
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Peptides were separated on an ekspert nanoLC 400 cHiPLC system (Eksigent)
supplemented with a 15 cm x 75 µm ChromXP C18-CL, 3 µm particle size by
application of a linear gradient from 8% buffer A to 35% buffer B at a flow rate of 300
nl/min for 60 min. Peptides were introduced by an electrospray source to a TripleTOF
5600 mass spectrometer (Sciex). Collision-induced dissociation was induced on the 30
most abundant ions per full MS scan using ramped collision energy and a unit quadrupole
isolation width of 0.7 amu. All fragmented precursor ions were actively excluded from
repeated selection for 15 s.

Raw data were analyzed using Peaks 7.0 software (Bioinformatics Solutions). Sequence
interpretation of MS/MS spectra were performed using a database containing all
annotated human SwissProt entries including translations of all six reading frames of the
sequenced HIV-1 IIIB genome in addition to translations of all known assigned HIV-1
protein coding regions (GenBank KJ925006). The false discovery rate was determined by
decoy database searches and a general cutoff below 5% was applied.
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Section 2.7 Figures and Tables
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Figure 2-1 Expression and immune recognition of the SIVmac766 5’ leader DRiP
KA9
A) Highlighter plot of HIV-1 half genome single genome sequences (SGSs). Horizontal
lines represent SGSs and tick marks denote mutations relative to the infecting stock
(SIVmac766). Green = mutation to A, Blue = C, Orange = G, Red = T, and Grey = gap.
B) Interferon-γ ELISPOT assays. Peptides and overlapping peptide pools used to
stimulate autologous PBMCs from macaque HD35 are indicated at the bottom. Plotted on
the y-axis are spot forming units/million PBMCs. All non-KA9 peptides encoded by the
5’ leader (p1+p2+p3 pool (-) KA9-like and m1+m2+m3 pool representing plus frame and
minus frame peptides, respectively) were not recognized by autologous PBMCs. KA9
and any KA9-containing peptide (e.g. CSYKGAGRYQTA) were recognized. The
selected variant at week 4 (see A) – KSAGRYQTA – was not recognized, demonstrating
complete viral escape. Positive controls include a Nef-(W9 peptide and
phytohemagglutinin (PHA). C) Ribosomal profiling of the SIVmac 766 5’ laeder. Shown
are the sites of ribosome protected fragments (x-axis) and the normalized number of
reads (y-axis) for experiments run under four conditions: red = lactimidomycin (LTM),
freezes initiating ribosomes; green = cyclohexamide, freezes initiating or elongating
ribosomes; blue = Pateamine A, freezes stalled ribosomes; and black = DMSO, drug
solvent control. Enriched LTM signal (red) indicates initiating ribosomes. Arrows
indicate two one-off AUG codons (ACGs) upstream of KA9 (shown below). Right:
Comparison of the wildtype and a start site mutant SIVmac766 in which the putative start
codons (ACG ACG, arrows) were replaced with two-off codons (UCG UCG). Panel
depicts zoom in on the ribosomal profile of the KA9 ORF for the wildtype (top) and start
site mutant (bottom) SIVmac766.
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Table 2-1 Prevalence of selection in longitudinal HIV-1 5’ leader sequence datasets
Subject

Subtype

R

U5/PBS

DIS/SD/Ψ

CH0236

C

x

x

CH0694

C

x

x

R463F

A

R880F

A

CH0325

C

x

CH1432

C

x

CH0256

C

CH0042

C

x

CH0164

C

x

CH0058

B

CH0198

C

CH0040

B

x

CAP210

C

x

CH0185

C

CH0107

C

CH0067

C

CH0077

B

CH0131

C

CH0159

C

CH0162

C

CH0264

C

CH0443

C

CH0569

C

CH0752

C

CH0470

B

CH0850

C

x

x
x

x

x
x
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First column indicates subject ID, second column subtype of HIV-1 infection, and
remainder represent regions of the 5’ leader. X indicates selection detected
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Figure 2-2 Viral load and CD4 counts for study subjects
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Table 2-2 HLA typing for study subjects
Participant Id

CH0236

CH0694

R463F

HLA-A allele 1

A*30:02/33

A*30:01

A*01:01

HLA-A allele 2

A*66:01/08

A*74:01/02/03/09

A*30:02

HLA-B allele 1

B*08:01/19N

B*42:02

B*15:03

HLA-B allele 2

B*18:01/17N

B*15:10

B*45:01

HLA-C allele 1

C*07:01/06/18/52/
57/116

C*17:01/02/03/04

C*02:10

HLA-C allele 2

C*17:01/02/03

C*03:04/06/09/19/23/24/26/32/37/44/46/48/54/
57/63/64/72/73/74/77/78

C*06:02
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Figure 2-3 Longitudinal whole genome SGS for subject CH0236
Depicted is a synonymous/nonsynonymous mutation highlighter plot. Horizontal lines represent sequences and tick marks denote
changes relative to the inferred transmitted founder virus (TF). Color code indicated at the bottom. Sequences are arranged
82

longitudinally from top to bottom with the trial time point indicated to the left. Alignment position (not HXB2) indicated at the
bottom. Genomic organization is shown at the bottom with relevant viral landmarks noted.
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Figure 2-4 Longitudinal whole genome SGS for subject CH0694

Figure 2-5 Longitudinal whole genome SGS for subject R463F
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Table 2-3Poisson fitter analysis
Subject

Star-like
phylogeny

p-value

Estimated Harmonic
95%
Days Post
mean
Confidence
Infection
(Days)
Interval

CH0236.5

Yes

0.895

17

CH0236.3

Yes

0.515

27

CH0694.5

Yes

0.390

9

CH0694.3

Yes

0.704

11

R463F

Yes

0.668

12

21

(18,24)

9

(6,12)

N/A

(6,18)

Sequences from the earliest time point were analyzed using Poisson Fitter v2. Sequences
used are indicated in the left column (.3 and .5 represent 3’ and 5’ half genomes,
repsecitvely). Nonsignificant p-value indicates a Poisson distribution of Hamming
Distances, consistent with random diversification from a single virus. Dates from
infection estimates are indicated. To obtain a single estimate for subjects with two date
estimates, the harmonic mean was taken. 95% confidence interval for the date of
infection estimates is indicated to the far right.
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Table 2-4 Sites under selection at week 24
CH0236
Region

5'L

Gag

Pol

Pol

Vif

Vif

Tat

Rev

Env

HXB2

680-719

1160-1177

2118-2130

3931-3965

5150

5318

5917

6022-6030

6705

#SGS

18/18

18/18

18/18

18/18

7/7

7/7

7/7

5/7

7/7

Region

Env

Env

Env

Env

Env

Env

Nef

Nef

Nef

HXB2

7113

7718-7723

7826

8587g

8657

8718

9110-9120

9308

9522

#SGS

7/7

7/7

5/7

7/7

5/7

6/7

6/7

5/7

5/7

Region

5'L

Gag

Tat

Env

Env

Env

Nef

HXB2

717-723

1242-1247

5947-5949

6618-6621

6658-6662

7397-7408

9347

#SGS

14/14

14/14

14/14

14/14

10/14

14/14

14/14

Region

5'L

5'L

Gag

Vpr

Tat

Tat/Rev

Vpu

Env

Env

HXB2

497-513

633

1804-1808

5789-5810

5933-5934

6019

6164-6172

6232-6246

6372

#SGS

29/30

30/30

30/30

77/82

52/52

52/52

48/52

52/52

46/52

Region

Env

Env

Env

Env

Env

Nef

Nef

Nef

U3

R

HXB2

7062-7063

7548-7555

7600-7601

8070

8728-8732

8867

9008

9049

9525-9538

9582-9591

#SGS

50/52

47/52

51/52

52/52

52/52

49/52

52/52

52/52

52/52

52/52

R463F

CH0694
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A sliding window of 45-nts (15 amino acids) was used to detect positive selection due to CTL escape (Goonetilleke, et al., 2009) in
sequences taken ~6 months post infection. Indicated is the region of the genome that the selection fell in, the HXB2 coordinates of the
span of nucleotide mutations, and the number of sequences of the total number with a mutation in that span.
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Figure 2-6 Immune recognition of a 5’ leader DRiP during CH0236 infection
A) Nucleotide highlighter plot of 5’ leader sequences taken from enrollment through
week 60. Color code same as Figure 2.1A. Landmarks of the 5’ leader are indicated at
the bottom. B) Interferon-γ ELISPOT data using pooled peptides from the six reading
frames of the 5’ leader (+1, +2, +3, -1, -2, -3), an autologous Nef peptide and PHA.
Reactivity above 50 SFUs was seen for the RF +1 pooled peptides. C) mapping of the 5’
leader epitope within RF+1 peptides to RR18 and the AR11 (left). Comparison of AR11
and ER10 at 4 peptide concentrations demonstrates that ER10 is the minimal epitope. D)
Nucleotide alignment translated into the ER10 RF demonstrating changes to the ER10
reading frame due to mutations observed in (A). Variants that were present in 3 or more
sequences were included. ER10 ORF spans from RNA position 178-312. One-off AUGs
highlighted in green, ER10 highlighted in yellow. Nucleotide mutations are highlighted
with the same color code as (A). Nonsynonymous changes are highlighted in red at the
amino acid level. E) IFN-γ ELISPOT assays of ER10 and variants observed over time
demonstrates complete abrogation of immune recognition.
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Figure 2-7 Kinetics of the autologous HIV-specific responses in CH0236
For the 19 autologous TF peptides recognized during the first year of infection (right), the percent of the total HIV-specific response is
plotted over time (calculated as #SFU/total SFUs for that timepoint).
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Figure 2-8 Immune recognition of the CH0694 5’ leader DRiP during infection
A) Nucleotide highlighter plot of longitudinal 5’ leader sequences, same as Figure 2.7A.
B) IFN-γ ELISPOT assays using pooled peptides from all 6 5’ leader reading frames
demonstrate reactivity toward RF+1 and RF+3 pools. C) Deconvolution of the RF+3
pool using week 16 cells reveals the responsible peptide, LL9. D) Mutations mapped to
the LL9 reading frame confer nonsynonymous changes or nonsense mutations. E)
Deconvolution of the RF+1 pool from (B) reveals immune recognition of two partially
overlapping peptides IA9 and RS9. F) Mutations mapped to the IA9/RS9 RF. Note –
included variants were present in 3 or more sequences. Multiple variants with mutation
at RNA positions 200+201 were present in the sequence dataset but did not appear 3 or
more times.
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Figure 2-9 Kinetics of the autologous HIV-specific responses in CH0694
For the 17 autologous TF peptides recognized during the first year of infection (right), the percent of the total HIV-specific response is
plotted over time (calculated as #SFU/total SFUs for that timepoint).
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Figure 2-10 Immune recognition of a 5’ leader DRiP during R463F infection
A) Nucleotide highlighter plot of longitudinal 5’ leader sequences, same as Figure 2.7A.
B) IFN-γ ELISPOT assays using pooled peptides from all 6 5’ leader reading frames
demonstrate reactivity toward RF+3 pool. C) Deconvolution of the RF+3 pool using
week 46 cells reveals the responsible peptide, AA10. D) Immune recognition of AA10,
but not variant AA10 observed at week 24 and beyond. E) Mutations mapped to the
AA10 RF. Note – because of limited sample availability, sequences from the original
near-full length sequencing were included here. The 5’ end of these sequences is 228 due
to primer placement.
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Figure 2-11 Location of 5’ leader mutations on the RNA secondary structure, DIS
ORF
3 subjects targeted peptides encoded by stem loop 1, also known as the DIS stem loop.
Shown is the RNA structure of this region as determined by SHAPE (Pollom, et al.,
2013) with the primer binding site (PBS), dimerization initiation site (DIS), and major
splice donor (SD1) indicated. The TF sequence from each of these three subjects was
substituted for the sequence used to determine the RNA folding. Watson-Crick base
pairing indicated with black bars, G-U base pairing in grey. Highlighted residues
demonstrated mutation during follow up (key bottom right). Carrots indicate insertions.
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Due to a 20 nt insertion, the R463F does not have homology to other viruses
immediately following the PBS. This region was therefore omitted.
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Figure 2-12 Location of the 5’ leader mutations on the RNA secondary structure, R
ORF
CH0694 targeted LL9, encoded by the TAR stem loop. Mutations are indicated as in
Figure 2.11. The asterisk indicates the selected variant, which converts a G-U base pair
to a Watson-Crick base pair.
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Figure 2-13 Comparison of experimenta LSLGALWLAREPTA fragmentation
spectra with synthetic peptide standard
For each spectrum, the detected mass over charge ratio [M+np]n (where n is the number
of charges), the PEAKS software peptide score and the measured precursor mass error
(in parts per million) are shown. The detected fragment ions in each spectrum are
displayed in the peptide sequence where b and y represent N- and C-terminal fragment
ions, respectively.
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Section 3.1 – Abstract
Introduction: HIV-1 5’ leader sequences exhibit multiple patterns of sequence evolution
in infected subjects over time. One pattern was recently shown to reflect escape from
CTL responses targeting 5’ leader peptides expressed from one-off AUG codons (e.g.
CUG). Here, we investigated another pattern within a motif called the primer
overextension sequence (POS). In vitro, HIV-1 reverse transcriptase (RT) periodically
overextends while copying the tRNA template by 4 nucleotides, incorporating TTGA into
the POS.
Results: We identified 11 subjects who were infected with single transmitted founder
(TF) viruses that did not match the canonical TTGA motif at 1 or 2 sites (nonoverextension variants, GCGA, CCGA, CAGA, or CTGA). Variants that matched the
TTGA motif (overextension variants) were subsequently observed in 10 of these subjects
and shown to increase in frequency over time. Interestingly, only 52% of M group
sequences matched the tRNA complement within the POS, leaving nearly half of HIV-1
strains with a one or two base pair mismatch relative to the tRNA. In an in vitro extension
assay, HIV-1 RT initiated polymerization despite a two-base pair mismatch within the
POS with 82% efficiency. We then identified 8 additional subjects whose TF viruses
matched the canonical TTGA motif. In one subject, the POS mutated away from TTGA
in concert with downstream cellular immune escape mutations in a newly identified 5’
leader open reading frame. In this case, different mutations in the POS deleted a one-off
AUG codon (bold, TTGA-> CGGA, CCGA, CAGA, TGGA, TCGA) and thus likely
abrogated the expression of the 5’ leader peptide.
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Conclusions: Sequence analysis of HIV-1 quasispecies in infected subjects over time
indicates that RT overextension incorporates a one-off AUG initiation codon within the
HIV-1 5’ leader. Cellular immune responses provide an antagonizing force that selects
for POS mutations that delete this one-off AUG. This finding provides new insight into
peptide expression from the HIV-1 5’ leader and may inform future interventions that
target this region of the genome.
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Section 3.2 – Introduction
The HIV-1 5’ leader is often cited as the most conserved region of the viral
genome (1-4). Nonetheless, we recently observed multiple patterns of non-random
mutation within the 5’ leaders of HIV-1 and SIVmac strains that were sequenced over
time (Chapter 2). One of these patterns – the toggling of mutations in a 27-62 nucleotide
span – resembled cytotoxic T lymphocyte (CTL) escape that is typically observed within
viral coding sequences (5, 6). This finding led to the hypothesis that the 5’ leader, a
designated “untranslated” region, expressed peptides that could serve as CTL antigens.
Using interferon-γ ELISPOT assays, we confirmed this hypothesis and demonstrated host
CTL recognition of multiple HIV-1 5’ leader encoded peptides (Chapter 2). Ribosomal
profiling studies revealed that translation of these peptides is initiated at one-off AUGlike start codons (one-off AUGs, e.g. CUG, Chapter 2, Warrier, R., Shaw, G.,
unpublished) (7-9). Thus, based on virus sequence evolution, we were able to identify a
novel class of HIV-1 Defective Ribosomal Products (DRiPs) that are expressed and
presented in the context of major histocompatibility complexes, and may serve as early
indicators of pathogen invasion (10-13).
In this study, we sought to identify other causes of 5’ leader mutation and to
correlate these to viral variants observed in vivo. Reverse transcriptase (RT)
overextension offered one such candidate (14). HIV-1 reverse transcription is primed by
an uncharged host tRNA(Lys,3), which anneals to the viral genome at the primer binding
site (PBS) (15, 16). During plus strand DNA synthesis, RT copies 18 nucleotides of this
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primer, replicating the PBS (14, 17-20). In vitro studies have suggested that RT pauses
elongation upon encountering the plus strand strong stop signal, a modified adenosine at
tRNA position 58 (m1A-58) (14, 17). This DNA intermediate must then undergo strand
transfer, anneal to the minus strand via the PBS, and prime RT extension. In vitro, RT
periodically overextends tRNA replication beyond the strong stop, yielding DNA
intermediates that harbor 4 or 21 additional nucleotides of the host tRNA sequence (21,
22). Muthuswami and colleagues demonstrated that the 4-nt overextended intermediate,
but not the 21-nt overextended one, could undergo strand transfer and prime RT
extension. Further, they found that >60% of HIV-1 strains matched the host tRNA
complement in the four nts adjacent to the PBS and named this region the primer
overextension sequence (POS, Figure 3.1). Based on their analysis, however, certain
HIV-1 strains would not match the tRNA complement at position 1 and/or 2 of the POS
(non-overextension variants). Strand transfer during reverse transcription of one of these
non-overextension variants would result in donor-acceptor strand mismatches (Figure
3.1), which may either mutate the virus (19, 20) or decrease RT extension efficiency (23,
24). To test for evidence of RT overextension in vivo, we applied a previously developed
experimental strategy based on single genome amplification of HIV-1 RNA and direct
amplicon sequencing (single genome sequencing, SGS) that can be used to infer the
genetic identity of the transmitted founder virus (25) and characterize molecular
pathways of virus evolution (26, 27). We applied this tool to evaluate POS sequence
evolution in subjects who had been longitudinally followed from acute infection.
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Section 3.3 – Results
We studied 5’ leader sequence evolution in a cohort of 19 subjects who were
followed starting from acute HIV-1 infection over 0.5-3 years. Single genome sequences
from 12 of these subjects have been previously published (26, 28). Poisson fitter analysis
of 5’ half genome sequences from the earliest time point demonstrated that each subjects
was infected with a single transmitted founder (TF) virus (data not shown) (25, 26, 28,
29). TF strains from 8 subjects matched the tRNA complement within the POS (TTGA,
overextension variants), whereas 11 did not (non-overextension variants).
To test for mutations consistent with overextension, we evaluated longitudinal
HIV-1 5’ leader sequences from the 11 subjects who were infected by non-overextension
variants. As shown in Table 1, these TF viruses demonstrated polymorphism at POS
positions 1 and 2: four viruses encoded CTGA, one CAGA, one CCGA, and five GCGA.
Sequences that encoded TTGA (overextension variants) were detected at subsequent time
points during infection in 10 out of 11 of these subjects. The prevalence of these
overextension variants increased over time: from 5.6% of sequences at enrollment to 25%
at week 60 in CH0236; from 11% at enrollment to 25% at week 85 in CH077; and from
10% at enrollment to 40% at week 24 in CH1432 (Figure 3.2). Thus, examination of
longitudinal HIV-1 5’ leader sequences revealed mutations consistent with RT
overextension in vivo.
To assess the diversity in POS motifs from globally circulating HIV-1 strains, we
obtained 979 HIV-1 group M sequences from the Los Alamos National Laboratory HIV
Database that included this region (HXB2 positions 635-659). Consistent with previous
103

findings (22), group M sequences showed conservation (>97% identity) throughout the
PBS and at positions 3 and 4 of the POS (Figure 3.3). Positions 1 and 2 of the POS,
however, were polymorphic. Only 512/979 sequences (52%) matched the host tRNA
throughout the POS (TTGA, Figure 3.4). 197/979 (20%) harbored a single base pair
mismatch and 234/979 (24%) harbored two base pair mismatches. These findings
demonstrate that polymorphism within the POS is primarily at positions 1 and 2.
To test if these mismatches between the tRNA and the POS affected RT extension
efficiency, we developed an in vitro extension assay. As outlined in Figure 3.5,
fluorescein-labeled primers 18-22 nucleotides in length were annealed to a 31-nt template
and incubated with purified HIV-1 reverse transcriptase. RT extension generated a 31-nt
product (upper band) that could be visualized on a gel and quantified using densitometry.
Three fluorescein-labeled primers were tested: an 18-nt primer representing the canonical
plus strand DNA intermediate (PBS); a 20-nt primer that contained two additional Ts at
its 3’ end (PBS+2); and a 22-nt primer that represented the overextended intermediate
(PBS+4, Figure 3.3). These primers were duplexed with one of two 31-nt templates: one
that was complementary to TTGA in the POS (match, overextension variants) and one
that was complementary to GCGA (mismatch, non-overextension variant). The PBS+2mismatch template duplex was included as a control, since a two-base pair mismatch at
the 3’ end should confer a decreased extension efficiency as long as conditions are not
saturating (23, 24). The PBS+4/mismatch duplex (lane 9) primed RT extension with 82%
extension efficiency as compared to duplexes with complete complementarity (lanes 2, 3,
5, and 8), which showed efficiencies ranging from 74% to 94% (Figure 3.5). Conversely,
104

a two base pair mismatch at the 3’ hydroxyl group decreased extension efficiency to 40%
(lane 6), suggesting that these conditions were not saturating. Along with the in vivo
evidence of RT overextension, these data suggest that RT can efficiently initiate
polymerization despite a two-base pair mismatch within the POS.
Based on the frequency of POS mutations observed in TF and group M viruses,
we hypothesized that mutations away from TTGA would also occur during infection. To
test this hypothesis, we examined sequence evolution in the 8 subjects infected with
overextension variants (TTGA). Evaluation of 5’ leader sequences in these subjects
revealed three patterns of evolution (Table 2). Three of the eight subjects retained TTGA
within the POS throughout the duration of follow up. Sequences from four of the five
remaining subjects demonstrated the same T-to-C transitions at position 1 of the POS
(HXB2 position 654, Figure 3.6). This CTGA variant is found in 13.5% of group M
sequences (Figure 3.6) and more commonly in non-primate lentiviruses (22). Finally,
viral sequences from subject CH0694 demonstrated substitutions at both positions 1 and
2 of the POS.
As described in Chapter 2, longitudinally collected 5’ leader sequences from
subject CH0694 accumulated non-random mutations during the course of his infection.
We confirmed that CH0694 cytotoxic T lymphocytes recognized two autologous 5’
leader peptides (IA9 and RS9, HXB2 positions 681-719) using interferon-γ ELISPOT
assays (Chapter 2). Translation of these peptides occurs at one-off AUG-like codons
(one-off AUGs), which can be mutated during virus escape from 5’ leader peptide
directed cellular immune responses (Chapter 2). Six one-off AUGs were observed
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throughout the IA9/RS9 reading frame (HXB2 positions 633, 648, 654, 681, 693, and
711). Four of these codons were upstream IA9/RS9, including a UUG that fell within the
POS (UUGA, green highlighting, Figure 3.7). The POS was mutated in 5 of 34 (14.7%)
day 695 variants and 11 of 27 (40.7%) day 1009 variants. All but one of these mutations
deleted the embedded one-off AUG. The only one-off AUG upstream of IA9 and RS9
that remained unaltered during immune escape fell within the invariant PBS (HXB2
position 648). We hypothesize that any mutations within this codon would rapidly revert
to match the PBS, similar to what has been observed with other PBS substitutions (19).
Thus, in the context of immune escape, one-off AUG codons within the POS can be
deleted.
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Section 3.4 – Conclusions
In this study, we evaluated intra-host sequence evolution of a 5’ leader motif
called the primer overextension sequence (POS) and correlated these observations with in
vitro functional studies of the reverse transcriptase. We observed mutations consistent
with RT overextension in subjects infected with non-overextension variants, providing
evidence that this process is not simply an in vitro phenomenon (Table 3.1). Moreover,
overextension variants gradually increased in population frequency (Figure 3.2),
suggesting that canonical plus strand intermediates are generated more commonly than
their overextended counterparts (ratio of ~3.3:1 in vitro) (14). Finally, we tested the effect
of a two base-pair mismatch within the POS on RT priming and observed little to no loss
in extension efficiency (Figure 3.5). These data indicate that RT overextension occurs in
vivo, even when the viral POS does not match the tRNA.
Next, we evaluated sequence evolution in subjects infected with overextension
variants and observed two different types of mutations. Viral sequences from four
subjects exhibited a T-to-C transition at the first position of the POS (Table 2 and Figure
3.6). This finding is consistent with the observation that RT favors transition over
transversion mutations (30) and that non-human lentiviruses often harbor CTGA within
the POS (14), but seemingly contradicts in vitro studies that have shown that m1A-58 is
most commonly decoded as an adenosine (17). Future biochemical studies of RT base
misincorporations while decoding modified bases may reconcile these differences.
Finally, we observed mutations that deleted a one-off AUG codon embedded in the POS
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(UUGA), suggesting that this change confers immune escape from a host T cell response
(Figure 3.7, Chapter 2).
Collectively, the data presented here suggest that RT overextension occurs in vivo
and incorporates a non-canonical translation initiation codon in the 5’ leader sequence.
This one-off AUG can initiate expression of a downstream peptide, which in the case of
subject CH0694 became the target of a CTL response. This link between RT
overextension and 5’ leader peptide expression is relevant to the development of HIV
vaccines targeting 5’ leader peptides. One concern for developing such a vaccine is that
HIV-1 strains can delete one-off AUG codons upstream of targeted peptides. The data
presented here indicates that certain mutated one-off AUGs can be restored by processes
like RT overextension. Interestingly, another one-off AUG is encoded by the PBS (Figure
3.7 AGG at position 648), which we hypothesize will not tolerate mutation (19, 20).
Thus, the findings presented add to 5’ leader biology and inform interventions that target
peptides encoded by this region of the genome.
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Section 3.5 – Methods
Single Genome Sequencing and Sequence Analysis. RNA extraction, complementary
DNA synthesis, and single genome amplification were performed as previously described
(29). Sequences were then aligned and analyzed using Geneious 7 software. Accession
numbers for previously published sequences are as follows (fill in): CH0040: , CH0058: ,
CH0077: , CH0131: , CH0159: , CH0198: , CH0256: , CH0185: , CH0470: , CH0162: ,
CH0164: , CH0042: .

M group sequences were obtained from the Los Alamos

Compendium and all sequences that did not include the 18 nucleotides of the PBS and 6
nucleotides downstream were excluded.

RT extension assay. In each condition, FAM-labeled primer was annealed to excess,
unlabeled template (1:1.5 ratio) by heating to 95C for 5 minutes and then slowly cooling
to room temperature. A master mix of 10 mM dNTPs, 1x RT reaction buffer, and 0.7
units of RT (ThermoFisher) was assembled and aliquoted into reaction tubes. Extension
reactions were initiated with 100nM of the primer:template duplexes, and were incubated
at 37C for 2 minutes. The reactions were quenched with formamide buffer with 10 mM
EDTA and were heated at 95C for 20 minutes. Samples were run on a preheated 20%
acrylamide-TBE/Urea gel at 50C for 30 minutes. Gels were imaged using a Typhoon
9410 (Amersham Biosciences). Intensities of unextended and extended primer bands
were calculated using Bio-Rad QuantityOne software after subtracting background
signal, and percent extensions were calculated by dividing the intensity of the extended
band by the total intensity of both unextended and extended bands.
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Section 3.8 – Figures and Tables

Figure 3-1 Graphical representation of reverse transcriptase overextension and
strand transfer
During minus strand synthesis (blue arrow), RNA in RNA:DNA heteroduplexes is
digested by reverse transcriptase’s RNase H activity (dotted gold line). Short RNA
sequences called the polypurine tracts are RNase-resistant and can prime plus strand
synthesis (green line). During canonical plus strand (green) synthesis, 18 nucleotides of
the host tRNA (pink) are reverse transcribed prior to strong stop, generating the plus
sense primer binding sequence (PBS, italics). During overextension, 4 additional
nucleotides—TTGA—are added to the nascent strand. After RNase digestion of the host
tRNA, plus strand DNA intermediates must undergo strand transfer and anneal to the
minus strand (bottom). Viruses can either match (overextension variant) or mismatch
(non-overextension variant) the four overextended tRNA encoded nucleotides.
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Table 3-1 Percent Overextension Variants
POS motif at
Transmission

Total Number of
Sequences

Percent
Overextension
Variants

CH0058

CTGA

36

8.3%

CH0131

CTGA

17

12%

CH0159

CTGA

16

6.3%

CH0164

CTGA

54

57%

CH0264

CAGA

136

2.9%

CH0752

CCGA

26

12%

CH0077

GCGA

36

11%

CH0185

GCGA

52

0.0%

CH0236

GCGA

367

8.2%

CH0470

GCGA

95

6.3%

CH1432

GCGA

20

25%

Subject ID

Percent single genome sequences that are overextension variants in longitudinally followed subjects
infected with a single transmitted founder virus. Transmitted founder (TF) viruses from 11 subjects did
not match TTGA (column 2). Between 16 and 367 sequences were available per subject (column 3). The
percent of these sequences that were TTGA variants, or overextension variants, is indicated in column 4.
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Figure 3-2 Accumulation of overextension variants in viral sequences from subjects
CH0236, CH0077, and CH1432
CH0236, CH0077, and CH1432 were infected with non-overextension variants (GCGA).
Depicted are nucleotide alignments of the PBS and POS variants observed over time,
organized by timepoint. The number of single genome sequences (SGS) that were TFmatched non-overextension variants (top), overextension-variants (second), or neither
(bottom) are indicated to the right. Sequences changes relative to the TF virus are
highlighted.
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Figure 3-3 Nucleotide conservation of the PBS and POS relative to the reverse
complement of tRNA(Lys,3)
Nucleotide frequency was plotted for each position with the color code indicated to the
right. The complement to the tRNA(Lys,3) is shown at the bottom. >99% conservation is
observed at sites throughout the PBS and >97% conservation is seen at positions 3 and 4
of the POS. Positions 1 and 2 of the POS exhibit polymorphism, with only 59.9% and
69.4% of sequences matching the tRNA complement, respectively.
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Figure 3-4 POS motifs present in published HIV-1 sequences
Relative abundance of each 4-nt motif is depicted in a pie chart. TTGA, the complement
of the tRNA(Lys,3) within the POS, is only observed in 52.3% of sequences.
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Figure 3-5 Effect of primer overextension 2-base pair mismatch on RT
polymerization efficiency
To test the effect of base pair mismatch during primer overextension of nonoverextension variants, we developed an in vitro RT extension assay. Primer template
pairs that were tested are represented graphically (top). PBS+4-template mismatch
duplexes (lane 9) recapitulate the mispairing that would be observed during primer
overextension of non-overextension variants. RT polymerization results in extension of
the primer (length: 18-22 nts) to 31 nts. No RT was added to lanes 1, 4, and 7.
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Table 3-2 Percent SGS mutated away from TTGA
Subject ID

POS motif at
Transmission

Total Number of
Sequences

Percent Mutated

CH0325

TTGA

35

0.0%

CH0042

TTGA

122

0.0%

CH0569

TTGA

57

0.0%

CH0198

TTGA

34

2.9%

CH0040

TTGA

55

5.5%

CH0850

TTGA

135

1.5%

CH0256

TTGA

109

13.8%

CH0694

TTGA

166

9.6%

Percent single genome sequences mutated away from TTGA in longitudinally
followed subjects infected with overextension variants
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Figure 3-6 T-to-C transition at POS position 1 in subjects infected with TTGA
variants
CH0040, CH0850, CH0256, and CH0198 were each infected with a TTGA POS variant.
During infection, CTGA variants were detected in all subjects.
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Figure 3-7 Mutation in the POS in concert with downstream CTL escape
Depicted is a longitudinal nucleotide/amino acid alignment in which identical sequences
from a given timepoint are collapsed. Changes relative to the inferred transmitted founder
variant (top) are highlighted both at the nucleotide and amino acid levels (key, right).
Timepoint and number of identical single genome sequences (SGS) are indicated to the
left. Numbering is relative to HXB2. Subject CH0694 T cells recognized two overlapping
5’ leader peptides, IA9 and RS9, as measured by interferon-γ ELISPOT assays (Chapter
2, position 681-719, yellow box). Translation initiation for such 5’ leader peptides occurs
at one-off AUG-like codons, e.g. CUG or UUG (all one-off AUGs highlighted in green
boxes). Changes within the POS at days 695 and 1009 mutated the embedded the one-off
AUG (TTGA).
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CHAPTER 4

STAGED INDUCTION OF HIV-1 GLYCAN-DEPENDENT
BROADLY NEUTRALIZING ANTIBODIES
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One sentence summary: Stages of V3-glycan neutralizing antibody development are
identified that explain the long duration required for their development.
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Section 4.1 – Abstract
A glycosylated site adjacent to the third variable loop (V3) of the HIV-1 envelope protein
is an epitope for broadly neutralizing antibodies (bnAbs) and a desirable vaccine target.
We identify here key events in the ontogeny of a V3-glycan bnAb. Two autologous
neutralizing antibody lineages selected for virus escape mutations and consequently
allowed initiation and affinity maturation of a V3-glycan bnAb lineage. The nucleotide
substitution required to initiate the bnAb linage occurred at a low probability site for
activation-induced cytidine deaminase activity. Cooperation of B-cell lineages and an
improbable mutation critical for bnAb activity define the necessary events leading to V3glycan bnAb development, explain why initiation of V3-glycan bnAbs is rare, and
suggest an immunization strategy for inducing V3-glycan bnAbs.
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Section 4.2 – Introduction
A vaccine to prevent HIV-1 infection should include immunogens that can induce
broadly neutralizing antibodies (bnAbs) (1, 2). Of the five major targets for bnAbs, the
glycan-rich apex of the HIV-1 envelope (Env) trimer and the base of the third variable
loop (V3) are distinguished by the potency of antibodies directed against them (3-8).
Although these antibodies have less breadth than those directed against the CD4 binding
site (CD4bs) or the gp41 membrane-proximal region (MPER), one current goal of
vaccine development is to elicit them in combination with other bnAb specificities to
achieve broad coverage of transmitted/founder (TF) viruses (1, 2).
Mapping the co-evolution of virus and antibody lineages over time informs vaccine
design by defining the succession of HIV-1 Env variants that evolve in vivo during the
course of bnAb development (9-11). Antibody lineages with overlapping specificities
can influence each other's affinity maturation by selecting for synergistic or antagonistic
escape mutations: an example of such "cooperating" lineages is provided by two CD4bsdirected bnAbs that we characterized previously (11, 12). Thus, cooperating antibody
lineages and their viral escape mutants allow identification of the specific Envs, among
the myriads present in the infected individual, that stimulate bnAb development and that
we wish to mimic in a vaccine.
Here we describe the co-evolution of an HIV-1 Env quasispecies and a memory B-cell
lineage of gp120 V3-glycan directed bnAbs. To follow virus evolution, we sequenced
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~1,200 HIV-1 env genes sampled over a 5 year period; to follow the antibody response,
we identified natural heavy- and light-chain pairs of six antibodies from a bnAb lineage,
designated DH270, and augmented this lineage by next generation sequencing (NGS).
Structural studies defined the position of the DH270 Fab on gp140. We also found two Bcell lineages (DH272 and DH475) with neutralization patterns that likely selected for
observed viral escape variants, which in turn stimulated the DH270 lineage to potent
neutralization breadth. We found a mutation in the DH270 heavy chain that occurred
early in affinity maturation at a disfavored activation-induced cytidine deaminase (AID)
site and that was necessary for bnAb lineage initiation. This improbable mutation can
explain the long period of antigenic stimulation needed for initial expansion of the bnAb
B-cell lineage in this individual.
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Section 4.3 – Results
Three N332 V3-glycan dependent antibody lineages
We studied an African individual (CH848) followed from the time of infection to
development of plasma neutralization breadth 3.5 years later. Reduced plasma
neutralization of N332A Env-mutated HIV-1 pseudoviruses and plasma neutralization
fingerprinting demonstrated the presence of N332-sensitive broadly neutralizing
antibodies (bnAbs) (table 4.S1)(13). To identify these antibodies, we screened memory B
cells from weeks 205, 232, and 234 post-infection using memory B cell cultures (14) and
antigen-specific sorting (15) and found three N332-sensitive lineages, designated DH270,
DH272 and DH475. Their genealogy was augmented by NGS of memory B-cell cDNA
from seven time points spanning week 11 to week 240 post-transmission.
DH270 antibodies were recovered from memory B cells at all three sampling times
(weeks 205, 232, and 234) and expansion of the clone did not occur until week 186 (Fig.
4.1A and table 4.S2). Clonal expansion was concurrent with development of plasma
neutralization breadth (table 4.S3), and members of the DH270 lineage also displayed
neutralization breadth (Fig. 4.1B). The most potent DH270 lineage bnAb (DH270.6) was
isolated using a fluorophore-labeled Man9 V3 glycopeptide that is a mimic of the V3glycan bnAb epitope (16). The lineage derived from a VH1~2*02 rearrangement that
produced a CDRH3 of 20 amino acid residues paired with a light chain encoded by
Vλ2~23 (fig. 4.S1). Neutralization assays and competition with V3-glycan bnAbs
PGT125 and PGT128 confirmed lineage N332-dependence (fig. 4.S2).
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The DH475 mAb was recovered from memory B cells at week 232 post-transmission
by antigen-specific sorting using the fluorophore-labeled Man9-V3 glycopeptide (16).
The earliest DH475 lineage VHDJH rearrangements were identified with NGS at week 64
post-transmission (fig. 4.S3A and table 4.S2). Its heavy chain came from VH3-23*01 (VH
mutation frequency = 10.1%) paired with a Vλ4-69*02 light chain (fig. 4.S3B).
The DH272 mAb came from cultured memory B cells obtained at week 205 posttransmission. DH272 lineage VHDJH rearrangements were detected as early as 19 weeks
post-transmission by NGS (fig 4.S3A and table 4.S2). The DH272 heavy chain used VH12*02, as did DH270, but it paired with a Vκ 2-30 light chain. Its CDRH3 was 17 amino
acids long; VH mutation was 14.9%. DH272, an IgA isotype, had a 6-nt deletion in
FRH3 (fig. 4.S3B).
For both DH272 and DH475 lineages, binding to CH848 TF Env gp120 depended on
the N332 potential N-linked glycosylation (PNG) site (fig. 4.S3C). DH272 binding also
depended on the N301 PNG site (fig. 4.S3C). Neither lineage had neutralization breadth
(fig. 4.S3D).

Evolution of the CH848 virus quasispecies
We sequenced 1,223 HIV-1 3'-half single-genomes from virus in plasma collected at 26
time points over 246 weeks. Analysis of sequences from the earliest plasma sample
indicated that CH848 had been infected with a single, subtype clade C founder virus, ~
17 (CI 14-19) days prior to screening (figs. 4.S4 and 4.S5). By week 51 post-infection,
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91% of the sequences had acquired an identical, 10-residue deletion in variable loop 1, a
region that includes the PGT128-proximal residues 133-135 and 141 (figs. 4.S6 and
4.S7).

Further changes accrued during the ensuing four years, including additional

insertions and deletions (indels) in V1, mutations in the

324

GDIR327 motif within the V3

loop, deletion or shifting of N-linked glycosylation sites at positions 301 and 322, and
mutations at PGT128-proximal positions in V1, V3, and C4, but none of these escape
variants went to fixation during 4.5 years of follow-up (figs. 4.S6-S9 and Supplemental
Text).

Ontogeny of DH270 lineage and acquisition of neutralization breadth
As with other V3-glycan bnAbs, viral neutralization clade specificity and intra-clade
breadth of DH270 depended primarily on the frequency of the N332 glycosylation site
within the relevant clade (Fig. 4.2A and Supplemental Text). Heterologous breadth and
potency of DH270 lineage antibodies increased with accumulation of VH mutations and
although DH270.UCA did not neutralize heterologous HIV-1, five amino-acid
substitutions in DH270.IA.4 (four in the heavy chain, one in the light chain) were
sufficient to initiate the bnAb lineage and confer heterologous neutralization (Fig.
4.2B,C).
The capacity of the early DH270 lineage members to neutralize heterologous viruses
correlated with the presence of short V1 loops (Fig. 4.2D). As the lineage evolved, it
gained capacity to neutralize viruses with longer V1 loops, although with reduced
potency (Fig. 4.2D and fig. 4.S10A-C). Neutralization of the same virus panel by V3
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glycan bnAbs 10-1074, PGT121 and PGT128 followed the same inverse correlation
between potency and V1 length (fig. 4.S10D-F).

Mutations in the DH270 antibody lineage that initiated heterologous neutralization
The likelihood of AID-generated somatic mutation has strong nucleotide-sequence
dependence (17, 18). Moreover, we have recently shown for CD4bs bnAbs that VH sites
of high intrinsic mutability indeed determine many sites of somatic hypermutation (11).
Like the VRC01-class CD4bs bnAbs, both DH270 and DH272 used VH1~2*02 although unlike the CD4bs bnAbs, V3 glycan bnAbs in general can use quite disparate
VH gene segments (3, 19-23) - and antibodies in both lineages have mutations at the same
amino acid positions that correspond to sites of intrinsic mutability that we identified in
the VH1-2*02 CD4bs bnAbs (11) (fig. 4.S11A).
Presence of the canonical VH1-2*02 allele in individual CH848 was confirmed by
genomic DNA sequencing (fig. 4.S11B). Four nucleotide changes in the DH270 UCA
conferred heterologous neutralization activity to the next intermediate antibody (IA4).
The G92A and G102A nucleotide mutations in DH270.IA4 (and in DH272) occurred at
"canonical" AID hotspots (DGYW); G164C (G164A for DH272) was in a "noncanonical" AID hotspot with a comparable level of mutability (17) (Fig. 4.3A). These
high probability mutations encoded amino acid substitutions G31D, M34I and S55T (N
for DH272). G31D and M31I became fixed in their respective lineages and S55T
eventually became prevalent also in the DH272 lineage (Fig. 4.3B). In contrast, the
G169C mutation in DH270.IA4, which encoded the G57R amino acid mutation, occurred
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at a site with a very low predicted level of mutability (17) and generated a canonical cold
spot (SYC) (Fig. 4.3A). Thus, once the rare G169C mutation had occurred, it had a high
probability of being maintained, and indeed it was present in 523/758 (68%) DH270
lineage VH sequences identified with NGS at week 186 post-transmission (Fig. 4.3C).
The G169C mutation in DH270.IA4 also disrupted an overlapping AID hotspot at the
adjacent guanine (170G).

While there were no mutations in DH272 at G169, the

overlapping AID hotspot at G170 did mutate, resulting in an initial G57V substitution
(Fig. 4.3A,C). Thus, both the DH270 bnAb and DH272 autologous neutralizing lineages
had mutations at Gly57, but the substitution in the DH270 lineage (G57R) was an
improbable event whereas the substitution (G57V) in the DH272 lineage was much more
likely. By week 111 post-transmission, all DH272 lineage VHDJH transcripts sequenced
by NGS harbored a mutation in the Gly57 codon, which resulted in the predominance of
an encoded aspartic acid (Fig. 4.3B). In contrast, only 6/758 (0.8%) DH270 lineage
transcripts isolated 186 weeks post-transmission had Val57 or Asp57; 48/758 (6.3%)
retained Gly57, while over two-thirds, 514/758 (67.8%), had G57R (Fig. 4.3B).
Reversion of Arg57 to Gly abrogated DH270.IA4 neutralization of autologous and
heterologous HIV-1 isolates (Fig. 4.3D). A DH270.IA4 R57V mutant, with the base
change that would have occurred had the overlapping AID hotspot been used, also greatly
reduced DH270.IA4 neutralization, confirming that Arg57, rather than the absence of
Gly57 was responsible for the acquired neutralizing activity (Fig. 4.3D). Finally, the
DH270.UCA G57R mutant neutralized both autologous and heterologous viruses,
confirming that G57R alone could confer neutralizing activity on the DH270 germline
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antibody (Fig. 4.3E). Thus, the improbable G169C mutation conferred reactivity against
autologous virus and initiated acquisition of heterologous neutralization breadth in the
DH270 lineage.

Autologous neutralizing antibody lineages that cooperated with DH270
Evidence for functional interaction among the three N332-dependent lineages came
from the respective neutralization profiles against a panel of 90 autologous viruses from
transmitted/founder to week 240 post-transmission (Fig. 4.4A). Both DH475 and DH272
neutralized autologous viruses isolated during the first year of infection that were
resistant to most DH270 lineage antibodies (only DH270.IA1 and DH270.4 neutralized
weakly) (Fig. 4.4A). DH475 neutralized viruses from week 15 through week 39 and
DH272 neutralized the CH848 transmitted/founder and all viruses isolated up to week 51,
when viruses that resisted DH475 and DH272 became strongly sensitive to all mature
antibodies in the DH270 lineage (Fig. 4.4A).
The identification of specific mutations implicated in the switch of virus sensitivity
was complicated by the high levels of mutations accumulated by virus Env over time (fig
4.S12). We identified virus signatures that defined the DH270.1 and DH272/DH475
immunotypes and introduced four of them, in various combinations, into the
DH272/DH475-sensitive virus that was closest in sequence to the DH270.1-sensitive
immunotype : a 10 amino-acid residue deletion in V1 (∆134-143); a D185N mutation in
V2, which introduced an N-linked glycosylation site; an N413Y mutation in V4, which
disrupted an N-linked glycosylation site; and a 2 amino-acid residue deletion (∆463-464)
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in V5 (see Supplemental text).

The large V1 deletion was critical for DH270.1

neutralization, with smaller contributions from the other changes; the V1 deletion
increased virus resistance to DH475 (3.5-fold increase). V1-loop-mediated resistance to
DH475 neutralization increased further when combined with the ∆463-464 V5 deletion
(5-fold increase) (Fig. 4.4B). The V1 loop of the transmitted/founder virus (34 residues)
was longer than the global mean of 28 (range 11 to 64) (24). As we found for
heterologous neutralization, DH270 lineage antibodies acquired the ability to neutralize
larger fractions of autologous viruses as maturation progressed by gaining activity for
viruses with longer V1 loops, although at the expense of lower potency (fig. 4.S13A-C).
This correlation was less clear for gp120 binding (fig. 4.S13D-F), however, suggesting
that the V1 loop-length dependency of V3 glycan bnAb neutralization has a
conformational component. Thus, DH475 cooperated with the DH270 bnAb lineage by
selecting viral escape mutants sensitive to bnAb lineage members.
For DH272, the variants that we made did not implicate a specific cooperating escape
mutation. The ∆134-143 (V1 deletion) mutated virus remained sensitive to DH272
neutralization; both combinations of the V1 deletion in our panel that were resistant to
DH272 and sensitive to DH270.1 included D185N, which on its own also caused DH272
resistance but did not lead to DH270.1 sensitivity (Fig. 4.4C). Thus, we have suggestive,
but not definitive, evidence that DH272 also participated in selecting escape mutants for
the DH270 bnAb lineage.

Structure of DH270 lineage members
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We determined crystal structures for the Fabs of DH270.UCA3, DH270.1, DH270.3,
DH270.5 and DH270.6, as well as for DH272 (Fig. 4.5; table 4.S6). The variable
domains of the DH270 antibodies all superposed well, indicating that antibody affinity
maturation modulated the antibody-antigen interface without substantially changing the
antibody conformation (Fig. 4.5A). Mutations accumulated at different positions for
DH270 lineage bnAbs in distinct branches (fig. 4.S14), possibly accounting for their
distinct neutralization properties. Because of uncertainty in the inferred sequence of the
germline precursor (fig. 4.S15A,B), we also determined the structure of DH270.UCA1,
which has a somewhat differently configured CDR H3 loop (fig. 4.S15C);
reconfiguration of this loop during early affinity maturation could account for the
observed increase (with respect to the UCA) in heterologous neutralization by several
intermediates. DH272 had a CDRH3 configured differently from that of DH270 lineage
members and a significantly longer CDRL1 (Fig. 4.5B), compatible with their distinct
neutralization profiles.
We also compared the structures of DH270 lineage members with those of other N332dependent bnAbs. All appear to have one long CDR loop that can extend through the
network of glycans on the surface of the gp120 subunit and contact the "shielded" protein
surface. The lateral surfaces of the Fab variable module can then interact with the
reconfigured or displaced glycans to either side. PGT128 has a long CDRH2 (Fig. 4.5C),
in which a 6-residue insertion is critical for neutralization breadth and potency (5, 19).
PGT124 has a shorter and differently configured CDR H2 loop, but a long CDR H3
instead (Fig. 4.5D) (25).
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Structure of the DH270 – HIV Env Complex
We determined a three-dimensional (3D) image reconstruction, from negative-stain
electron microscopy (EM), of the DH270.1 Fab bound with a gp140 trimer (92Br
SOSIP.664) (Fig. 4.5E,F and fig. 4.S15). The three DH270.1 Fabs project laterally, with
their axes nearly normal to the threefold of gp140, in a distinctly more "horizontal"
orientation than seen for PGT124 and PGT128 (Fig. 4.5G,H). This orientational
difference is consistent with differences between DH270 and PGT124 or PGT128 in the
lengths and configurations of their CDR loops, which required an alternative DH270
bnAb position when docked onto the surface of the Env trimer. We docked the BG505
SOSIP coordinates (26) and the Fab into the EM reconstruction, and further constrained
the latter by the observed effects of mutations in the gp140 surface (fig 4.S16, 4.S17).
Asp325 was essential for binding DH270.1; it is a potential partner for Arg57 on the Fab.
Mutating Asp321 led to a modest loss in affinity; R327A had no effect (fig. 4.S18).
These data further distinguish DH270 from PGT124 and PGT128. Mutating W101,
Y105, D107, D115, Y116 or W117 in DH270.1 individually to alanine substantially
reduced binding to the SOSIP trimer, as did pairwise mutation to alanines of S106 and
S109. The effects of these mutations illustrate the critical role of the CDRH3 loop in
binding with HIV-1 Env (fig. 4.S18).

137

Section 4.4 - Discussion
We can reconstruct from the data presented here a plausible series of events during the
development of a V3-glycan bnAb in a natural infection. The DH272 and DH475
lineages neutralized the autologous TF and early viruses, and the resulting escape viruses
were neutralized by the DH270 lineage. In particular, V1 deletions were necessary for
neutralization of all but the most mature DH270 lineage antibodies. DH475 (and possibly
DH272) escape variants stimulated DH270 affinity maturation, including both somatic
mutations at sites of intrinsic mutability (11) and a crucial, improbable mutation at an
AID coldspot within CDRH2 (G57R). The G57R mutation initiated expansion of the
DH270 bnAb lineage. The low probability of this heterologous neutralization-conferring
mutation and the complex lineage interactions that occurred likely explains why it took
4.5 years for the DH270 lineage to expand.
The CH848 viral population underwent a transition from a long V1 loop in the TF (34
residues) to short ones (16-17 residues) when escaping DH272/DH475 and facilitating
expansion of DH270, to restoration of longer V1 loops later in infection as resistance to
DH270 intermediates developed. Later DH270 antibodies adapted to viruses with longer
V1 loops, allowing recognition of a broader spectrum of Envs and enhancing breadth.
DH270.6 could neutralize heterologous viruses regardless of V1 loop length, but viruses
with long loops tended to be less sensitive to it. Association of long V1 loops with
reduced sensitivity was evident for three other V3 glycan bnAbs and may be a general
feature of this class.
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Since we cannot foresee the susceptibility to a particular bnAb lineage of each specific
potential transmitted/founder virus to which vaccine recipients will be exposed, it will be
important for a vaccine to induce bnAbs of multiple specificities to minimize
transmitted/founder virus escape (27, 28).
What stimulated the UCA of the DH270 bnAb lineage? The absence of detectable
binding to the CH848 TF envelope as gp120, gp140 or membrane bound trimers (Fig.
4.6) raises two possibilities. One is that the lineage arose at the end of year 1, either from
a primary response to viruses present at that time (e.g., with deletions in V1-V2) or from
subversion of an antibody lineage initially elicited by some other antigen. The other is
that some altered form of the CH848 TF envelope protein -- e.g. shed gp120, or a
fragment of it -- exposed the V3 loop and the N301 and N332 glycans in a way that
bound and stimulated the germline BCR, even though the native CH848 TF Env did not.
The latter explanation is in keeping with our observation that the DH270 lineage
intermediate antibodies did not recognize free glycans or cell surface membrane
expressed gp160 trimers (Fig. 4.6). It is also consistent with the observation that a
synthetic glycopeptide mimic of the V3-glycan bnAb gp120 epitope (Man9-V3
glycopeptide) binds to the DH270 UCA (fig 4.S19A). The synthesis, antigenicity and
ability of the Man9-V3 glycopeptide to reflect the native Env V3-glycan bnAb epitope are
described in detail by Alam and colleagues in the companion manuscript (16). DH270
UCA also bound to the aglycone form of the same peptide (fig. 4.S19B). Similarly, the
early intermediate antibodies (IA4, IA3, IA2) each bound to both the Man9V3
glycopeptide and its aglycone form, and their binding was stronger to the aglycone V3
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peptide than to the Man9-V3 glycopeptide (fig. 4.S19B).

Binding to the Man9-V3

glycopeptide was low (>10μM) (fig. 4.S19A). DH270.1 bound the glycopeptide with
higher affinity than did the aglycone (Kd,glycopeptide = 331nM), correlated with an increased
nucleotide mutation frequency (5.6%) (fig. 4.S19A,B). As mutations accumulated in the
DH270 bnAb lineage, binding of the Man9-V3 glycopeptide increased, culminating in a
Kd of 188 nM in the most potent bnAb, DH270.6, which does not bind the aglycone-V3
peptide (fig. 4.S19A,B). Thus, both the Man9-V3 glycopeptide and the aglycone-V3
peptide bound to the DH270.UCA and antibody binding was independent of glycans until
the DH270 lineage had acquired a nucleotide mutation frequency of ~6%. These
observations suggest that a denatured, fragmented or otherwise modified form of Env,
with the V3-glycan epitope optimally exposed for binding the DH270 UCA, initiated the
DH270 lineage (29, 30).
It will be important to define how often an improbable mutation such as G57R
determines the time it takes for a bnAb lineage in an HIV-1 infected individual to
develop, and how many of the accompanying mutations are necessary for potency or
breadth rather than being non-essential mutations at AID mutational hotspots (11, 31).
Mutations of the latter type might condition the outcome or modulate the impact of a key,
improbable mutation, without contributing directly to affinity. Should the occurrence of
an unlikely mutation be rate-limiting for breadth or potency in many other cases, a
program of rational immunogen design will need to focus on modified envelopes most
likely to select very strongly for improbable yet critical antibody nucleotide changes. A
search for an Env that might select for the critical G57R mutation in DH270 UCA or
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IA4-like antibodies yielded Env 10.17 from week 135 of infection (fig. 4.S20A,B), which
derived from the only autologous virus Env that DH270.IA4 could bind.
The following proposal for a strategy to induce V3 glycan bnAbs recreates the events
that led to bnAb induction in CH848: start by priming with a ligand that binds the bnAb
UCA, such as the synthetic glycopeptide mimic of the V3-glycan bnAb gp120 epitope,
then boost with an Env that can select G57R CDR H2 mutants, followed by Envs with
progressive V1 lengths (fig. 4.S20C). We hypothesize that more direct targeting of V3glycan UCAs and intermediate antibodies can accelerate the time of V3-glycan bnAb
development in the setting of vaccination.
Finally, our study describes a general strategy for the design of vaccine immunogens that
can select specific antibody mutations thereby directing antibody lineage maturation
pathways.

141

Section 4.5 – References
1. D. R. Burton, J. R. Mascola, Antibody responses to envelope glycoproteins in HIV-1
infection. Nature immunology 16, 571-576 (2015).
2. J. R. Mascola, B. F. Haynes, HIV-1 neutralizing antibodies: understanding nature's
pathways. Immunol. Rev. 254, 225-244 (2013).
3. L. M. Walker, M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J. P. Julien, S. K.
Wang, A. Ramos, P. Y. Chan-Hui, M. Moyle, J. L. Mitcham, P. W. Hammond, O. A.
Olsen, P. Phung, S. Fling, C. H. Wong, S. Phogat, T. Wrin, M. D. Simek, W. C. Koff,
I. A. Wilson, D. R. Burton, P. Poignard, Broad neutralization coverage of HIV by
multiple highly potent antibodies. Nature 477, 466-470 (2011).
4. L. M. Walker, S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T.
Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A.
Olsen, S. M. Frey, P. W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff,
P. Poignard, D. R. Burton, Broad and potent neutralizing antibodies from an African
donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
5. K. J. Doores, L. Kong, S. A. Krumm, K. M. Le, D. Sok, U. Laserson, F. Garces, P.
Poignard, I. A. Wilson, D. R. Burton, Two classes of broadly neutralizing antibodies
within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol.
89, 1105-1118 (2015).
6. D. Sok, K. J. Doores, B. Briney, K. M. Le, K. L. Saye-Francisco, A. Ramos, D. W.
Kulp, J. P. Julien, S. Menis, L. Wickramasinghe, M. S. Seaman, W. R. Schief, I. A.
142

Wilson, P. Poignard, D. R. Burton, Promiscuous glycan site recognition by antibodies
to the high-mannose patch of gp120 broadens neutralization of HIV. Science
translational medicine 6, 236ra263 (2014).
7. D. Sok, U. Laserson, J. Laserson, Y. Liu, F. Vigneault, J. P. Julien, B. Briney, A.
Ramos, K. F. Saye, K. Le, A. Mahan, S. Wang, M. Kardar, G. Yaari, L. M. Walker,
B. B. Simen, E. P. St John, P. Y. Chan-Hui, K. Swiderek, S. H. Kleinstein, G. Alter,
M. S. Seaman, A. K. Chakraborty, D. Koller, I. A. Wilson, G. M. Church, D. R.
Burton, P. Poignard, The effects of somatic hypermutation on neutralization and
binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS
pathogens 9, e1003754 (2013).
8. H. Mouquet, L. Scharf, Z. Euler, Y. Liu, C. Eden, J. F. Scheid, A. Halper-Stromberg,
P. N. Gnanapragasam, D. I. Spencer, M. S. Seaman, H. Schuitemaker, T. Feizi, M. C.
Nussenzweig, P. J. Bjorkman, Complex-type N-glycan recognition by potent broadly
neutralizing HIV antibodies. Proc. Natl. Acad. Sci. U. S. A. 109, E3268-3277 (2012).
9. B. F. Haynes, G. Kelsoe, S. C. Harrison, T. B. Kepler, B-cell-lineage immunogen
design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423433 (2012).
10. H. X. Liao, R. Lynch, T. Zhou, F. Gao, S. M. Alam, S. D. Boyd, A. Z. Fire, K. M.
Roskin, C. A. Schramm, Z. Zhang, J. Zhu, L. Shapiro, J. C. Mullikin, S. Gnanakaran,
P. Hraber, K. Wiehe, G. Kelsoe, G. Yang, S. M. Xia, D. C. Montefiori, R. Parks, K.
E. Lloyd, R. M. Scearce, K. A. Soderberg, M. Cohen, G. Kamanga, M. K. Louder, L.
M. Tran, Y. Chen, F. Cai, S. Chen, S. Moquin, X. Du, M. G. Joyce, S. Srivatsan, B.
143

Zhang, A. Zheng, G. M. Shaw, B. H. Hahn, T. B. Kepler, B. T. Korber, P. D. Kwong,
J. R. Mascola, B. F. Haynes, Co-evolution of a broadly neutralizing HIV-1 antibody
and founder virus. Nature 496, 469-476 (2013).
11. M. Bonsignori, T. Zhou, Z. Sheng, L. Chen, F. Gao, M. G. Joyce, G. Ozorowski, G.
Y. Chuang, C. A. Schramm, K. Wiehe, S. M. Alam, T. Bradley, M. A. Gladden, K.
K. Hwang, S. Iyengar, A. Kumar, X. Lu, K. Luo, M. C. Mangiapani, R. J. Parks, H.
Song, P. Acharya, R. T. Bailer, A. Cao, A. Druz, I. S. Georgiev, Y. D. Kwon, M. K.
Louder, B. Zhang, A. Zheng, B. J. Hill, R. Kong, C. Soto, J. C. Mullikin, D. C.
Douek, D. C. Montefiori, M. A. Moody, G. M. Shaw, B. H. Hahn, G. Kelsoe, P. T.
Hraber, B. T. Korber, S. D. Boyd, A. Z. Fire, T. B. Kepler, L. Shapiro, A. B. Ward, J.
R. Mascola, H. X. Liao, P. D. Kwong, B. F. Haynes, Maturation Pathway from
Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell 165, 449-463
(2016).
12. F. Gao, M. Bonsignori, H. X. Liao, A. Kumar, S. M. Xia, X. Lu, F. Cai, K. K.
Hwang, H. Song, T. Zhou, R. M. Lynch, S. M. Alam, M. A. Moody, G. Ferrari, M.
Berrong, G. Kelsoe, G. M. Shaw, B. H. Hahn, D. C. Montefiori, G. Kamanga, M. S.
Cohen, P. Hraber, P. D. Kwong, B. T. Korber, J. R. Mascola, T. B. Kepler, B. F.
Haynes, Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing
antibodies. Cell 158, 481-491 (2014).
13. M. Pancera, T. Zhou, A. Druz, I. S. Georgiev, C. Soto, J. Gorman, J. Huang, P.
Acharya, G. Y. Chuang, G. Ofek, G. B. Stewart-Jones, J. Stuckey, R. T. Bailer, M. G.
Joyce, M. K. Louder, N. Tumba, Y. Yang, B. Zhang, M. S. Cohen, B. F. Haynes, J.
144

R. Mascola, L. Morris, J. B. Munro, S. C. Blanchard, W. Mothes, M. Connors, P. D.
Kwong, Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature
514, 455-461 (2014).
14. M. Bonsignori, K. K. Hwang, X. Chen, C. Y. Tsao, L. Morris, E. Gray, D. J.
Marshall, J. A. Crump, S. H. Kapiga, N. E. Sam, F. Sinangil, M. Pancera, Y.
Yongping, B. Zhang, J. Zhu, P. D. Kwong, S. O'Dell, J. R. Mascola, L. Wu, G. J.
Nabel, S. Phogat, M. S. Seaman, J. F. Whitesides, M. A. Moody, G. Kelsoe, X. Yang,
J. Sodroski, G. M. Shaw, D. C. Montefiori, T. B. Kepler, G. D. Tomaras, S. M. Alam,
H. X. Liao, B. F. Haynes, Analysis of a clonal lineage of HIV-1 envelope V2/V3
conformational epitope-specific broadly neutralizing antibodies and their inferred
unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
15. E. S. Gray, M. A. Moody, C. K. Wibmer, X. Chen, D. Marshall, J. Amos, P. L.
Moore, A. Foulger, J. S. Yu, B. Lambson, S. Abdool Karim, J. Whitesides, G. D.
Tomaras, B. F. Haynes, L. Morris, H. X. Liao, Isolation of a monoclonal antibody
that targets the alpha-2 helix of gp120 and represents the initial autologous
neutralizing-antibody response in an HIV-1 subtype C-infected individual. J. Virol.
85, 7719-7729 (2011).
16. S. M. Alam, B. Aussedat, Y. Vohra, R. R. Meyerhoff, E. M. Cale, W. E. Walkowicz,
N. A. Radakovich, K. Anasti, L. Armand, R. J. Parks, M. G. Joyce, M. Pancera, A.
Druz, I. S. Georgiev, T. Von Holle, A. Eaton, M. K. Louder, R. T. Bailer, L. Morris,
S. A. Karim, M. Cohen, H. X. Liao, D. C. Montefiori, P. K. Park, A. FernándezTejada, K. Wiehe, T. B. Kepler, K. O. Saunders, J. Sodroski, P. D. Kwong, J. R.
145

Mascola, M. Bonsignori, M. A. Moody, S. Danishefsky, B. F.Haynes, Mimicry of an
HIV Broadly Neutralizing Antibody Epitope with a Synthetic Glycopeptide.
Submitted
17. G. Yaari, J. A. Vander Heiden, M. Uduman, D. Gadala-Maria, N. Gupta, J. N. Stern,
K. C. O'Connor, D. A. Hafler, U. Laserson, F. Vigneault, S. H. Kleinstein, Models of
somatic hypermutation targeting and substitution based on synonymous mutations
from high-throughput immunoglobulin sequencing data. Frontiers in immunology 4,
358 (2013).
18. We accessed the SF5 mutability model dataset at
http://clip.med.yale.edu/shm/download.php.
19. R. Pejchal, K. J. Doores, L. M. Walker, R. Khayat, P. S. Huang, S. K. Wang, R. L.
Stanfield, J. P. Julien, A. Ramos, M. Crispin, R. Depetris, U. Katpally, A. Marozsan,
A. Cupo, S. Maloveste, Y. Liu, R. McBride, Y. Ito, R. W. Sanders, C. Ogohara, J. C.
Paulson, T. Feizi, C. N. Scanlan, C. H. Wong, J. P. Moore, W. C. Olson, A. B. Ward,
P. Poignard, W. R. Schief, D. R. Burton, I. A. Wilson, A potent and broad
neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334,
1097-1103 (2011).
20. L. Kong, J. H. Lee, K. J. Doores, C. D. Murin, J. P. Julien, R. McBride, Y. Liu, A.
Marozsan, A. Cupo, P. J. Klasse, S. Hoffenberg, M. Caulfield, C. R. King, Y. Hua, K.
M. Le, R. Khayat, M. C. Deller, T. Clayton, H. Tien, T. Feizi, R. W. Sanders, J. C.
Paulson, J. P. Moore, R. L. Stanfield, D. R. Burton, A. B. Ward, I. A. Wilson,

146

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope
glycoprotein gp120. Nature structural & molecular biology 20, 796-803 (2013).
21. J. P. Julien, D. Sok, R. Khayat, J. H. Lee, K. J. Doores, L. M. Walker, A. Ramos, D.
C. Diwanji, R. Pejchal, A. Cupo, U. Katpally, R. S. Depetris, R. L. Stanfield, R.
McBride, A. J. Marozsan, J. C. Paulson, R. W. Sanders, J. P. Moore, D. R. Burton, P.
Poignard, A. B. Ward, I. A. Wilson, Broadly neutralizing antibody PGT121
allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base
and multiple surrounding glycans. PLoS pathogens 9, e1003342 (2013).
22. M. Pancera, Y. Yang, M. K. Louder, J. Gorman, G. Lu, J. S. McLellan, J. Stuckey, J.
Zhu, D. R. Burton, W. C. Koff, J. R. Mascola, P. D. Kwong, N332-Directed broadly
neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from
heavy-light chain complementation of function. PloS one 8, e55701 (2013).
23. P. L. Moore, E. S. Gray, C. K. Wibmer, J. N. Bhiman, M. Nonyane, D. J. Sheward, T.
Hermanus, S. Bajimaya, N. L. Tumba, M. R. Abrahams, B. E. Lambson, N.
Ranchobe, L. Ping, N. Ngandu, Q. Abdool Karim, S. S. Abdool Karim, R. I.
Swanstrom, M. S. Seaman, C. Williamson, L. Morris, Evolution of an HIV glycandependent broadly neutralizing antibody epitope through immune escape. Nat. Med.
18, 1688-1692 (2012).
24. LANL HIV Sequence Database
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html)

147

25. F. Garces, D. Sok, L. Kong, R. McBride, H. J. Kim, K. F. Saye-Francisco, J. P.
Julien, Y. Hua, A. Cupo, J. P. Moore, J. C. Paulson, A. B. Ward, D. R. Burton, I. A.
Wilson, Structural evolution of glycan recognition by a family of potent HIV
antibodies. Cell 159, 69-79 (2014).
26. J. H. Lee, N. de Val, D. Lyumkis, A. B. Ward, Model Building and Refinement of a
Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron
Microscopy. Structure 23, 1943-1951 (2015).
27. M. Bonsignori, D. C. Montefiori, X. Wu, X. Chen, K. K. Hwang, C. Y. Tsao, D. M.
Kozink, R. J. Parks, G. D. Tomaras, J. A. Crump, S. H. Kapiga, N. E. Sam, P. D.
Kwong, T. B. Kepler, H. X. Liao, J. R. Mascola, B. F. Haynes, Two distinct broadly
neutralizing antibody specificities of different clonal lineages in a single HIV-1infected donor: implications for vaccine design. J. Virol. 86, 4688-4692 (2012).
28. K. Wagh, T. Bhattacharya, C. Williamson, A. Robles, M. Bayne, J. Garrity, M. Rist,
C. Rademeyer, H. Yoon, A. Lapedes, H. Gao, K. Greene, M. K. Louder, R. Kong, S.
A. Karim, D. R. Burton, D. H. Barouch, M. C. Nussenzweig, J. R. Mascola, L.
Morris, D. C. Montefiori, B. Korber, M. S. Seaman, Optimal Combinations of
Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C
Infection. PLoS Pathog. 12:e1005520 (2016).
29. M. Kuraoka, A. G. Schmidt, T. Nojima, F. Feng, A. Watanabe, D. Kitamura, S. C.
Harrison, T. B. Kepler, G. Kelsoe, Complex Antigens Drive Permissive Clonal
Selection in Germinal Centers. Immunity 44, 542-552 (2016).

148

30. L. Hangartner, R. M. Zinkernagel, H. Hengartner, Antiviral antibody responses: the
two extremes of a wide spectrum. Nature reviews. Immunology 6, 231-243 (2006).
31. L. S. Yeap, J. K. Hwang, Z. Du, R. M. Meyers, F. L. Meng, A. Jakubauskaite, M.
Liu, V. Mani, D. Neuberg, T. B. Kepler, J. H. Wang, F. W. Alt, Sequence-Intrinsic
Mechanisms that Target AID Mutational Outcomes on Antibody Genes. Cell 163,
1124-1137 (2015).
32. G. D. Tomaras, N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, A. C.
Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, M. Cohen, J. Eron, C. B. Hicks, H. X.
Liao, S. G. Self, G. Landucci, D. N. Forthal, K. J. Weinhold, B. F. Keele, B. H. Hahn,
M. L. Greenberg, L. Morris, S. S. Karim, W. A. Blattner, D. C. Montefiori, G. M.
Shaw, A. S. Perelson, B. F. Haynes, Initial B-cell responses to transmitted human
immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG
antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial
viremia. J. Virol. 82, 12449-12463 (2008).
33. E. E. Giorgi, B. Funkhouser, G. Athreya, A. S. Perelson, B. T. Korber, T.
Bhattacharya, Estimating time since infection in early homogeneous HIV-1 samples
using a poisson model. BMC bioinformatics 11, 532 (2010).
34. G. M. Shaw, E. Hunter, HIV transmission. Cold Spring Harb Perspect Med 2,
a006965 (2012).
35. W. B. Williams, H. X. Liao, M. A. Moody, T. B. Kepler, S. M. Alam, F. Gao, K.
Wiehe, A. M. Trama, K. Jones, R. Zhang, H. Song, D. J. Marshall, J. F. Whitesides,
149

K. Sawatzki, A. Hua, P. Liu, M. Z. Tay, K. E. Seaton, X. Shen, A. Foulger, K. E.
Lloyd, R. Parks, J. Pollara, G. Ferrari, J. S. Yu, N. Vandergrift, D. C. Montefiori, M.
E. Sobieszczyk, S. Hammer, S. Karuna, P. Gilbert, D. Grove, N. Grunenberg, M. J.
McElrath, J. R. Mascola, R. A. Koup, L. Corey, G. J. Nabel, C. Morgan, G.
Churchyard, J. Maenza, M. Keefer, B. S. Graham, L. R. Baden, G. D. Tomaras, B. F.
Haynes, HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by
gp41-microbiota cross-reactive antibodies. Science 349, aab1253 (2015).
36. D. C. Montefiori, Evaluating neutralizing antibodies against HIV, SIV, and SHIV in
luciferase reporter gene assays. Curr Protoc Immunol Chapter 12, Unit 12 11 (2005).
37. H. X. Liao, M. C. Levesque, A. Nagel, A. Dixon, R. Zhang, E. Walter, R. Parks, J.
Whitesides, D. J. Marshall, K. K. Hwang, Y. Yang, X. Chen, F. Gao, S. Munshaw, T.
B. Kepler, T. Denny, M. A. Moody, B. F. Haynes, High-throughput isolation of
immunoglobulin genes from single human B cells and expression as monoclonal
antibodies. J. Virol. Methods 158, 171-179 (2009).
38. T. B. Kepler, Reconstructing a B-cell clonal lineage. I. Statistical inference of
unobserved ancestors. F1000Res 2, 103 (2013).
39. T. Magoc, S. L. Salzberg, FLASH: fast length adjustment of short reads to improve
genome assemblies. Bioinformatics 27, 2957-2963 (2011).
40. T. B. Kepler, S. Munshaw, K. Wiehe, R. Zhang, J. S. Yu, C. W. Woods, T. N. Denny,
G. D. Tomaras, S. M. Alam, M. A. Moody, G. Kelsoe, H. X. Liao, B. F. Haynes,

150

Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity
Maturation. Frontiers in immunology 5, 170 (2014).
41. L. G. Cowell, T. B. Kepler, The nucleotide-replacement spectrum under somatic
hypermutation exhibits microsequence dependence that is strand-symmetric and
distinct from that under germline mutation. J. Immunol. 164, 1971-1976 (2000).
42. A. G. Betz, C. Rada, R. Pannell, C. Milstein, M. S. Neuberger, Passenger transgenes
reveal intrinsic specificity of the antibody hypermutation mechanism: clustering,
polarity, and specific hot spots. Proc. Natl. Acad. Sci. U. S. A. 90, 2385-2388 (1993).
43. R. Bransteitter, P. Pham, P. Calabrese, M. F. Goodman, Biochemical analysis of
hypermutational targeting by wild type and mutant activation-induced cytidine
deaminase. J. Biol. Chem. 279, 51612-51621 (2004).
44. M. S. Seaman, H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T.
Coffey, L. Harris, B. Wood, M. G. Daniels, T. Bhattacharya, A. Lapedes, V. R.
Polonis, F. E. McCutchan, P. B. Gilbert, S. G. Self, B. T. Korber, D. C. Montefiori, J.
R. Mascola, Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for
assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
45. X. Wu, Z. Y. Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S.
D. Schmidt, L. Wu, L. Xu, N. S. Longo, K. McKee, S. O'Dell, M. K. Louder, D. L.
Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P. D. Kwong, M. Roederer,
R. T. Wyatt, G. J. Nabel, J. R. Mascola, Rational design of envelope identifies

151

broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861
(2010).
46. J. F. Salazar-Gonzalez, M. G. Salazar, B. F. Keele, G. H. Learn, E. E. Giorgi, H. Li, J.
M. Decker, S. Wang, J. Baalwa, M. H. Kraus, N. F. Parrish, K. S. Shaw, M. B.
Guffey, K. J. Bar, K. L. Davis, C. Ochsenbauer-Jambor, J. C. Kappes, M. S. Saag, M.
S. Cohen, J. Mulenga, C. A. Derdeyn, S. Allen, E. Hunter, M. Markowitz, P. Hraber,
A. S. Perelson, T. Bhattacharya, B. F. Haynes, B. T. Korber, B. H. Hahn, G. M.
Shaw, Genetic identity, biological phenotype, and evolutionary pathways of
transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206,
1273-1289 (2009).
47. B. F. Keele, E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G.
Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F.
Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A.
Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C.
Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C.
Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, G. M. Shaw,
Identification and characterization of transmitted and early founder virus envelopes in
primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105, 7552-7557 (2008).
48. M. A. Larkin, G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H.
McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J.
Gibson, D. G. Higgins, Clustal W and Clustal X version 2.0. Bioinformatics 23,
2947-2948 (2007).
152

49. M. Kearse, R. Moir, A. Wilson, S. Stones-Havas, M. Cheung, S. Sturrock, S. Buxton,
A. Cooper, S. Markowitz, C. Duran, T. Thierer, B. Ashton, P. Meintjes, A.
Drummond, Geneious Basic: an integrated and extendable desktop software platform
for the organization and analysis of sequence data. Bioinformatics 28, 1647-1649
(2012).
50. P. Hraber, B. Korber, K. Wagh, E. E. Giorgi, T. Bhattacharya, S. Gnanakaran, A. S.
Lapedes, G. H. Learn, E. F. Kreider, Y. Li, G. M. Shaw, B. H. Hahn, D. C.
Montefiori, S. M. Alam, M. Bonsignori, M. A. Moody, H. X. Liao, F. Gao, B. F.
Haynes, Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution
(LASSIE) Identifies Immune-Selected HIV Variants. Viruses 7, 5443-5475 (2015).
51. J. L. Kirchherr, X. Lu, W. Kasongo, V. Chalwe, L. Mwananyanda, R. M. Musonda,
S. M. Xia, R. M. Scearce, H. X. Liao, D. C. Montefiori, B. F. Haynes, F. Gao, High
throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods
143, 104-111 (2007).
52. E. P. Go, A. Herschhorn, C. Gu, L. Castillo-Menendez, S. Zhang, Y. Mao, H. Chen,
H. Ding, J. K. Wakefield, D. Hua, H. X. Liao, J. C. Kappes, J. Sodroski, H. Desaire,
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1
Envelope Glycoprotein Trimers and Soluble gp140. J. Virol. 89, 8245-8257 (2015).
53. D. Fera, A. G. Schmidt, B. F. Haynes, F. Gao, H. X. Liao, T. B. Kepler, S. C.
Harrison, Affinity maturation in an HIV broadly neutralizing B-cell lineage through
reorientation of variable domains. Proc. Natl. Acad. Sci. U. S. A. 111, 10275-10280
(2014).
153

54. Z. Otwinowski, W. Minor, Processing of X-ray diffraction data collected in
oscillation mode. Macromolecular Crystallography, Pt A 276, 307-326 (1997).
55. A. J. McCoy, Solving structures of protein complexes by molecular replacement with
Phaser. Acta crystallographica. Section D, Biological crystallography 63, 32-41
(2007).
56. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J.
Read, Phaser crystallographic software. Journal of applied crystallography 40, 658674 (2007).
57. T. Zhou, J. Zhu, X. Wu, S. Moquin, B. Zhang, P. Acharya, I. S. Georgiev, H. R.
Altae-Tran, G. Y. Chuang, M. G. Joyce, Y. D. Kwon, N. S. Longo, M. K. Louder, T.
Luongo, K. McKee, C. A. Schramm, J. Skinner, Y. Yang, Z. Yang, Z. Zhang, A.
Zheng, M. Bonsignori, B. F. Haynes, J. F. Scheid, M. C. Nussenzweig, M. Simek, D.
R. Burton, W. C. Koff, J. C. Mullikin, M. Connors, L. Shapiro, G. J. Nabel, J. R.
Mascola, P. D. Kwong, Multidonor analysis reveals structural elements, genetic
determinants, and maturation pathway for HIV-1 neutralization by VRC01-class
antibodies. Immunity 39, 245-258 (2013).
58. P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J.
Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W.
Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C.
Terwilliger, P. H. Zwart, PHENIX: a comprehensive Python-based system for
macromolecular structure solution. Acta crystallographica. Section D, Biological
crystallography 66, 213-221 (2010).
154

59. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. Acta
crystallographica. Section D, Biological crystallography 60, 2126-2132 (2004).
60. K. Cowtan, P. Main, Miscellaneous algorithms for density modification. Acta
crystallographica. Section D, Biological crystallography 54, 487-493 (1998).
61. I. W. Davis, A. Leaver-Fay, V. B. Chen, J. N. Block, G. J. Kapral, X. Wang, L. W.
Murray, W. B. Arendall, 3rd, J. Snoeyink, J. S. Richardson, D. C. Richardson,
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.
Nucleic Acids Res 35, W375-383 (2007).
62. R. W. Sanders, R. Derking, A. Cupo, J. P. Julien, A. Yasmeen, N. de Val, H. J. Kim,
C. Blattner, A. T. de la Pena, J. Korzun, M. Golabek, K. de Los Reyes, T. J. Ketas,
M. J. van Gils, C. R. King, I. A. Wilson, A. B. Ward, P. J. Klasse, J. P. Moore, A
next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140,
expresses multiple epitopes for broadly neutralizing but not non-neutralizing
antibodies. PLoS pathogens 9, e1003618 (2013).
63. G. Tang, L. Peng, P. R. Baldwin, D. S. Mann, W. Jiang, I. Rees, S. J. Ludtke,
EMAN2: an extensible image processing suite for electron microscopy. J. Struct.
Biol. 157, 38-46 (2007).
64. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C.
Meng, T. E. Ferrin, UCSF Chimera--a visualization system for exploratory research
and analysis. J Comput Chem 25, 1605-1612 (2004).

155

65. S. Guindon, J. F. Dufayard, V. Lefort, M. Anisimova, W. Hordijk, O. Gascuel, New
algorithms and methods to estimate maximum-likelihood phylogenies: assessing the
performance of PhyML 3.0. Systematic biology 59, 307-321 (2010).
66. D. C. Nickle, L. Heath, M. A. Jensen, P. B. Gilbert, J. I. Mullins, S. L. Kosakovsky
Pond, HIV-specific probabilistic models of protein evolution. PloS one 2, e503
(2007).
67. E. Paradis, J. Claude, K. Strimmer, APE: Analyses of Phylogenetics and Evolution in
R language. Bioinformatics 20, 289-290 (2004).
68. S. Gnanakaran, M. G. Daniels, T. Bhattacharya, A. S. Lapedes, A. Sethi, M. Li, H.
Tang, K. Greene, H. Gao, B. F. Haynes, M. S. Cohen, G. M. Shaw, M. S. Seaman, A.
Kumar, F. Gao, D. C. Montefiori, B. Korber, Genetic signatures in the envelope
glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS
computational biology 6, e1000955 (2010).
69. T. Bhattacharya, M. Daniels, D. Heckerman, B. Foley, N. Frahm, C. Kadie, J.
Carlson, K. Yusim, B. McMahon, B. Gaschen, S. Mallal, J. I. Mullins, D. C. Nickle,
J. Herbeck, C. Rousseau, G. H. Learn, T. Miura, C. Brander, B. Walker, B. Korber,
Founder effects in the assessment of HIV polymorphisms and HLA allele
associations. Science 315, 1583-1586 (2007).
70. G. E. Crooks, G. Hon, J. M. Chandonia, S. E. Brenner, WebLogo: a sequence logo
generator. Genome Res. 14, 1188-1190 (2004).

156

71. F. Garces, J. H. Lee, N. de Val, A. T. de la Pena, L. Kong, C. Puchades, Y. Hua, R. L.
Stanfield, D. R. Burton, J. P. Moore, R. W. Sanders, A. B. Ward, I. A. Wilson,
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on
Accommodating or Avoiding Glycans. Immunity 43, 1053-1063 (2015).
72. A. C. Siepel, A. L. Halpern, C. Macken, B. T. Korber, A computer program designed
to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res.
Hum. Retroviruses 11, 1413-1416 (1995).
73. L. Kong, A. Torrents de la Pena, M. C. Deller, F. Garces, K. Sliepen, Y. Hua, R. L.
Stanfield, R. W. Sanders, I. A. Wilson, Complete epitopes for vaccine design derived
from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195
in complex with an HIV-1 Env trimer. Acta crystallographica. Section D, Biological
crystallography 71, 2099-2108 (2015).
74. P. Wang, W. Kim. L. B. Pickens, X. Gao, Y. Tang, Heterologous expression and
manipulation of three tetracycline biosynthetic pathways. Angew Chem Int Ed Engl
51, 11136-11140 (2012).

157

Section 4.6 – Acknowledgements and Contributions
Acknowledgments. The authors thank Michael C. Mangiapani, Robert J. Parks, Callie
Vivian, Krissey Lloyd, Daniel M. Kozink, Florence Perrin, Abby J. Cooper, Andrew
Foulger, Giovanna Hernandez, Jamie Pritchett, Sabrina Arora, Thaddeus Gurley,
Lawrence Armand, Amanda Martelli and Amy Wang for technical assistance; John
Whitesides and Dawn Marshall of the DHVI Flow Core Facility for single-cell sorting;
Gerald H. Learn, Timothy G. Decker, and Yingying Li for single genome sequencing and
analysis; the beam line staff at Advanced Photon Source 24-ID-C and 24-ID-E for
support during data collection and Harvard Medical School electron microscopy staff for
training and assistance with EM data; and Kelly Soderberg for project management. The
authors thank the HIV Vaccine Trials Network (HVTN) for the continued use of NGS
pre-vaccination samples from the HVTN082 and HVTN204 trials (31). E.F.K is
supported by a Ruth L. Kirschstein National Research Service Award F30 AI112426.
D.F. is supported by a F32 fellowship (1F32AI116355-01) from the NIH. R.R.M is
supported by a Medical Scientist Training Program (MSTP) training grant
T32GM007171 and by a Ruth L. Kirschstein National Research Service Award F30AI122982-0, NIAID. K.O.S. is supported by a NIAID extramural project grant R01AI120801. This work was funded by UM-1- AI100645 from NIH, NIAID, Division of
AIDS, Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discover
(CHAVI-ID) to B.F.H.

158

Authors contributions. MB, BHH, SCH, BTK and BFH coordinated and designed the
study, evaluated data, wrote and edited manuscript and figures; MB, EFK, DF, TB, KW,
KOS, AM, BTK and SCH produced figures; MB directed memory B cell cultures and
functional primary screenings, performed intrinsic mutability analysis; EFK isolated
viruses, analyzed data, wrote and edited text; DF, BWP, CAJ and SCH performed
structural analyses; RRM isolated antibodies; TB performed site directed mutagenesis
and NGS, and analyzed data; KW analyzed NGS and antibody clonal lineage data, wrote
and edited text; BA, WEW and SJD synthesized the Man9V3 glycopeptide; SMA
analyzed data and provided intellectual contributions; KKH, MAG and AM executed
memory B cell cultures and functional screenings of purified antibodies, tabulated and
graphed data; KOS performed glycan analyses, made figures; RZ, AT, KOS, HXL
produced plasmids, expressed recombinant proteins; AK, FG produced pseudoviruses
and made pseudovirus mutants; SMX, MC, MKL, KMK, RTB, JRM and DCM
performed neutralization studies; GK, JRM, GMS provided guidance and intellectual
contributions; WBW provided VH1-2*02 NGS data from HIV-1-negative individuals;
LM directed neutralization and epitope mapping studies on CH848 plasma; JK produced
transfected cell lines; KW, PTH, BTK performed virus signature analyses, analyzed virus
evolution, GK and MSC supervised clinical sites; TBK performed and supported
computational analysis of antibody clones; MAM directed antigen-specific memory B
cell sorting; BFH conceived the study, evaluated all data, wrote and edited the paper. All
authors approved the paper.

159

Section 4.7 – Figures

Figure 4-1 DH270 lineage with time of appearance and neutralization by selected
members
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(A) Phylogenetic relationship of 6 mAbs and 93 NGS VHDJH sequence reads in the
DH270 clonal lineage. External nodes (filled circles) represent VHDJH nucleotide
sequences of either antibodies retrieved from cultured and sorted memory B cells
(labeled) or a curated dataset of NGS VHDJH rearrangement reads (unlabeled). Coloring
is by time of isolation. Samples from week 11, 19, 64, 111, 160, 186 and 240 were tested
and time-points from which no NGS reads within the lineage were retrieved are reported
in table 4.S2. The majority of NGS sequence reads were retrieved from week 186 (green
circles; see details in Methods). Internal nodes (open circles) represent inferred ancestral
intermediate sequences. Units for branch-length estimates are nucleotide substitution per
site. (B) Neutralization dendrograms display single mAb neutralization of a genetically
diverse panel of 207 HIV-1 isolates. Coloring is by IC50.
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Figure 4-2 Heterologous breadth in the DH270 lineage
(A) Neutralizing activity of DH270.1, DH270.5 and DH270.6 bnAbs (columns) for 207
tier 2 heterologous viruses (rows). Coloring is by neutralization IC50 (μg/ml). Keys to the
presence of an N332 N-glycosylation site and clade are on the left. (B). Heterologous
neutralization of all DH270 lineage antibodies for a 24-virus panel. Coloring follows
panel A. See fig. S1 (C) Co-variation between VH mutation frequencies (x-axis),
neutralization breadth (y-axis, top panels) and potency (y-axis, bottom panels) of
individual antibodies against N332 viruses from the larger (left) and smaller (right)
pseudovirus panels. (D) Correlation between viral V1 loop length and DH270 lineage
antibody neutralization. Top panel: neutralization of 17 viruses (with N332 and sensitive
to at least one DH270 lineage antibody) by selected DH270 lineage antibodies from UCA
to mature bnAbs (x-axis). Viruses are identified by their respective V1 loop lengths (yaxis); for each virus, neutralization sensitivity is indicated by a clear circle and resistance
by a solid circle. The p-value is a Wilcoxon rank sum comparison of V1 length
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distributions between sensitive and resistant viruses. Bottom panel: regression lines (IC50
for neutralization vs. V1 loop length) for DH270.1 and DH270.6, with a p-value based on
Kendall’s tau.
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Figure 4-3 A single disfavored mutation early during DH270 clonal development
conferred neutralizing acitivty to the V3 glycan bnAb DH270 precursor antibodies
(A) Nucleotide (nt) alignment of DH270.IA4 and DH272 to VH1-2*02 sequence at the
four VH positions that mutated from DH270.UCA to DH270.IA4. The codons that encode
the amino acids (aa) affected by the mutations are highlighted in yellow. AID hotspots
are indicated by red and orange lines (canonical and non-canonical, respectively); AID
cold spots by blue lines (solid: canonical; dotted: non-canonical)(16). At position 169,
DH270.IA4 retained positional conformity with DH272 but not identity conformity (red
164

boxes). (B) Sequence logo plot of aa mutated from germline (top) in NGS reads of the
DH270 (middle) and DH272 (bottom) lineages at weeks 186 and 111 post-transmission,
respectively. Red asterisks indicate aa mutated in DH270.IA4. The black arrow indicates
lack of identity conformity between the two lineages at aa position 57. (C) Sequence logo
plot of nucleotide mutations (position 165-173) in the DH270 and DH272 lineages at
weeks 186 and 111 post-transmission, respectively. The arrow indicates position 169. (D)
Effect of reversion mutations on DH270.IA4 neutralization. Coloring is by IC50. (E)
Effect of G57R mutation on DH270.UCA autologous (top) and heterologous (bottom)
neutralizing activity.
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Figure 4-4 Cooperation among DH270, DH272, and DH475 N332 dependent V3
glycan nAb lineages
(A) Neutralizing activity of DH272, DH475 and DH270 lineage antibodies against
CH848 viruses. Heat map summarizing neutralization data from 90 pseudoviruses (row)
and 10 DH270 lineage mAbs plus DH272 and DH475 (columns). Neutralization potency
(IC50) is shown in different colors from white (>50μg/ml) to dark red (<0.5μg/ml), as
indicated in the bar. The Env pseudoviruses were generated for the CH848 TF virus and
variants from weeks 11 to 246 post-transmission and were assayed in the TZM-bl cellbased neutralization assay. For each pseudovirus, presence of an N332 PNG site and V1
loop length are indicated on the right. (B, C) Susceptibility to DH270.1 and to (B)
DH475 or (C) DH272 of autologous viruses bearing selected immunotype-specific
mutations. Heat map as described for panel A.
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Figure 4-5 Fab crystal structures and 3D reconstruction of DH270.1 bound with the
92BR SOSIP.664 trimer
Superposition of backbone ribbon diagrams for DH270 lineage members: UCA1 (gray),
DH270.1 (green), and DH270.6 (blue): (A) alone, (B) with the DH272 cooperating
antibody (red), (C) with PGT 128 (magenta), and (D) with PGT124 (orange). Major
differences in CDR regions are indicated by an arrow. (E) Top and (F) side views of a fit
of the DH270.1 Fab (green) and the BG505 SOSIP trimer (gray) into a map obtained
from negative-stain EM. (G) Top and (H) side views of the BG505 trimer (PDB ID:
5ACO)(25) (gray, with V12 and V3 loops highlighted in red and blue, respectively)
bound with PGT122 (PDB ID: 4NCO)(20) (orange), PGT128 (PDB ID: 3TYG)(18)
(magenta), PGT135 (PDB ID: 4JM2)(19) (cyan) and DH270.1 (green), superposed to
illustrate the different positions of the several Fabs on gp140. The arrows indicate the
direction of the principal axis of each of the bnAb Fabs; the color of each arrow is the
color that represents the corresponding bnAb.
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Figure 4-6 DH270 lineage antibody binding to autologous CH0848 Env components
(A) DH270 lineage antibodies (column) were tested by ELISA for binding to 120 CH848
autologous gp120 Env glycoproteins (rows) isolated from time of infection (CH848.TF)
to 245 weeks post-infection. CH848 Envs are grouped based on week of isolation. Day of
isolation is also shown. The first column indicates presence or absence of an N-linked
glycosylation site in position 332 with the color scheme of Figure 1. The second column
shows V1 length of each CH848 virus. The binding of individual antibodies is expressed
as log area under the curve (LogAUC) in a heat map color-coded as indicated. (B) Left:
Binding to CH848.TF mutants with disrupted N301 and/or N332 glycan sites. Results are
expressed as LogAUC. Middle: Binding to CH848 Env trimer expressed on the cell
surface of CHO cells. Results are expressed as maximum percentage of binding and are
representative of duplicate experiments. DH270 antibodies are shown in red. Palivizumab
is the negative control (gray area). Right: Binding to free glycans measured on a
microarray. Results are the average of background-subtracted triplicate measurements
and are expressed in RU.
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Section 4.8 – Materials and Methods

Study Design
The CH848 donor, from which the DH270, DH272 and DH475 antibody lineages
were isolated, is an African male enrolled in the CHAVI001 acute HIV-1 infection cohort
(32) and followed for 5 years, after which he started antiretroviral therapy. During this
time viral load ranged from 8,927 to 442,749 copies/ml (median = 61,064 copies/ml), and
CD4 counts ranged from 288 to 624 cells/mm3 (median = 350 cells/ mm3). The time of
infection was estimated by analyzing the sequence diversity in the first available sample
using the Poisson Fitter tool (33) as described in (10). Results were consistent with a
single founder virus establishing the infection (34).
MAbs DH270.1 and DH270.3 were isolated from cultured memory B cells isolated
205 weeks post-transmission (14).

DH270.6 and DH475 mAbs were isolated from

Man9-V3 glycopeptide-specific memory B cells collected 232 and 234 weeks posttransmission, respectively, using direct sorting. DH270.2, DH270.4 and DH270.5 mAbs
were isolated from memory B cells collected 232 weeks post-transmission that bound to
Consensus C gp120 Env but not to Consensus C N332A gp120 Env using direct sorting
Experimental methods
Detailed description of experimental methods is provided in Supplementary Materials
and
Flow Cytometry, Memory B Cell Cultures and mAb Isolation
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A total of 30,700 memory B cells from individual CH848 were isolated from PBMC
collected 205 weeks post-transmission using magnetic-activated cell sorting as described
in (14). Memory B cells were cultured at limiting dilution at a calculated concentration of
2 cells/well for 2 weeks as described in (11) using irradiated CD40L L cells (7,500 cGy)
as feeder cells at a concentration of 5,000 cells/well; culture medium was refreshed 7
days after plating. Cell culture supernatants were screened for neutralization of
autologous CH848.TF virus using the tzm-bl neutralization assay (14, 36) and for binding
to CH848.TF gp120 Env, CH848.TF gp140 Env, Consensus C gp120 Env and consensus
C N332A gp120 Env. Concurrently, cells from each culture were transferred in RNAlater
(Qiagen) and stored at -80°C until functional assays were completed.
MAbs DH270.1 and DH270.3 were isolated from cultures that bound to CH848.TF
gp120 Env and Consensus C gp120 but did not bind to C N332A gp120 Env. DH272 was
isolated from a culture that neutralized 99% CH848.TF virus infectivity. DH272
dependency to N332-linked glycans was first detected on the transiently transfected
recombinant antibody tested at higher concentration and confirmed in the purified
recombinant antibody (37). From the stored RNAlater samples, mRNA of cells from
these cultures was extracted and retrotranscribed as previously described (14).
DH270.6 and DH475 mAbs were isolated from Man9-V3 glycopeptide-specific
memory B cells collected 232 and 234 weeks post-transmission, respectively, using direct
sorting (16). Briefly, biotinylated Man9–V3 peptides were tetramerized via streptavidin
that was conjugated with either AlexaFluor 647 (AF647; ThermoScientific) or Brilliant
Violet 421 (BV421) (Biolegend) dyes. Peptide tetramer quality following conjugation
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was assessed by flow cytometry to a panel of well-characterized HIV-1 V3 glycan
antibodies (PGT128, and 2G12) and linear V3 antibodies (F39F) attached to polymer
beads. PBMCs from donor CH848 were stained with LIVE/DEAD Fixable Aqua Stain
(ThermoScientific), anti-human IgM (FITC), CD3 (PE-Cy5), CD235a (PE-Cy5), CD19
(APC-Cy7), and CD27 (PE-Cy7) (BD Biosciences); anti-human antibodies against IgD
(PE); anti-human antibodies against CD10 (ECD), CD38 (APC-AF700), CD19 (APCCy7), CD16 (BV570), CD14 (BV605) (Biolegend); and Man9GlcNac2 V3 tetramer in
both AF647 and BV421. PBMCs that were Aqua Stain -, CD14-, CD16-, CD3-, CD235a, positive for CD19+, and negative for surface IgD were defined as memory B cells; these
cells were then gated for Man9–V3+ positivity in both AF647 and BV421, and were
single-cell sorted using a BD FACS Aria II into 96-well plates containing 20 μl of
reverse transcriptase buffer (RT).
DH270.2, DH270.4 and DH270.5 mAbs were isolated from memory B cells collected
232 weeks post-transmission that bound to Consensus C gp120 Env but not to Consensus
C N332A gp120 Env using direct sorting. Reagents were made using biotinylated
Consensus C gp120 Env and Consensus C N332A gp120 Env by reaction with
streptavidin that was conjugated with either AlexaFluor 647 (AF647; ThermoScientific)
or Brilliant Violet 421 (BV421) (Biolegend) dyes, respectively. Env tetramer quality
following conjugation was assessed by flow cytometry to a panel of well-characterized
HIV-1 V3 glycan antibodies (PGT128, and 2G12) and linear V3 antibodies (F39F)
attached to polymer beads. PBMCs were stained as outlined for DH475 and DH270.6,
however these cells were then gated for Consensus C gp120 positivity and Consensus C
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N332A gp120 negativity in AF647 and BV421, respectively, and were single cell sorted
and processed as outlined for DH475 and DH270.6.
For all antibodies, cDNA synthesis, PCR amplification, sequencing and V(D)J
rearrangement analysis were conducted as previously described (11). Reported mutation
frequency is calculated as frequency of nucleotide mutations in the V gene region of
antibody sequence. CDRH3 lengths reported are defined as the number of residues after
the invariant Cys in FR3 and before the invariant Trp in FR4.

Antibody production
Immunoglobulin genes of mAbs DH270.1 through DH270.6, DH272 and DH475 were
amplified from RNA from isolated cells, expression cassettes made, and mAbs expressed
as described (12). Inference of unmutated common ancestor (UCA) and intermediate
antibodies DH270.IA1 through DH270.IA4 was conducted using methods previously
described (38).
Heavy chain plasmids were co-transfected with appropriate light chain plasmids at an
equal ratio in Expi 293 cells using ExpiFectamine 293 transfection reagents (Thermo
Fisher Scientific) according to the manufacturer’s protocols. We used the enhancer
provided with the kit, transfected cultures were incubated at 37°C 8% CO2 for 2-6 days,
harvested, concentrated and incubated overnight with Protein A beads at 4°C on a
rotating shaker before loading the bead mixture in columns for purification; following
PBS/NaCl wash, eluate was neutralized with trizma hydrochloride and antibody
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concentration was determined by Nanodrop. Purified antibodies were tested in SDS-Page
Coomassie and western blots, and stored at 4°C.

Next-generation sequencing
PBMC-extracted RNA from weeks 11, 19, 64, 111, 160, 186, and 240 post-infection
were used to generate cDNA amplicons for next-generation sequencing (Illumina Miseq)
as described previously (35). Briefly, RNA isolated from PBMCs was separated into two
equal aliquots before cDNA production; cDNA amplification and NGS were performed
on both aliquots as independent samples (denoted A and B). Reverse transcription (RT)
was carried out using human IgG, IgA, IgM, Igκ and Igλ primers as previously described
(37). After cDNA synthesis, IgG isotype IGHV1 and IGHV3 genes were amplified
separately from weeks 11, 19, 64, 111, 160, and 186. IGHV1-IGHV6 genes were
amplified at week 240. A second PCR step was performed to add Nextera index
sequencing adapters (Illumina) and libraries were purified by gel extraction (Qiagen) and
quantified by quantitative PCR using the KAPA SYBR FAST qPCR kit (KAPA
Biosystems). Each replicate library was sequencing using the Illumina Miseq V3 2x
300bp kit.
NGS reads were computationally processed and analyzed as previously described (35).
Briefly, forward and reverse reads were merged with FLASH (39) with average read
length and fragment read length parameters set to 450 and 300, respectively. Reads were
quality filtered using FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) for sequences
with a minimum of 50 percent of bases with a Phred quality score of 20 or greater
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(corresponding to 99% base call accuracy). Primer sequences were discarded and only
unique nucleotide sequences were retained. To mitigate errors introduced during PCR
amplification, reads detected in sample A and B with identical nucleotide VHDJH
rearrangement sequences were delineated as replicated sequences. The total number of
unique reads per sample and total number of replicated sequences (“Overlap”) across
samples for each time point is listed in table S2. We used replicated sequences to define
presence of antibody clonal lineages at any time-point.
We identified clonally-related sequences to DH270, DH272 and DH475 from the
longitudinal NGS datasets by the following procedure. First, the CDR H3 of the probeidentified clonal parent sequence was BLASTed (E-value cutoff =.01) against the pooled
sample A and B sequence sets at each timepoint to get a candidate set of putative clonal
members (“candidate set”). Next we identified replicated sequences across samples A and
B in the candidate set. We then performed a clonal kinship test with the Cloanalyst
software

package

(http://www.bu.edu/computationalimmunology/research/software/)

(38, 40) as previously described (35) on replicated sequences.

Clonally-related

sequences within Sample A and B (including non-replicated sequences) were identified
by performing the same clonal kinship test with Cloanalyst on the candidate set prior to
identifying replicated sequences.
Clonal lineage reconstruction was performed on the NGS replicated sequences and
probe-identified sequences of each clone using the Cloanalyst software package.

A

maximum of 100 sequences were used as input for inferring phylogenetic trees of clonal
lineages. Clonal sequence sets were sub-sampled down to 100 sequences by collapsing to
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one sequence within a 2 or 9 base pair difference radius for the DH272 and DH270
clones, respectively.
The pre-vaccination NGS samples that were analyzed in fig. S11A were obtained from
HIV-1 uninfected participants of the HVTN082 and HVTN204 trials as previously
described (35).

Sequence Analysis of Antibody Clonal Lineages
Unmutated common ancestors (UCA) and ancestral intermediate sequences were
computationally inferred with the Cloanalyst software package (38). Cloanalyst uses
Bayesian inference methods to infer the full unmutated V(D)J rearrangement thereby
including a predicted unmutated CDR3 sequence. For lineage reconstructions when only
cultured or sorted sequences were used as input, the heavy and light chain pairing
relationship was retained during the inference of ancestral sequences. UCA inferences
were performed each time a new member of the DH270 clonal lineage was
experimentally isolated and thus several versions of the DH270 UCA were produced and
tested. UCA1 and UCA3 were used for structural determination. UCA4 (referred to as
DH270.UCA throughout the text), which was inferred using the most observed DH270
clonal members and had the lowest uncertainty of UCAs inferred (as quantified by the
sum of the error probability over all base positions in the sequence), was used for binding
and neutralization studies. Subsequently, the DH270 UCA was also re-inferred when
NGS data became available. We applied a bootstrapping procedure to infer the UCA
with the NGS data included, resampling clonal lineage trees 10 times with 100 input
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NGS sequences each. The UCA4 amino acid sequence was recapitulated by 7 out of 10
UCA inferences of the resampled NGS trees confirming support for UCA4.
Each inference of V(D)J calls is associated with a probability. The probability of the
DH270 lineage to use the VH1-2 family gene was 99.99% and that of using allele 02
(VH1-2*02) was 98.26%. Therefore, there was a 0.01% probability that the family was
incorrectly identified and a 1.74% probability that the allele was incorrectly identified.
Therefore, we sequenced genomic DNA of individual CH848. As previously reported,
positional conformity is defined as sharing a mutation at the same position in the V gene
segment and identity conformity as sharing the same amino acid substitution at the same
position (11).
We refer to the widely established AID hot and cold spots (respectively WRCY and
SRY and their reverse-complements) as “canonical” and to other hot and cold spots
defined by Yaari et al. as “non-canonical” (17, 41-43).
Sequencing of germline variable region from genomic DNA.
Genomic DNA was isolated from donor CH848 from PBMCs 3 weeks after infection
(QIAmp DNA Blood mini kit; Qiagen). IGVH1-2 and IGVL2-23 sequences were
amplified using 2 independent primer sets by PCR. To ensure amplification of nonrearranged variable sequences, both primer sets reverse primers aligned to sequences
present in the non-coding genomic DNA downstream the V-recombination site. The
forward primer for set 1 resided in the IGVH1-2 and IGVL2-23 leader sequences and
upstream of the leader in set 2. The PCR fragments were cloned into a pcDNA2.1
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(TOPO-TA kit; Life technologies) and transformed into bacteria for sequencing of
individual

colonies.

tcctcttcttggtggcagcag;

The

following

VH1-2_2_S:

primers

were

used:

tacagatctgtcctgtgccct;

VH1-2_1_S:

VH1-2_1_tmAS:

ttctcagccccagcacagctg; VH1-2_2_TmAS: gggtggcagagtgagactctgtcaca; VL2-23_2_S:
agaggagcccaggatgctgat;

VL2-23_1_S:

actctcctcactcaggacaca;

VL2-23_1_AS:

tctcaaggccgcgctgcagca; VL2-23_2_AS: agctgtccctgtcctggatgg.
We identified two variants of VH1-2*02: the canonical sequence and a variant that
encoded a VH that differed by 9 amino acids. Of these 9 amino acids, only 1 was shared
among DH270 antibodies whereas 8 amino acids were not represented in DH270 lineage
antibodies (fig. S11B). The VH1-2*02 variant isolated from genomic DNA did not
encode an arginine at position 57. We conclude that between the two variants of VH12*02 identified from genomic DNA from this individual, the DH270 lineage is likely
derived from the canonical VH1-2*02 sequence.
Direct binding ELISA
Direct-binding ELISAs were performed as described (11). Briefly, 384-well plates
were blocked for 1 h at room temperature (RT) or overnight at 4°C (both procedures were
previously validated); primary purified antibodies were tested at a starting concentrations
of 100μg/ml, serially three-fold diluted and incubated for 1 h at RT; HRP-conjugated
human IgG antibody was added at optimized concentration of 1:30,000 in assay diluent
for 1 hour and developed using TMB substrate; plates were read at 450 nm in a
SpectraMax 384 PLUS reader (Molecular Devices, Sunnyvale, CA); results are reported
as logarithm area under the curve (LogAUC) unless otherwise noted.
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For biotinylated avi-tagged antigens, plates were coated with streptavidin (2µg/ml);
blocked plates were stored at -20°C until used and biotinylated avi-tagged antigens were
added at 2 µg/ml for 30 minutes at RT.
Competition ELISAs were performed using 10µl of primary purified monoclonal
antibody, starting at 100µg/ml and diluted in a two-fold concentration, incubated for 1 h
at RT. Ten µl of biotinylated target Mab was added at the EC50 determined by a direct
binding of biotinylated-Mab for one hour at RT. After background subtractions, percent
inhibition was calculated as follows: 100-(test Ab triplicate mean/no inhibition control
mean)*100.

Assessment of virus neutralization
Antibody and plasma neutralization was measured in TZM-bl cell-based assays
performed as described previously (36). Neutralization breadth of DH270.1, DH270.5
and DH270.6 was assessed using the 384-well plate declination of the assay using an
updated panel of 207 geographically and genetically diverse Env-pseudoviruses
representing the major circulating genetic subtypes and recombinant forms as described
(44, 45). The data were calculated as a reduction in luminescence units compared with
control wells, and reported as IC50 in µg/ml (36).

Single genome sequencing and pseudovirus production
3’ half genome single genome sequencing of HIV-1 from longitudinally collected
plasma was performed as previously described (46, 47). Sequence alignment was
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performed using ClustalW (version 2.11) (48) and was adjusted manually using Geneious
8 (version 8.1.6)(49). Env amino acid sequences were then aligned and evaluated for sites
under selection using code derived from the Longitudinal Antigenic Sequences and Sites
from Intra-host Evolution (LASSIE) tool (50). Using both LASSIE-based analysis and
visual inspection, 100 representative env genes were selected for pseudovirus production.
CMV promoter-ligated env genes were prepared and used to generate pseudotyped
viruses as previously described (51).

Generation of cell surface-expressed CH848 Env trimer CHO cell line.
The membrane-anchored CH848 TF Env trimer was expressed in CHO-S cells.
Briefly, the CH848 env sequence was codon-optimized and cloned into an HIV-1-based
lentiviral vector. A heterologous signal sequence from CD5 was inserted replacing that of
the HIV-1 Env. The proteolytic cleavage site between gp120 and gp41 was altered,
substituting serine residues for Arg508 and Arg511, the tyrosine at residues 712 was
changed to alanine (Y712A), and the cytoplasmic tail was truncated by replacing the
Lys808 codon with a sequence encoding (Gly)3 (His)6 followed immediately by a TAA
stop codon. This env-containing sequences was inserted into the vector immediately
downstream of the tetracycline (tet)-responsive element (TRE), and upstream of an
internal ribosome entry site (IRES) and a contiguous puromycin (puro)-T2A-EGFP open
reading frame (generating K4831), as described previously for the JRFL and CH505
Envs (52).
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CHO-S cells (Invitrogen) modified to constitutively express the reverse tet
transactivator (rtTA) were transduced with packaged vesicular stomatitis virus (VSV) G
glycoprotein-pseudotyped CH848 Env expression vector. Transduced cells were
incubated in culture medium containing 1μg/ml of doxycycline (dox) and selected for 7
days in medium supplemented with 25 µg/ml of puromycin, generating the Env
expressor-population cell line termed D831. From D831, a stable, high-expressor clonal
cell line was derived, termed D835. The integrity of the recombinant env sequence in the
clonal cell lines was confirmed by direct (without cloning) sequence analysis of PCR
amplicons.

Cell surface-expressed trimeric CH848 Env binding.
D831 Selected TRE2.CH848.JF-8.IRS6A Chinese Hamster Ovary Cells were cultured
in DMEM/F-12 supplemented with HEPES and L-glutamine (Thermo Fischer,
Cat#11330057) 10% heat inactivated fetal bovine serum [FBS] (Thermo Fischer,
Cat#10082147) and 1% Penicillin-Streptomycin (Thermo Fischer, Cat#15140163) and
harvested when 70-80% confluent by trypsinization. A total 75,000 viable cells/well were
transferred in 24-well tissue culture plates. After a 24-to-30-hour incubation at 37°C/5%
CO2 in humidified atmosphere, CH848 Envs expression was induced with 1µg/mL
doxycycline (Sigma-Aldrich, Cat#D9891) treatment for 16-20 hours. Cells were then
washed in Stain buffer [PBS/2% FBS] and incubated at 4°C for 30 minutes. Stain buffer
was removed from cells and 0.2ml/well of DH270 lineage antibodies, palivizumab
(negative control) or PGT128 (positive control) were added at optimal concentration of
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5µg/mL for 30 minutes at 4°C. After a 2X wash, cells were stained with 40 ul of APCconjugated mouse anti-Human IgG (BD Pharmigen, Cat#562025) per well (final volume
0.2 ml/well) for 30 minutes at 4°C. Unstained cells were used as further negative control.
Cells were washed 3X and gently dissociated with 0.3ml/well PBS/5mM EDTA for 30
minutes at 4°C, transferred into 5mL Polystyrene Round-Bottom Tubes (Falcon,
Cat#352054), fixed with 0.1mL of BD Cytofix/Cytoperm Fixation solution (BD
Biosciences, Cat#554722) and kept on ice until analyzed using a BD LSRFortessa Cell
Analyzer. Live cells were gated through Forward/Side Scatter exclusion, and then gated
upon GFP+ and APC.

Oligomannose Arrays.
Oligomannose arrays were printed with glycans at 100, 33, and 10 μM (Z Biotech).
Arrays were blocked for 1h in Hydrazide glycan blocking buffer. Monoclonal antibodies
were diluted to 50 μg/mL in Hydrazide Glycan Assay Buffer, incubated on an individual
subarray for 1 h, and then washed 5 times PBS supplemented with 0.05% tween-20
(PBS-T). Subarrays that received biotinylated Concanavalin A were incubated with
streptavidin-Cy3 (Sigma), whereas all other wells were incubated with anti-IgG-Cy3
(Sigma) for 1h while rotating at 40 rpm covered from light. The arrays were washed 5
times with 70 μL of PBS-T and then washed once with 0.01X PBS. The washed arrays
were spun dry and scanned with a GenePix 4000B (Molecular Devices) scanner at
wavelength 532 nm using GenePix Pro7 software. The fluorescence within each feature
was background subtracted using the local method in GenePix Pro7 software (Molecular
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Devices).

To determine glycan specific binding, the local background corrected

fluorescence of the print buffer alone was subtracted from each feature containing a
glycan.

Affinity measurements
Antibody binding kinetic rate constants (ka, kd) of the Man9-V3 glycopeptide and its
aglycone form (16) were measured by Bio-layer Interferometry (BLI, ForteBio Octet Red96)
measurements. The BLI assay was performed using streptavidin coated sensors (ForteBio) to
capture either biotin-tagged Man9-V3 glycopeptide or Aglycone-V3 peptide. The V3 peptide
immobilized sensors were dipped into varying concentrations of antibodies following
blocking of sensors in BSA (0.1%). Antibody concentrations ranged from 0.5 to 150 μg/mL
and non-specific binding interactions were subtracted using the control anti-RSV
Palivizumab (Synagis) mAb. Rate constants were calculated by global curve fitting analyses
to the Bivalent Avidity model of binding responses with a 10 min association and 15 min
dissociation interaction time. The dissociation constant (Kd) values without avidity
contribution were derived using the initial components of the association and dissociation
rates (ka1 and kd1) respectively. Steady-state binding Kd values for binding to Man9-V3
glycopeptide with avidity contribution were derived using near steady-state binding
responses at varying antibody concentrations (0.5-80μg/mL) and using a non-linear 4paramater curve fitting analysis.

HIV-1 Env site-directed mutagenesis
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Deletion Mutant of CH0848.d0274.30.07 env gene was constructed using In Fusion
HD EcoDry Cloning kit (Clontech, Mountain View, CA) as per manufacturer
instructions. Quick Change II Site-Directed Mutagenesis kit (Agilent Technologies, Santa
Clara, CA) was used to introduce point mutations. All final env mutants were confirmed
by sequencing.

Antibody site-directed mutagenesis
Site-directed mutagenesis of antibody genes was performed using the Quikchange II
lightening multi-site-directed mutagenesis kit following manufacturer’s protocol
(Agilent). Mutant plasmid products were confirmed by single-colony sequencing.
Primers

used

for

introducing

mutations

were:

DH270_IA4_D31G:

cccagtgtatatagtagccggtgaaggtgtatcca;

DH270.IA4

I34M:

tcgcacccagtgcatatagtagtcggtgaaggtgt;

DH270.IA4

T55S:

gatggatcaaccctaactctggtcgcacaaactat;

DH270.IA4

R57G:

tgtgcatagtttgtgccaccagtgttagggttgat;

DH270.IA4

R57V:

cttctgtgcatagtttgtgacaccagtgttagggttgatc;

DH270.UCA

G57R:

atcaaccctaacagtggtcgcacaaactatgcaca.

Env glycoprotein expression
The codon-optimized CH848-derived env genes were generated by de novo synthesis
(GeneScript, Piscataway, NJ) or site-directed mutagenesis in mammalian expression
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plasmid pcDNA3.1/hygromycin (Invitrogen, Grand Island, NY) as described (10), and
stored at −80°C until use.

Expression and purification of DH270 lineage members
The heavy- and light-chain variable and constant domains of the DH270 lineage Fabs
were cloned into the pVRC-8400 expression vector using Not1 and Nhe1 restriction sites
and the tissue plasminogen activator signal sequence. The C terminus of the heavy-chain
constructs contained a noncleavable 6x histidine tag. Site-directed mutagenesis was
carried out, using manufacturer’s protocols (Stratagene), to introduce mutations into the
CDR regions of DH270.1.
Fabs were expressed and purified as described previously (53).

Crystallization, structure determination, and refinement
All His-tagged Fabs were crystallized at 20-25 mg/mL. Crystals were grown in 96well format using hanging drop vapor diffusion and appeared after 24–48 h at 20 °C. Fab
crystals were obtained in the following conditions: 2.5 M ammonium sulfate and 100 mM
sodium acetate, pH 5.0 for DH272; 1.5M ammonium sulfate and 100mM sodium acetate
pH 4.0 for UCA1; 20% PEG 4K, 100 mM sodium acetate, pH 5 and 100 mM magnesium
sulfate for UCA3; 10% PEG 8K, 100 mM PIPES pH 6 and 1M NaCl for DH270.1; 1.4M
lithium sulfate and 100 mM sodium acetate, pH 4.5 for DH270.3; 40% PEG 400 and 100
mM sodium citrate, pH 4.0 for DH270.5; and 30% PEG 4K, 100 mM PIPES pH 6, 1M
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NaCl for DH270.6. All crystals were harvested and cryoprotected by the addition of 20–
25% glycerol to the reservoir solution and then flash-cooled in liquid nitrogen.
Diffraction data were obtained at 100 K from beam lines 24-ID-C and 24-ID-E at the
Advanced Photon Source using a single wavelength. Datasets from individual crystals
(multiple crystals for UCA1, DH270.1 and DH270.5) were processed with HKL2000
(54). Molecular replacement calculations for the free Fabs were carried out with
PHASER (55, 56), using I3.2 from the CH103 lineage [Protein Data Bank (PDB) ID
4QHL](53) or VRC01 from the VRC01/gp120 complex [Protein Data Bank (PDB) ID
4LST](57) as the starting models. Subsequent structure determinations were performed
using DH270 lineage members as search models. The Fab models were separated into
their variable and constant domains for molecular replacement.
Refinement was carried out with PHENIX (58), and all model modifications were
carried out with Coot (59). During refinement, maps were generated from combinations
of positional, group B-factor, and TLS (translation/libration/screw) refinement
algorithms. Secondary-structure restraints were included at all stages for all Fabs;
noncrystallographic symmetry restraints were applied to the DH270.1 and UCA3 Fabs
throughout refinement. The resulting electron density map for DH270.1 was further
improved by solvent flattening, histogram matching, and non-crystallographic symmetry
averaging using the program DM (60). Phase combination was disabled in these
calculations. After density modification, restrained refinement was performed using
Refmac in Coot. Structure validations were performed periodically during refinement
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using the MolProbity server (61). The final refinement statistics are summarized in Table
S4.

Design of the 92BR SOSIP.664 construct
To generate the clade B HIV-1 92BR SOSIP.664 expression construct we followed
established SOSIP design parameters (62). Briefly, the 92BR SOSIP.664 trimer was
engineered with a disulfide linkage between gp120 and gp41 by introducing A501C and
T605C mutations (HxB2 numbering system) to covalently link the two subunits of the
heterodimer (62). The I559P mutation was included in the heptad repeat region 1 (HR1)
of gp41 for trimer stabilization, and part of the hydrophobic membrane proximal external
region (MPER), in this case residues 664–681 of the Env ectodomain, was deleted (62).
The furin cleavage site between gp120 and gp41 (508REKR511) was altered to
506RRRRRR511

to enhance cleavage (62). The resulting, codon-optimized 92BR

SOSIP.664 env gene was obtained from GenScript (Piscataway, NJ) and cloned into
pVRC-8400 as described above for Fabs using Nhe1 and NotI.

Purification of Envs for analysis by biolayer interferometry and negative stain EM
SOSIP.664 constructs were transfected along with a plasmid encoding the cellular
protease furin at a 4:1 Env:furin ratio in HEK 293F cells. Site-directed mutagenesis was
performed using manufacturer’s protocols (Stratagene) for mutations in the V3 region
and glycosylation sites. The cells were allowed to express soluble SOSIP.664 trimers for
5–7 days. Culture supernatants were collected and cells were removed by centrifugation
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at 3800 x g for 20 min, and filtered with a 0.2 µm pore size filter. SOSIP.664 proteins
were purified by flowing the supernatant over a lectin (Galanthus nivalis) affinity
chromatography column overnight at 4°C. The lectin column was washed with 1x PBS
and proteins were eluted with 0.5 M methyl-α-D-mannopyranoside and 0.5 M NaCl. The
eluate was concentrated and loaded onto a Superdex 200 10/300 GL column (GE Life
Sciences) prequilibrated in a buffer of 10 mM Hepes, pH 8.0, 150 mM NaCl and 0.02%
sodium azide for EM, or in 2.5mM Tris, pH 7.5, 350 mM NaCl, 0.02% sodium azide for
binding analysis, to separate the trimer-size oligomers from aggregates and gp140
monomers.

Electron Microscopy
Purified 92BR SOSIP.664 trimer was incubated with a five molar excess of DH270.1
Fab at 4 °C for 1 hour. A 3 µL aliquot containing ∼0.01 mg/ml of the Fab - 92BR
SOSIP.664 complex was applied for 15 s onto a carbon coated 400 Cu mesh grid that had
been glow discharged at 20 mA for 30 s, followed by negative staining with 2% uranyl
formate for 30 s. Samples were imaged using a FEI Tecnai T12 microscope operating at
120kV, at a magnification of 52,000x that resulted in a pixel size of 2.13 Å at the
specimen plane. Images were acquired with a Gatan 2K CCD camera using a nominal
defocus of 1500 nm at 10° tilt increments, up to 50°. The tilts provided additional particle
orientations to improve the image reconstructions.

Negative Stain Image Processing and 3D Reconstruction
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Particles were picked semi-automatically using EMAN2 (63) and put into a particle
stack. Initial, reference-free, two-dimensional (2D) class averages were calculated and
particles corresponding to complexes (with three Fabs bound) were selected into a
substack for determination of an initial model. The initial model was calculated in
EMAN2 using 3-fold symmetry and EMAN2 was used for subsequent refinement using
3-fold symmetry. In total, 5,419 particles were included in the final reconstruction for the
3D average of 92BR SOSIP.664 trimer complex with DH270.1. The resolution of the
final model was determined using a Fourier Shell Correlation (FSC) cut-off of 0.5.

Model fitting into the EM reconstructions
The cryo-EM structure of PGT128-liganded BG505 SOSIP.664 (PDB ID: 5ACO) (26)
and crystal structure of DH270.1 were manually fitted into the EM density and refined by
using the UCSF Chimera ‘Fit in map’ function (64).

Biolayer Interferometry
Kinetic measurements of Fab binding to Envs were carried out using the Octet QKe
system (ForteBio); 0.2 mg/mL of each His-tagged Fab was immobilized onto an antiHuman Fab-CH1 biosensor until it reached saturation. The SOSIP.664 trimers were
tested at concentrations of 200 nM and 600 nM in duplicate. A reference sample of buffer
alone was used to account for any signal drift that was observed during the experiment.
Association and dissociation were each monitored for 5 min. All experiments were
conducted in the Octet instrument at 30 °C in a buffer of 2.5 mM Tris, pH 7.5, 350 mM
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NaCl and 0.02% sodium azide with agitation at 1,000 rpm. Analyses were performed
using nonlinear regression curve fitting using the Graphpad Prism software, version 6.

Protein Structure Analysis and Graphical Representations.
The Fabs and their complexes analyzed in this study were superposed by least squares
fitting in Coot. All graphical representations with protein crystal structures were made
using PyMol.

Definition of immunological virus phenotypes and virus signature analysis
The maximum likelihood trees depicting the heterologous virus panel and the full set
of Env sequences for the subject CH848 were created using the Los Alamos HIV
database PhyML interface (65).

HIV substitution models (66) were used and the

proportion of invariable sites and the gamma parameters were estimated from the data.
Illustrations were made using the Rainbow Tree interface that utilizes Ape (67). The
analysis that coupled neutralization data with the within-subject phylogeny based on
Envs that were evaluated for neutralization sensitivity was performed using LASSIE (50).
Signature analysis was performed using the methods fully described in (68, 69).

Statistical analysis
Statistical analysis was performed using R (http://www.R-project.org). Heat maps and
logo plots (70) were generated using the Los Alamos HIV database web interfaces
(www.hiv.lanl.gov, version Dec. 2015, HEATMAP and Analyze Align).
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Accession Numbers
Coordinates and structure factors for UCA1, UCA3, DH270.1, DH270.3, DH270.5,
DH270.6, and DH272 have been deposited in the Protein Data Bank with accession code
T.B.D., T.B.D., T.B.D., T.B.D., T.B.D., T.B.D., and T.B.D., respectively.
Section 4.9 – Supplementary Text

Evolution of the CH848 virus quasispecies
Figure S6 shows that simultaneously with the first detection of the DH270 lineage
at week 186, four distinctive phylogenetic lineages emerged in individual CH848 and
each clade functionally defined a distinct immunological resistance profiles (i.e.
immunotype). Figure S9 shows the position of the four virus immunotypes on the full
CH848 tree. The first profile was a set of Envs that all shifted the PNG site at N332 to
334 (fig. S6, open circles). Despite this mutation being associated with complete
resistance to all antibodies in the DH270 lineage, this mutation was detected at relatively
low frequency in CH848 (7-33% per sample), and was only detected transiently, not
observed among 50 sequences from the last time point sampled (week 246). This
suggested a balance where immune escape was countered by a cost in virological fitness.
As noted above, the PNG site N332 was required for heterologous neutralization; the
limited exposure in vivo may not have been adequate for selection of antibodies that
could compensate for its loss. Env in the other 3 resistance profiles all retained N332,
and all were embedded in clades that persisted through the last time point sampled. Envs
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in the second profile were completely neutralization resistant, and their gp120s did not
bind to the DH270 antibodies (fig. S6, triangles and Additional Data table S3). The
gp120s of the other two sets could bind to DH270 gp120; one had weak neutralization
sensitivity but only to later antibodies in the lineage (fig. S6, “X”) the other had no
detectable neutralization (fig. S6, “+”).

The selection for resistance to the DH270

lineage as soon as it became established is clear: persistence of four divergent clades in
CH848 Env protein, each with distinctive immunological resistance phenotypes, suggest
multiple distinctive immune escape routes are explored and selected. This would allow
continuing Env escape mutations to accrue in distinct frameworks, and exposure of the
antibody to Env diversity in the context of these frameworks may select for antibodies
that provide greater breadth.

Ontogeny of DH270 lineage and acquisition of neutralization breadth
Only one of 62 pseudoviruses tested that lack the PNG site at N332, the B clade
virus 5768.04, was sensitive to DH270.5 and DH270.6 (Additional Dataset S1). Across
the full M group HIV-1 virus isolate panel used in neutralization assays, the loss of the
PNG N332 sites accounted for 70% of the observed neutralization resistance. The
circulating recombinant form CRF01, commonly found in Asia, very rarely has this
glycosylation site (3% of sequences in the Los Alamos database and 4% (1/23) in our test
panel) and, as shown in Fig. 2A, DH270 lineage antibodies did not neutralize CRF01
strains.
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Other V3-glycan bnAbs (10-1074, PGT121 and PGT128) shared this N332 glycan
dependency but PGT121 and PGT128 were not as restrictive (Additional Dataset S1)(5,
6, 8). Antibody 10-1074 was similar to DH270.6 in that it more strictly required the N332
PNG site, and its neutralization potency correlated with that of DH270.6 (Pearson’s p =
8.0e-13, r = 0.63)(8).
As a consequence of the N332 PNG site requirement of V3 glycan bnAbs to
neutralize, in vitro estimation of neutralizing breadth was impacted simply by the fraction
of CRF01 viruses included in the panel. Therefore, to evaluate the impact of other virus
characteristics relevant to DH270 lineage neutralizing, we excluded viruses lacking the
N332 PNG from the analysis. In addition, reagents that target this epitope would be a
poor choice for use in Asian populations where CRF01 is frequently observed.

CH848 Env signatures
We previously studied cooperation between lineages that occurred soon after
infection, at a time when diversity in the autologous quasispecies was limited (12). In
contrast, in CH848 the earliest autologous quasispecies transition in sensitivity to
DH272/DH475 neutralization to DH270 lineage members occurred between week 39 and
week 51, when multiple virus variants were circulating.

Viral diversity made it

impractical to test all the possible permutations or mutations from the transmitted founder
virus. To select a smaller pool of candidate mutations, we sought the two most similar
CH848 Env sequences at the amino acid level with opposite sensitivity to DH272/DH475
and DH270.1 neutralization around week 51 and identified clones CH0848.3.d0274.30.07
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and CH0848.3.d0358.80.06 being the most similar (sim: 0.98713).

Among the

differences in amino acid sequences between these two clones, the four that we selected
(∆134-143 in V1); D185N in V2; N413Y in V4; ∆463-464 in V5) were the only ones
consistently different among all clones with differential sensitivity to DH272 and
DH270.1. We elected to use DH270.1 for these cooperating studies as the least mutated
representative of DH270 antibodies that gained autologous neutralization at week 51.
The D185N and N413Y mutations were also identified by the signature analysis shown in
fig. S12 and Additional dataset S4.
Among these four mutations, the large V1 deletion selected by DH475 was critical
for DH270.1 neutralization. This V1 deletion removed a PNG site at position 137. While
the hypervariable nature of the V1 loop (which evolves by insertion and deletion,
resulting in extreme length heterogeneity, as well as extreme variation in number of PNG
sites) complicated the interpretation of direct comparisons between two unrelated HIV-1
strains, it is worth noting that a PNG in this region specified as N137 in donor 17 was
shown to be important for regulating affinity maturation of the PGT121 V3 glycan bnAb
family, with some members of the lineage evolving to bind (PGT121-123) and others
(PGT124) to accommodate or avoid this glycan (71).
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Figure 4.S1. Characteristics of DH270 lineage monoclonal antibodies. (A)
Immunogenetics of DH270 lineage monoclonal antibodies; (B) Phylogenetic relationship
of VHDJH rearrangements of the unmutated common ancestor (DH270.UCA) and
maturation intermediates DH270.IA1 through DH270.IA4 inferred from mature
antibodies DH270.1 through DH270.5. DH270.6 was not included and clusters close to
DH270.4 and DH270.5 as shown in Figure 1. DH270.6 addition did not modify the
overall topology of the tree. Importantly, it did not affect the inference of DH270.UCA
and DH270.IA4 (details in Supplemental Text). (C) Amino acid alignment of the VHDJH
rearrangements of the inferred UCA and intermediate antibodies and DH270.1 through
DH270.6 mature antibodies. (D) Amino acid alignment of VLJL rearrangements
rearrangements of the inferred UCA and intermediate antibodies and DH270.1 through
DH270.6 mature antibodies. For DH270.6, all experimental data presented in this
manuscript were obtained using the light chain sequence reported here. The light chain
sequence of DH270.6 was subsequently revised to amino acids Q and A in positions 1
and 3 (instead of T and L). This difference did not affect neutralization and binding of
DH270.6.
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Figure 4.S2. DH270 lineage displays a N332-dependent V3 glycan bnAb functional
profile. (A) DH270 antibody lineage neutralization of five HIV-1 pseudoviruses and
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respective N332A mutants. Data are expressed as IC50 μg/ml. Positivity <10 μg/ml is
shown in bold. (B,C) DH270.1 ability to compete gp120 Env binding of V3 glycan
bnAbs PGT125 and PGT128. DH270.1 (cold Ab) inhibited binding of PGT125 (B) and
PGT128 (C) to JRFL gp120 Env with IC50 = 0.4μg/ml for both (black line). Inhibition by
cold PGT125 or PGT128 (grey line) was used as control (see Methods). Dotted line
indicates 50% inhibition.
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Figure 4.S3. DH475 and DH272 are strain-specific, N332-glycan dependent antibodies.
(A) Phylogenetic trees of DH475 (top) and DH272 (bottom) clonal lineages. External
nodes (filled circles) representing VHDJH observed sequences retrieved from cultured and
sorted memory B cells (labeled) or NGS antibody sequences (unlabeled) are colored
according to time point of isolation. Internal nodes (open circles) represent inferred
ancestral intermediate sequences.
Branch length estimates units are nucleotide
substitution per site. (B) Immunogenetics of DH475 and DH272 monoclonal antibodies;
(C) Binding of DH475 (top) and DH272 (bottom) monoclonal antibodies to wild-type
CH848TF gp120 Env (wild-type (wt), on the x-axis, and mutants with disrupted the 301
and/or 332 N-linked glycosylation sites. Results are expressed as LogAUC. (D)
Heterologous neutralization profile of DH475 and DH272 monoclonal antibodies
expressed as IC50 µg/ml on a multiclade panel of 24 viruses. White square indicates IC50
> 50 µg/ml, the highest antibody concentration tested. Clades are reported on the left and
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virus identifiers on the right. DH475 neutralized no heterologous viruses and DH272
neutralized one Tier 1 heterologous virus.

A:Green, T:Red, G:Orange, C:Light blue, Gaps:Gray
CH0848.3.d0017.10.02
CH0848.3.d0017.10.06
CH0848.3.d0017.210.33
CH0848.3.d0017.10.07
CH0848.3.d0017.10.03
CH0848.3.d0017.500.20
CH0848.3.d0017.210.48
CH0848.3.d0017.210.66
CH0848.3.d0017.10.04
CH0848.3.d0017.210.19
CH0848.3.d0017.210.27
CH0848.3.d0017.210.43
CH0848.3.d0017.210.54
CH0848.3.d0017.210.50
CH0848.3.d0017.210.56
CH0848.3.d0017.210.24
CH0848.3.d0017.210.39
CH0848.3.d0017.210.31
CH0848.3.d0017.500.01
CH0848.3.d0017.500.03
CH0848.3.d0017.210.59
CH0848.3.d0017.500.12
CH0848.3.d0017.500.18
CH0848.3.d0017.210.71
CH0848.3.d0017.210.80
CH0848.3.d0017.500.04
CH0848.3.d0017.500.23
CH0848.3.d0017.10.08
CH0848.3.d0017.210.87
CH0848.3.d0017.500.02
CH0848.3.d0017.500.21
CH0848.3.d0017.210.83
CH0848.3.d0017.210.18
CH0848.3.d0017.210.44
CH0848.3.d0017.210.16
CH0848.3.d0017.210.46
CH0848.3.d0017.500.13
CH0848.3.d0017.500.16
CH0848.3.d0017.210.53
CH0848.3.d0017.210.67
CH0848.3.d0017.210.52
CH0848.3.d0017.500.14
CH0848.3.d0017.210.17
CH0848.3.d0017.210.21
CH0848.3.d0017.500.10
CH0848.3.d0017.210.35
CH0848.3.d0017.500.22
CH0848.3.d0017.210.03
CH0848.3.d0017.500.17
CH0848.3.d0017.210.85
CH0848.3.d0017.210.70
CH0848.3.d0017.210.13
CH0848.3.d0017.210.49
CH0848.3.d0017.210.01
CH0848.3.d0017.210.45
CH0848.3.d0017.210.62
CH0848.3.d0017.210.36
CH0848.3.d0017.210.38
CH0848.3.d0017.210.05
CH0848.3.d0017.210.32
CH0848.3.d0017.210.23
CH0848.3.d0017.210.06
CH0848.3.d0017.210.61
CH0848.3.d0017.500.06
CH0848.3.d0017.210.28
CH0848.3.d0017.210.42
CH0848.3.d0017.210.63
CH0848.3.d0017.210.04
CH0848.3.d0017.210.81
CH0848.3.d0017.210.47
CH0848.3.d0017.210.88
CH0848.3.d0017.500.05
CH0848.3.d0017.210.20
CH0848.3.d0017.500.15
CH0848.3.d0017.210.84
CH0848.3.d0017.210.89
CH0848.3.d0017.210.26
CH0848.3.d0017.210.57
CH0848.3.d0017.210.86
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8924

6924

HXB2 nucleotide coordinate
Figure 4.S4. CH848 was infected by a single transmitted founder virus. 79 HIV-1 3’
half single genome sequences were generated from screening timepoint plasma. Depicted
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is
a
nucleotide
Highlighter
plot
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/HIGHLIGHT_XYPLOT/highli
ghter.html ) demonstrating that this subject was infected with a single transmitted founder
virus. Horizontal lines represent single genome sequences and tic marks denote
nucleotide changes relative to the inferred TF sequence (key at top, nucleotide position
relative to HXB2). Sequences exhibited random diversification from the TF virus as
demonstrated by analysis using the Poisson Fitter v2 tool (pgoodness of fit = 0.806)(33).
Transmission likely occurred approximately 17 days prior to screening (CI: 14-19).
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Figure 4.S5. CH848 was infected by a subtype C virus. (A) PhyML (65) was used to
construct a maximum likelihood phylogenetic tree comparing the CH848 transmitted
founder virus to representative sequences from subtypes A1, A2, B, C, D, F1, F2, G, H,
and K (substitution model: GTR+I+G, scale bar bottom right). The CH848 TF sequence
(red) clusters with subtype C viruses, consistent with the 98.6% prevalence of this
subtype in Malawi, where CH848 was enrolled during acute seroconvertion (
www.hiv.lanl.gov/components/sequence/HIV/geo/geo.comp). (B) The TF virus was
typed using the Rega HIV-1 subtyping tool and the Recombination Identification
Program (RIP)(72). Shown similarity plot was generated using RIP. Similarity to each
subtype reference sequence is plotted on the y-axis and nucleotide position is plotted the
x-axis (window size = 400 nt, significance threshold = 0.95, key to right). The two bars
below the x-axis indicate which reference sequence is most similar to the CH848 TF
sequence (“Best Match”) and whether this similarity is statistically significant relative to
the second best match (“Significant”). Both analyses demonstrated that the CH848 3’ half
genome represents a subtype C sequence with no evidence of inter-subtype
recombination.
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Figure 4.S6. Co-evolution of CH848 autologous virus and N332-dependent V3 glycan
antibody lineages DH272, DH475 and DH270. Mutations relative to the CH848
transmitted founder virus in the alignment of CH848 sequences with accompanying
neutralization data (Insertion/deletions = black. Substitutions: red = negative charge; blue
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= positive charge; cyan = PNG sites)(50). The transition between DH272/DH475
sensitive and DH270 lineage sensitive virus immunotypes at day 356 (week 51) is
indicated by the green line. Time points after week 186 (for which antibody isolation and
NGS provided evidence of DH270 lineage presence) are highlighted. At this juncture
four viral clades are established that co-exist and persist, each clade characterized by
viruses with a distinct immunologically-defined DH270 resistance phenotypes (distinct
patterns were defined by loss of N332 PNG site, gp120 binding and neutralization
resistance). The sequences that represent these clades can be tracked through the full tree
of all CH848 sequences (fig. S9).
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Figure 4.S7. Mutations in CH848 Env over time. (A) Variable positions that are close to
the PGT128 epitope in a trimer structure (PDB ID: 4TVP)(13) are represented by spheres
color-coded by the time post-infection when they first mutate away from the CH848 TF
sequence. The PGT128 antibody structure (PDB ID: 5C7K)(73) was used as a surrogate
for DH270, as a high resolution structure is not yet available for DH270. Env positions
with either main chain, side chain or glycans within 8.5Å of any PGT128 heavy atom
were considered to be proximal to PGT128. All such Env positions are shown in yellow
surface and brown ribbon representations. Mutations in the V3 region do not begin to
accrue until after the first year of infection when the DH270 lineage was first detected;
V1 mutations arise early. (B) Same as (A) for mutating Env sites that were autologous
antibody signatures of antibody sensitivity and resistance.
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Figure 4.S8. Accumulation of amino acid mutations in CH848 virus over time. This
figure shows all of the readily aligned positions near the contact site of V3 glycan
antibodies in Fig. S7, (excluding amino acids that are embedded in the V1 hypervariable
regions). The magenta O is a PNG site, whereas an N is an Asn that is not embedded in a
glycosylation site. The logo plots represent the frequency of amino acids at each position,
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and the TF amino acid is left blank to highlight the differences over time.
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Figure 4.S9. Multiple viral lineages persisted during bnAb development. 1,223 Env
protein sequences translated from single genome sequences were used to generate a
Maximum Likelihood phylogenetic tree (65) rooted on the transmitted founder sequence.
Sequences sampled prior to the development of Tier 2 heterologous breadth (week 186)
are shaded in grey and sequences from after week 186 are highlighted using the color
scheme from fig. S6. By week 186, the quasispecies resolved into at least four distinct
lineages with different DH270 binding and neutralization profiles. Envs indicated with a
circle simultaneously lack the PNG site (NXS/T) at HXB2 position 301 and shift the
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PNG site at 332 to 334. Loss of critical V3 glycan bnAb-binding amino acids conferred
complete resistance to DH270 lineage Abs, and by week 246 this virus was undetected.
Binding and neutralization assays using representative members of each of these lineages
revealed that certain variants escape DH270 lineage pressure by abrogating antibody
binding (circle and triangle) while other maintaining binding while disrupting
neutralization (X and cross).
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Fig. 4.S10. Inverse-correlation between the potency of V3 glycan broadly neutralizing
antibodies and V1 length shown for the full panel of 207 viruses. (A-C) In Fig. 2D, the
impact of V1 loop length on potency for the panel of 24 viruses is shown. The impact of
V1 length on potency and breadth diminishes as the antibody develops. The same
phenomenon is shown for each of the three DH270 lineage antibodies that were evaluated
using the 207 virus heterologous panel. Correlation p-values are non-parametric two
sided, Kendall’s tau. Slopes are of the linear regression. The impact of V1 length is over
3 fold greater on DH270.1 than DH270.6, but still evident and statistically supported in
DH270.6. In this figure you can also see the details of the increase in potency over the
full set of Envs as the lineage evolves; the medians were provided in Fig. 2C, bottom left
panel, to enable a comparison with the mutations in the antibody. The impact of V1
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length on potency and breadth diminishes as the antibody develops. (D-E). Inversecorrelation between the potency of other V3 glycan antibodies 10-1074, PG121, PG128
and V1 length. 10-1074 was the most impacted by V1 loop length.

A

B

Figure 4.S11. Role of VH1-2*02 intrinsic mutability in determining DH270 lineage
antibody somatic hypermutation. (A) The sequence logo plot shows the frequency of
VH1-2*02 amino acid (aa) mutations from germline at each position, calculated from an
alignment of 10,995 VH1-2*02 reads obtained from 8 HIV-1 negative individuals by
NGS (35). To distinguish genuine mutations from error introduced during PCR
amplification, only sequences that replicated across two independent Illumina
experiments were included in this analysis. Frequency of mutated aa at each position is
shown in the logo plot. In this dataset, 20 positions mutated frequently (>20%, indicated
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by the red line). The VH aa sequences of DH270 lineage antibodies, DH272 and VRC01
are aligned on the top. In the DH270 lineage, 12 of these 20 positions were also
frequently mutated (red vertical stripes). Mutations of the DH270 lineage antibodies
were defined as “frequent” when they occurred in more than 25% of the isolated
antibodies (inferred intermediate VH sequences were excluded from this analysis) Of
these 12 positions, 11 mutated to one of the two most frequent aa mutated in non-HIV-1
VH1-2*02 sequences (identity conformity). G57R was the lone exception. DH272
mutated in 6 of these 12 positions and VRC01 mutated in 11 out of 12 positions. (B) VH
aa encoded by VH1-2 sequences from genomic DNA aligned to DH270 lineage
antibodies aa sequences (see “Sequencing of germline variable region from genomic
DNA” in methods).
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Figure 4.S12. Virus signature analysis. Logo plots represent the frequency of amino
acids mutations in CH848 virus quasispecies from transmitted founder at indicated
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positions over time. Red indicates a negatively charged amino acid, blue positive, black
neutral; the light blue O is a PNG site. The signatures outlined in detail in Additional
Dataset S4 are summarized in the bottom right column where a red amino acid is
associated with resistance to the antibody on the right, a blue amino acid with sensitivity.
Sites 325 and 624 are associated with mutual acquisition of resistance whereas the other
seven are candidates for cooperativity.
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Figure 4.S13. Autologous Env V1 length associations with DH270 lineage neutralization
(A-C) and gp120 binding (D-F). Eighty-two virus Envs (the subset from Additional
dataset S3 that were assayed for both neutralization and binding) were evaluated. The 3
Envs that had lost the PNG site at N332 were not included, as they were negative for all
antibodies tested independently of V1 length. Only points from positive results were
plotted: IC50 <50 μg/ml for neutralization in panels A-C, and AUC >1 for binding in
panels D-F. DH270.1 gp120 Env binding is slightly negatively impacted by longer loops,
but most Envs can be bound and the association with V1 length is essentially lost for
DH270.5 and DH270.4. In contrast, DH270 lineage neutralization potency is profoundly
impacted by V1 loop length. The ability to detectably neutralize autologous CH848
viruses increases as the lineage develops: N is the number of positive sample and ranges
from N=45 (55%) for DH270.1 up to N=75 (91%) for DH270.4. These gains are mostly
among viruses with long loops. The slope and relationship is most profound for
DH270.4, because the viruses with short V1 loops are more potently neutralized (shifting
points on the left hand side of the plot down) and the viruses with long V1 loops - which
were not neutralized by earlier members of the DH270 lineage - are weakly neutralized.
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Figure 4.S14. Accumulation of mutation in DH270 lineage antibodies. Mutations are
highlighted as spheres on the Fv region of each antibody, where the CDR regions, labeled
on the backbone of the UCA, face outward. The G57R mutation is shown in red; the
other mutations incurred between the UCA and IA4 are shown in orange. Mutations
between intermediates are colored as follows: between IA2 and IA4, yellow; between
IA1 and IA2, green; between IA3 and IA4, magenta. Mutations between the late
intermediates and DH270.1, DH270.2, DH270.3, DH270.4, and DH270.5 are in brown,
light purple, dark purple, blue, and dark blue, respectively.

217

Figure 4.S15. UCA Differences. Sequence alignments of UCA3 and UCA1. (A) Heavy
chains and (B) light chains, whose structures were obtained in this study, are aligned with
UCA4, the germline antibody for the DH270 lineage (DH270.UCA). The UCA3 and
UCA4 light chains are identical. Asterisks indicate positions in which the amino acids are
the same. Colon “:”, period “.” And blanks “ “ correspond to strictly conserved,
conserved and major differences, respectively. (C) Superposition of UCA3 (cyan) and
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UCA1 (gray).

Structural differences in CDR regions are indicated with an arrow.
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Figure 4.S16. Negative stain EM of DH270 Fab in complex with the 92BR SOSIP.664
trimer. (A) 2D class-averages of the complex. Fabs are indicated with a red arrow. (B)
The Fourier shell correlation curve for the complex, along with the resolution determined
using FSC = 0.5.
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Figure 4.S17. Binding Kinetics. DH270.1 and 92BR SOSIP.664. (A) Glycans forming a
“funnel” are shown on the surface of the trimer. V1-V2 and V3 loops are colored red and
blue. (B) Association and dissociation curves, using biolayer interferometry, against
different
92BR
SOSIP.664
glycan
mutants.
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Figure 4.S18. Binding Kinetics: DH270.1 and 92BR SOSIP.664. (A) Sequence Logo of
the V3 region of CH848 autologous viruses are shown. (B) Binding kinetics, using
biolayer interferometry, against different 92BR SOSIP.664 V3 loop region mutants. (C)
DH270.1 heavy chain mutants and 92BR SOSIP.664.
Biolayer interferometry
association and dissociation curves for the indicated Fab mutants for binding to 92BR
SOSIP.664 (600nM curves are shown) Not shown are curves for DH270.1 heavy chain
mutants K32A, R72A, D73A, S25D, S54D, S60D and double mutant S75/77A for which
there was little or no reduction in affinity.
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Figure 4.S19. Man9-V3 glycopeptide binding of DH270 lineage antibodies. DH270
lineage tree (A, top left) is shown with VH mutations of intermediates and mature
antibodies. DH270.6 mAb, which clusters close to DH270.4 and DH270.5, is not shown
in the phylogenetic tree. Binding of Man9-V3 glycopeptide (74) and its aglycone form to
DH270 lineage antibodies was measured by BLI assay using either biotinylated Man9-V3
(A) or biotinylated aglycone V3 (B) as described in methods. DH270 lineage antibodies
were each used at concentrations of 5, 10, 25, 50, 100, 150 µg/mL. Insets in (A) for UCA
(150 µg/mL), IA4 (100, 50, 25 µg/mL), IA3 and IA2 (100, 50, 25, 10 µg/mL) show
rescaled binding curves following subtraction of non-specific signal on a control antibody
(Palivizumab). Rate (ka, kd) and dissociation constants (Kd) were measured for
intermediate IA1 and mature mAbs with glycan-dependent binding to Man9-V3. Kinetics
analyses were performed by global curve fitting using bivalent avidity model and as
described in methods (“Affinity measurements” section). Inset in (B) show overlay of
binding of each mAbs to Man9-V3 (blue) and aglycone V3 (red) at the highest
concentration used in each of the dose titrations.

224

C

Figure 4.S20. Example of an immunization regimen derived from studies of virusbnAb coevolution in CH848. (A) CH848 autologous gp120 Env clone d0949.10.17
binding depends on presence of Arg57 in DH270.IA4 and DH270.UCA. DH270.IA4
variants, reverted to UCA at positions of each of the 4 amino acids in VH that had
mutated in DH270.IA4 from their identities in DH270.UCA (colored circles), were tested
by ELISA for binding to CH848.d0949.10.17 gp120, the only autologous Env bound by
wild-type DH270.IA4 (black squares and Fig. 6A). Antibodies were serially diluted with
a starting concentration of 100 μg/ml. Mean and standard deviation from duplicate
observations are indicated for each datapoint and curve fitting (non-linear, 4-parameters)
is shown for each dataset. Binding is quantified as background subtracted OD450 values.
Reversion of R57G was necessary and sufficient to abrogate binding. (B) Introduction of
G57R (red) in DH270.UCA (black) was sufficient to generate detectable binding with
CH848.d0949.10.17 gp120 Env. (C) An immunization strategy composed of the
following steps: first, prime with an immunogen that binds the UCA and the boost with
immunogens with the following characteristics: i. engagement of DH270.IA4-like
antibodies and selection for the G57R mutation; ii. Selection of antibodies that favor
recognition of trimeric Env and expand the variation in the autologous signature residue
to potentially expand recognition of diversity in population; iii. Exposing maturing
antibodies to viruses with longer loops, even though these viruses are not bound or
neutralized as well as viruses with shorter V1 loops, as this is the main constrain on
antibody heterologous population neutralization breadth.
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Table 4.S1. N332-dependent CH848 plasma neutralization.

CH848 plasma neutralization, week 186 post-transmission (EC50 titer)

HIV-1 strain

Wild-type A

N332A mutant

Fold-difference

Q23.17

962

150

6

Du156

170

<40

4

TRO.11

204

<40

5

Consensus C

4,261

1,569

3

Fold difference in CH848 plasma neutralization IC50 of selected wild-type and N332
mutant HIV-1 strains
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Table 4.S2. NGS longitudinal sampling of VHDJH rearrangements assigned to the
DH270, DH272 and DH475 lineages from memory B cell mRNA.
A. DH270 Lineage
Weeka

Sample A

Sample B

Overlapd

Totale

11

0

0

0

32,732

19

0

0

0

31,179

64

1

0

0

19,383

111

0

0

0

87,224

160

0

0

0

114,729

186

9,365

14,268

776

161,104

240c

3

251

1

171,012

B. DH272 Lineage
Weeka

Sample A

Sample B

Overlap

Total

11

0

0

0

32,732

19

1,634

2,782

105

31,179

64

48

0

0

19,383

111

558

684

42

87,224

160

0

0

0

114,729

186

596

509

36

161,104

240c

0

7

0

171,012

C. DH475 Lineage
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Weekb

Sample A

Sample B

Overlap

Total

11

0

0

0

30,764

19

0

0

0

39,784

64

378

276

3

21,353

111

0

0

0

30,925

160

0

0

0

96,301

186

788

1590

50

37,648

240c

0

0

0

171,012

a
Reads
from
VH1
family-targeted
b
Reads
from
VH3
family-targeted
c Reads from VH1 through VH6 families-targeted Illumina
d Number of clonally-related VHDJH sequences that replicated across samples A and B
e Total number of replicated sequences at each timepoint
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Illumina
Illumina

Table 4.S3. CH848 plasma neutralization breadth over time.
Week post-transmission, neutralization IC50 µg/ml

HIV-1 strain

51

100

111

113

136

160

186

205

Du172.17

31

81

117

95

61

101

83

415

6535.3

<10

<10

<10

32

<10

115

460

1,363

Q23.17

<10

<10

<10

<10

64

<10

37

1,483

Du156.12

<10

<10

<10

<10

<10

25

280

682

SC422661.8

<10

<10

<10

<10

<10

38

92

207

Q842.d12

<10

<10

<10

<10

<10

50

74

54

QH0692.42

<10

<10

<10

<10

<10

<10

56

100

PVO.4

<10

<10

<10

<10

<10

<10

32

251

AC10.0.29

<10

<10

<10

<10

<10

<10

21

209

RHPA4259.7

<10

<10

<10

<10

<10

<10

59

250

Du422.1

<10

<10

<10

<10

<10

<10

152

341

ZM197M.PB7

<10

<10

<10

<10

<10

<10

43

105

Q259.d2.17

<10

<10

<10

<10

<10

<10

<10

112

ZM214M.PL15

<10

<10

<10

<10

<10

<10

<10

37

Q769.d22

<10

<10

<10

<10

<10

<10

<10

<10

CAP45.2.00.G3

<10

<10

<10

<10

<10

<10

<10

<10

SVA-MLV

<10

<10

<10

<10

<10

<10

<10

<10
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Table 4.S4. Data collection and refinement statistics

Data Collection
Resolution (Å)
Space group
Unit cell
a,b,c (Å)
Unit cell
α, β, γ (°)
Total reflections
Unique reflections

UCA1
50 - 3.31
(3.37 - 3.31)
R32
209.1, 209.1,
83.5

UCA3
50 - 2.26
(2.30 - 2.26)
C121
98.5, 76.9,
137.1

DH270.1
50 - 3.47
(3.53 - 3.47)
P 1 21 1
83.8, 219.4,
103.1

DH270.3
50 - 2.50
(2.54 - 2.50)
P 21 21 21
63.2, 69.3,
115.2

DH270.5
50 - 1.85
(1.88 - 1.85)
C121
135.1, 68.8,
59.5

DH270.6
50 - 2.73
(2.78 - 2.73)
P 1 21 1
67.1, 73.7,
112.7

DH272
50 - 2.68
(2.73 - 2.68)
I222
60.9, 124.5,
146.2

90 90 120

90,102, 90

90, 109, 90

90, 90, 90

90,113, 90

90, 107, 90

90, 90, 90

65247
10410

142800
46692

168772
42952

57856
17599

126544
42441

57894
27592

47496
15439

Redundancy

6.3 (5.0)

3.1 (3.0)

3.9 (2.2)

3.3 (3.0)

3.0 (2.1)

2.1 (2.1)

1.7 (1.6)

Completeness (%)

97.6 (90.5)

99.1 (98.9)

94.1 (68.7)

97.1 (98.4)

96.2 (83.9)

97.2 (92.8)

97.5 (94.4)

<I/σI>
Rmerge
Refinement

7.0 (1.9)
21.0 (88.3)

7.3 (1.5)
9.6 (87.8)

6.7 (2.0)
18.3 (32.0)

6.8 (1.9)
11.0 (66.2)

5.6 (1.7)
12.8 (56.0)

6.00 (1.4)
11.2 (64.2)

9.3 (2.6)
11.9 (63.8)

26.4/27.6
(34.6/41.2)

23.6/26.5
(33.8/37.6)

22.5/25.3
(28.8/31.1)

21.2/24.8
(33.0/42.0)

17.6/21.4
(23.9/26.3)

24.3/26.5
(34.0/35.7)

22.0/26.7
(34.1/44.7)

3215

19474

3250

3303

6568

0

6428
1
195

0

114

353

0

3376
30
41

0.004
1.15

0.005
1.02

0.006
1.28

0.005
1.04

0.007
1.22

0.004
0.91

0.005
0.89

39.00

50.70
30.00
46.00

34.50

47.10

26.80

50.00

38.30

39.80

49.60
69.20
36.90

Rwork/Rfree (%)
No. atoms
Protein
Ligand
Water
R.M.S. deviations
Bond lengths (Å)
Bond angles (°)
B-factors (Å2)
Protein
Ligand
Solvent

Statistics for the highest-resolution shell are shown in parentheses.
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CHAPTER 5

HIV-1 THERAPY WITH MONOCLONAL ANTIBODY 3BNC117
ELICITS HOST IMMUNE RESPONSES AGAINST HIV-1
Reprinted from the publication:
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T,
Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman
MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC. HIV1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against
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Section 5.1 – Abstract
3BNC117 is a broad and potent anti-HIV-1 neutralizing antibody that targets the CD4
binding site on the viral envelope spike. When administered passively, this antibody can
prevent infection in animal models and suppress viremia in HIV-1-infected individuals.
Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 impacts
host antibody responses in viremic subjects and in individuals receiving anti-retroviral
therapy. In comparison to untreated controls that showed little change in their
neutralizing activity over a six-month period, 3BNC117 infusion significantly improved
neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We
conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to
HIV-1.
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Section 5.2 – Main Text
Development of serum neutralization breadth during HIV-1 infection typically occurs
after several years and exists on a continuum with ~50% of infected individuals
developing some level of broad neutralization and a small fraction of individuals
acquiring serum neutralizing activity of extraordinary breadth and potency (1-4).
Antibody cloning experiments revealed that this activity is due to one or more potent
broadly neutralizing antibodies (bNAbs) that target one or more epitopes on the viral
spike protein, gp160 (1, 5-10).

bNAbs show exceptional breadth and potency in vitro, and can protect against or
suppress active infection in humanized mice (11-13) and macaques (14, 15). Moreover,
in a phase I clinical trial, a single injection of 3BNC117, a CD4-binding-site specific
bNAb (6) was safe and effective in suppressing HIV-1 viremia by an average of 1.48 logs
(16).

In addition to direct effects on target cells and pathogens, antibody-mediated
immunotherapies have the potential to engage the host immune system and induce both
innate and adaptive immune responses (17). In particular the Fc domains of antibodies
interact with receptors on innate cells such as natural killer (NK) cells and phagocytes to
enhance the clearance of viral particles and the killing of infected cells (Lu, 2016; Martin,
2016).
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A single 3BNC117 infusion was administered to HIV-1-infected individuals at doses of
1, 3, 10, or 30 mg/kg (Fig. 1A, Table S1A) (16). To determine whether 3BNC117 therapy
is associated with changes in viral sensitivity and serologic responses to autologous
viruses, we cultured HIV-1 from peripheral blood mononuclear cells (PBMCs) of 9
viremic individuals before (d0) and 4 weeks (wks) after 3BNC117 infusion (16). On d0,
all but one of the cultured viruses were sensitive to 3BNC117 with IC50 values ranging
from 0.09 - 8.8 µg/ml (Fig. 1B and (16)). At wk 4, we found increased resistance to
3BNC117 in most individuals indicating selection for viral escape variants (Fig. 1B and
(16)).

When the same viral isolates were tested for sensitivity to the matched individual’s
immunoglobulins (IgG) obtained before (d0) and 24 wks after 3BNC117 infusion (Fig.
1A), we found increased neutralizing activity in the wk 24 IgG against both d0 and wk 4
autologous viruses (p=0.0078, Fig. 1C, Table S2). Thus, while 3BNC117 infusion
selected for 3BNC117-resistant HIV-1 variants, neutralizing antibody responses
continued to develop against autologous viruses (18).

To test for changes in heterologous neutralizing activity following 3BNC117 treatment,
we assayed patients’ d0 and wk 24 IgG against a panel of tier 1 (n=1) and tier 2 (n=12)
HIV-1 pseudoviruses that included globally circulating HIV-1 strains (19) (Fig. 2, Table
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S1, S3, Table S4). Neutralizing activity was compared between the two time points by
measuring the area under the neutralization curve for subjects’ isolated IgG against each
virus (AUC) (Table S4B). 15 subjects that received 3BNC117 were not on anti-retroviral
therapy (ART) and had starting viral loads from 640 - 53,470 copies/ml (Table S1A).
Paired control IgGs were obtained from 36 viremic individuals, who did not receive
3BNC117 and had starting viral loads ranging from 150 – 303,200 copies/ml (Fig. 2,
Table S1B).

During a 6-month observation period, control individuals’ neutralizing activity showed
no consistent improvement in either breadth or potency (Fig. 2A and B, Fig. S1A, S2,
Table S4, S5) (4, 20). In contrast, all but one of the 15 viremic individuals infused with
3BNC117 showed increased breadth and/or potency against the pseudovirus panel at wk
24 (p=7.1 x 10-7, Fig. 2A, S1B, S2, Table S4, S5, S6). The absolute change in
neutralizing activity varied between viruses and individuals, ranging from small effects to
dramatic increases (Fig. 2C, Table S1, S4, S5, S6). Significant differences were also
evident between treated and control groups regardless whether sera from all individuals
were considered in aggregate, or examined against individual viruses (p=1.9 x 10-9, Fig.
2B, D).

In addition to viremic subjects, we examined 12 individuals that received 3BNC117
while on ART, with no detectable or low-level viremia (<20 - 100 copies/ml). In
235

comparison to viremic subjects, the increase in heterologous neutralizing activity was less
pronounced in ART-treated individuals (p=0.037, Fig. 2A, B, and D, S1B, S2, Table S4,
S5).

The observed improvement in neutralizing activity could not be explained by
confounding factors such as differences in initial viral load and CD4+ T cell levels (Fig.
S3, Table S1, S7). Moreover, we found no correlation between d0 neutralizing activity
and neutralization improvement (Fig. S4). A comparison of the pattern of neutralization
increase with 3BNC117’s neutralization profile ruled out that remaining antibody is
responsible for the effect (Fig. S5, Table S8). We conclude that 3BNC117 enhances host
immunity to heterologous tier 2 HIV-1 viruses irrespective of initial neutralization
breadth and potency.

To examine the effects of 3BNC117 immunotherapy on the plasma viral population of
treated individuals, we performed single genome sequencing (SGS) of over 1,000
plasma-derived gp160 env genes (gp160) before (d0) and 4 (6), 12, or 24 weeks (wks)
after infusion (Fig. 3A, B and S6, Table S9). With the exception of two individuals who
were sexual partners, all other volunteers had epidemiologically unrelated infections (Fig.
3A). On d0, env sequences from subjects 2A1, 2A3, and 2C4 comprised multiple
lineages, which was reflected in a multimodal distribution of pairwise diversity
measurements from these individuals (Fig. 3B, S6). Analysis of env sequences from
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subsequent time points revealed significant shifts in both nucleotide (6 out of 9
individuals, Fig. 3B) and amino acid sequence diversity (7 out of 9 individuals, Fig. S6).
Consistent with the observation that env diversity is associated with neutralization
breadth (21-23), there was a strong correlation between the initial level of neutralizing
activity and the initial diversity of the circulating viral swarm (R2 = 0.92, Fig. 3C).

We next evaluated viral sequence evolution in each of the 3BNC117-treated subjects over
time. Shifts in the viral quasispecies were evident regardless of initial 3BNC117
neutralization sensitivity and bNAb dose (Fig. 4, S7). However, the nature of these shifts
differed depending on the subject (Fig. 4, S7-S9). For example, in subject 2A1, 15/27 d0
sequences fell into a single clade marked “group A” (Fig. 4A, S8). Four weeks following
3BNC117 infusion, group A viruses contracted (2/25 sequences) and group C viruses
expanded (16/25). At wk 24, the viral quasispecies was primarily comprised of group B
and D viruses (Fig. 4A, S8). This pattern of “clade shifting” was also seen in subjects
2A3 and 2C4 (Fig. S7). Subjects with lower initial env diversities, such as 2E1, did not
harbor distinct viral sublineages at d0 (Fig. 3A, B), but continued to accrue mutations
some of which became fixed during the 24-week follow up (e.g. changes in V1/V2 in
2E1, Fig. S9).

To assess viral sequence changes following 3BNC117 infusion, we generated
longitudinal logo plots depicting 3BNC117 contact residues (24, 25) for each subject
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(Fig. 4B, S7, S10). While viruses from all nine subjects exhibited mutations within
3BNC117 contact residues relative to the d0 consensus sequence, their number and
position varied considerably as exemplified by subjects 2A1 and 2E1 (Fig. 4B, Fig. S7,
S10). Using LASSIE (Longitudinal Antigenic Sequences and Sites from Intrahost
Evolution)(26), we scanned the entire env protein sequence for sites selected within the
24 wk time frame (selection cutoff ≥80% relative to d0 consensus) (Table S10). While
selected sites were identified in all subjects, no consistent mutational pattern was
observed (Table S10). These data suggest that 3BNC117 immunotherapy is associated
with shifts in circulating quasispecies and a number of different env mutations, some of
which persist even after the infused antibody levels drop below detection.

To better understand the virus host-interactions that led to the development of enhanced
heterologous neutralizing breadth, we performed neutralization assays on 63
pseudoviruses expressing the gp160s found in the circulation on d0, wk 4, 12 and 24
from 5 individuals (Fig. 4, S7, Table S11). The pseudoviruses were tested for sensitivity
to the corresponding individual’s IgG obtained on d0 and wk 24. In all cases, we were
able to identify d0 or wk 4 viruses that exhibited greater neutralization sensitivity to wk
24 IgG compared to d0 IgG (Fig. 4, Fig. S7, Table S11). For example, all 2A1 and 2E1
viruses were 3BNC117 sensitive and exhibited a wk 24/d0 fold change of 1.7 and 4.8 in
IgG IC50 respectively (Fig. 4). On the other hand, all 2C4 viruses were 3BNC117resistant (mean IC50: >20 μg/ml), yet they were 5.8-fold more sensitive to wk 24 IgG
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versus d0 IgG (Fig. S7). In conclusion, viremic individuals receiving 3BNC117 produced
antibodies to autologous viruses that were both sensitive and resistant to 3BNC117.

While exceptional broadly neutralizing antibodies to HIV-1 develop only sporadically in
a fraction of infected individuals, most HIV-1 infected individuals develop some level of
neutralization breadth (1-4). Here we show that 3BNC117 immunotherapy accelerates
this process. This boost in heterologous breadth occurs irrespective of demographic,
virologic, or dosage factors and was associated with both transient and lasting changes to
the viral quasi-species. Of note, neutralization improvements observed were modest in
most individuals, potentially owing to the transient nature of therapy with a single
antibody as well as the short timeframe of observation.

Although the effect of 3BNC117 on neutralizing responses to heterologous HIV-1 viruses
may seem surprising, anti-HIV-1 antibodies have been associated with enhanced
immunity in infants born to HIV-1-infected mothers that have circulating anti-HIV-1
antibodies and macaques treated with monoclonal antibodies or neutralizing serum (2729).

How passively administered antibodies to HIV-1 accelerate the emergence of bNAbs is
not completely understood. One possibility is that 3BNC117 infusion selected for viral
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variants with altered antigenic properties, which in turn stimulated new B cell lineages.
(21-23, 30-32). A second possibility is that immune complexes formed by 3BNC117 and
circulating viruses act as potent immunogens, a phenomenon that is believed to be
responsible for the enhanced CD8+ T cell immunity to tumor antigens in individuals
receiving monoclonal antibody based immunotherapy (33, 34).

Irrespective of the mechanism(s), the enhanced antibody response found in individuals
receiving 3BNC117 therapy indicates that immunotherapy boosts host immunity to HIV1. Moreover, the finding that antibody responses to heterologous tier 2 viruses develop in
nearly all 3BNC117-treated individuals suggests that host genetics or a specific viral
envelope sequence do not limit the development of neutralizing antibodies to HIV-1.
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Section 5.5 - Figures

Figure 5-1 Virus sensitivity to 3BNC117 and autologous antibody responses
A. Graph displays kinetics of 3BNC117 antibody decay in HIV-1-infected individuals as
determined by a validated anti-idiotype ELISA (16). Each sample measured in duplicates.
Graphs show the mean antibody concentration of all patients infused for each of the
indicated dose groups (n=3 (1 mg/kg), 3 (3 mg/kg), 8 (10 mg/kg), 13 (30 mg/kg)). Red
arrows indicate the timepoints of IgG purification. B. Autologous virus sensitivity to
3BNC117 before (day 0, grey) and 4 wks (black) after 3BNC117 infusion. Y-axis shows
IC50s for 3BNC117 on viral culture supernatants from PBMCs determined by TZM.bl
assay. Neutralization assays performed in duplicates. C. Graph shows the AUC of the
neutralization curves of purified IgGs obtained from sera on day 0 (orange) or wk 24
(green) against day 0 (left panel) or wk 4 (right panel) autologous viruses. Neutralization
assays performed in duplicates. p-values determined by Wilcoxon signed-rank test.

247

Figure 5-2 Heterologous antibody responses
A. Graph shows the difference in overall AUC (mean AUC change) per individual in
TZM.bl assays against 13 heterologous viruses (see 2D) for day 0 vs. wk 24 IgG obtained
from 36 untreated viremic controls, 15 viremic individuals infused with 3BNC117, and
12 ART-treated individuals receiving 3BNC117 infusion (16). Neutralization assays
performed in duplicates. p-values determined by unpaired Wilcoxon rank-sum test. B.
Graph shows the aggregated differences in AUC between d0 and wk 24 IgG assayed by
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TZM.bl for all viruses and all individuals. Each dot represents a single AUC difference
for a single virus from one individual displayed in A. p-values determined using
generalized estimating equations (35). C. Graph shows 3BNC117 antibody levels and
TZM.bl neutralization titer against tier 2 strain Q769.d22 in subject 2A3 D. Mean AUCs
of IgGs of all individuals at d0 (grey) and wk 24 (color of respective group) for each
HIV-1 pseudovirus tested. Changes in neutralization of viremic control individuals
without 3BNC117 infusion are shown in yellow (left). Change in neutralization of
3BNC117-treated individuals shown in dark (off ART, middle) and light blue (on ART,
right). p-values determined using unpaired Wilcoxon test (rank-sum test). Red stars
indicate significant p-values after Bonferroni-correction (threshold p < 0.0038).
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Figure 5-3 HIV-1 quasispecies diversity before and after 3BNC117 infusion
A. Maximum likelihood phylogenetic tree of single genome-derived env sequences from
d0 plasma, before therapy with 3BNC117 (Table S9). Asterisks indicate bootstrap values
of 100%. Individual viral sequences are color coded as indicated. B. Scatter plots
depicting pairwise nucleotide sequence diversity of plasma env sequences on d0, and wk
4 (2E5, wk 6), 12 and 24 after infusion. Each dot represents the pairwise genetic
difference between two sequences at a given timepoint. Colored bars indicate median
diversity, while black bars indicates the interquartile range. P-values were determined
using a two-sample U-statistic based Z-test(36). C. Graph showing the relationship
between d0 mean heterologous neutralizing AUC against a panel of tier 1 (n=1) and tier 2
(n=12) viruses (abscissa) and the median pairwise nucleotide diversity (ordinate).
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Figure 5-4 Antibody responses to the evolving viral quasispecies
A. Maximum-likelihood phylogenetic trees of single genome-derived env gene sequences
from subjects 2A1 and 2E1 sampled on d0 and wk 4, 12, and 24 after 3BNC117 infusion
(left). Clades with bootstrap support ≥ 70% are indicated by a black asterisk and are
arbitrarily named groups A-D in case of subject 2A1. Bar graphs (middle) indicate the
timepoints from which sequences in the tree are derived. Heat maps (right) show the
3BNC117 IC50, d0 IgG IC50 and wk 24 IgG IC50 values against autologous pseudoviruses
using envs as indicated by colored stars. Neutralization assays performed in duplicates.
B. Sequence logo plots illustrating longitudinal amino acid changes in and around known
3BNC117-contact residues (24, 25) in subject 2A1 and 2E1. White boxes indicate that
sequence matches to the d0 consensus, grey boxes indicate gaps in alignment. Colors
251

indicate basic (dark blue) and acidic (red) residues and a turquoise “O” is used instead of
“N” to indicate a potential N-glycosylation site. Logo plots were generated using
LASSIE (26). + indicate 3BNC117 contact residues confirmed by two crystal structures
(24, 25)
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Section 6.1 – HIV-1 5’ leader sequence evolution during infection

Cytotoxic T lymphocyte responses against 5’ leader peptides

We recently demonstrated that the SIVmac766 5’ leader sequence, despite its
alternative designation as an “untranslated” region, expresses a T cell antigen (KA9).
This finding stemmed from the observation of viral escape mutations within the 5’
leaders of SIVmac strains sequenced longitudinally during infection. To test if similar
patterns of sequence evolution and peptide expression occurred during HIV-1 infection, I
studied a cohort of acutely infected human subjects who were followed for 1-4 years of
infection. As described in Chapter 2, I used longitudinal single genome sequencing, ex
vivo immunologic assays, and a mass spectrometry-based approach to identify six
different 5’ leader peptides that were expressed during HIV-1 infection either in vivo or
in vitro. These peptides were encoded by reading frames +1, +2, and +3 and overlapped
with either the R element or the Ψ packaging signal. As discussed in Chapter 2, these
findings suggest that HIV-1 translation initiation, which has been a controversial topic
within the field, is mediated through cap-dependent ribosomal scanning (1-5). Moreover,
5’ leader encoded peptides can be classified as viral Defective Ribosomal Products, or
DRiPs. DRiPs are a class of T cell epitopes that are rapidly presented in major
histocompatibility (MHC) complexes following translation and may play an important
role in early immune surveillance of invading pathogens (6-9).
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Due to some constraints of our initial analysis, future studies will be needed to
characterize the extent of 5’ leader DRiP expression during HIV-1 infection. A major
limitation of our study was the method we employed to discover 5’ leader DRiPs. By
testing for virus escape mutations in longitudinal sequence datasets, we only detected
DRiPs that were bound to the human leukocyte antigen (HLA) class I alleles expressed
by the infected individual. To address this problem, we could implement two
complementary approaches; we could 1) screen for 5’ leader sequence evolution in a
large, diverse acute infection cohort and 2) apply the mass spectrometry approach
introduced in Chapter 2 in cell lines and donor cells that express diverse MHCs. The U.S.
Army has recently conducted a trial called RV 217 in Africa and Thailand in which study
volunteers who were at high risk for HIV-1 infection were screened twice weekly for
seroconversion. If a study volunteer became infected, s/he was sampled twice weekly for
four weeks and every three months thereafter (10). With over 112 subjects longitudinally
sampled from acute infection, this cohort would be ideal for screening a large number of
HIV-1 infected humans for 5’ leader responses. Our current 5’ leader PCR protocol
requires two amplification reactions to obtain the entire 5’ leader sequence. To make this
process more high throughput, we could implement a 5’ Rapid Amplification of cDNA
Ends (RACE) protocol to amplify the entire 5’ leader sequence in a single PCR reaction
(11). 5’ RACE and amplicon sequencing of samples taken at an acute time point and ~six
months post-infection in RV217 subjects could then be used to test for sequence changes
suggestive of CTL escape. This approach would not only assist in the identification of
new subjects who mount 5’ leader T cell responses, it would also give an accurate
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estimate of the frequency of these responses during typical HIV-1 infection. While this
approach will increase the number of viruses and subjects tested, it may still be limited by
the human leukocyte antigen (HLA) genotype expressed by the study subjects. Thus, in
parallel, we could extend the application of mass spectrometry-based approaches for
peptide identification to include many donors or cell lines that express diverse HLA
genotypes (12). Using multiple donors would potentially allow for a more complete
characterization of protein expression and subsequent MHC-complex presentation of 5’
leader peptides expressed by a particular virus (12). The combination of these two
methods could give insight into the extent of 5’ leader DRiP expression and the diversity
of 5’ leader ORFs among globally circulating HIV-1 strains.
Because 5’ leader peptides represent a novel set of DRiPs, we hypothesized that
they will be rapidly cell surface expressed in MHC complexes (8,9,13). One approach to
test the kinetics of 5’ leader peptide expression could be through implementation of the
rhesus cytomegalovirus (RhCMV) 68.1 vaccine platform. This vaccine vector is capable
of eliciting T cell responses against ~7 MHC-E and MHC-class II epitopes per 100 amino
acids of vaccine insert in an MHC class-I independent manner (14-16). T cells are very
sensitive to peptide-MHC complexes (requiring fewer than 10 on the cell surface for
activation), so RhCMV-vaccine-primed PBMCs could serve as a sensitive reagent to
screen for peptide-MHC surface expression of their target antigen (17). In preliminary
experiments, we generated three RhCMV 68.1 vaccine vectors – one encoding each
forward reading frame of the SIVmac766 5’ leader – and vaccinated macaques with one
or all three vectors. PBMCs from each vaccinated macaque specifically reacted with
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SIV-infected CD4+ T cells, demonstrating that 5’ leader peptides are expressed from all
three forward reading frames and that these primed PBMCs could be used to monitor for
cell-surface expression of 5’ leader DRiP-MHC complexes (Figure 6.1). Moving
forward, we can use these vaccine-primed PBMCs to generate 5’ leader peptide-specific
T cell lines that could be used in cytotoxicity and viral suppression assays (18-20). For
comparison to canonical epitopes, we could run these same assays using PBMCs from
macaques vaccinated using the RhCMV/gag, RhCMV/rtn (rev/tat/nef), or RhCMV/env
(21). Finally, we will be using these 5’leader-RhCMV vectors in a vaccine efficacy trial
to test whether macaques vaccinated against 5’ leader DRiPs can clear newly acquired
SIV infection (16,22).
If 5’ leader DRiP vaccination proves effective in the rhesus-SIV model system,
the next step will be identifying conserved vaccine targets in globally circulating HIV-1
strains. While the HIV-1 5’ leader RNA sequence and structure are heavily conserved,
the open reading frames (ORFs) are not (Fischer, W., Kreider, E., Shaw, G., Korber, B.,
unpublished). Insertions and deletions are common within the 5’ leader and sometimes
clade-specific. For instance, ~61% of Subtype A viruses encode a single nucleotide
deletion in the Tat binding bulge of TAR (23). Further, in Chapter 2 I reported that 5’
leader CTL escape mutations included start site mutations, nonsense mutations, and
insertions/deletions. Despite this heterogeneity, we have identified 12 conserved regions
in the HIV-1 5’ leader that could serve as vaccine targets (Fischer, W., Korber, B.,
unpublished). These 12 regions, which are comprised of ~140 amino acids, could be used
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to generate a 5’ leader vaccine insert that, if immunogenic and expressed by HIV-1
strains, may elicit cross-subtype immune responses.
While the data I have presented thus far demonstrate that the HIV-1 5’ leader
expresses peptides, they do not address an important question: do 5’ leader peptides
perform a function? T cell recognition of an influenza alternative reading frame was
previously used to discover a novel influenza protein, PB1-F2. In vitro and in vivo studies
of PB1-F2 revealed that this protein compromises mitochondrial function, signals
apoptosis, and can modify pathogenesis of both the primary viral infection and secondary
bacterial pneumonia (24-26). An interesting future study could be a comparison of viral
dynamics, T cell responses, and pathology in Mamu-B*29+ and Mamu-B*29- rhesus
macaques infected with either the wildtype SIVmac766 clone or the 5’L-KA9 start site
mutant (KA9 is a Mamu-B*29-restricted epitope). While I am unable to predict the
outcome of such an experiment, even a negative result would be informative since it
would indicate that KA9 expression is dispensable for viral replication and pathogenesis.

Overextension mutation and expression of 5’ leader DRiPs

Longitudinal analysis of HIV-1 5’ leaders has revealed multiple patterns of
sequence evolution that did not fall in cognate CTL epitopes. One region that consistently
exhibited mutation among different subjects was a 4-nt motif called the primer
overextension sequence (POS) (27). In Chapter 3, I used longitudinal single genome
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sequencing, an in vitro extension assay, and ex vivo immunologic assays to provide
evidence for two mechanisms that underlie this sequence variation. The first was reverse
transcriptase (RT) overextension, a phenomenon in which RT replicates 22 nucleotides
(nts) of tRNA sequence instead of 18, incorporating an additional TTGA downstream of
the primer binding site (PBS) (27,28). Embedded in these four nts is a one-off AUG
(UUGA) that lies upstream of a 5’ leader open reading frame (ORF) that I described in
Chapter 2. A second pattern of POS mutation was the mutation of this one-off AUG
during immune escape from a 5’ leader-directed T cell response. Collectively, these two
findings demonstrated that processes like RT overextension can restore one-off AUGs in
the 5’ leader that are deleted during virus immune escape.
While the data presented in Chapter 3 support the conclusion that RT
overextension incorporates TTGA into the POS, the mechanism by which this mutation
occurs remains unclear. A recent study of the simian immunodeficiency virus clone
SIVmac239 has sparked a debate surrounding this topic (29-31). SIVmac239 differs from
the host tRNA(Lys,3) at one position within the PBS and this site is rapidly mutated to
match the tRNA upon viral passage in vitro and in vivo (30). Fennessey and colleagues
argued that this base pair mismatch within the PBS conferred a fitness cost to the virus
and invoked DNA mismatch repair mechanisms to explain the rapid rate with which this
mutation is reverted (30,32). Berkhout and colleagues, however, contested this
interpretation, arguing that there is no fitness impact of a single base pair mismatch
within the PBS and that the rapid reversion is likely due to the preferential incorporation
of the tRNA(Lys,3) into assembling virions (31). Further, they argued that cell division
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likely occurs too soon after proviral integration for mismatch repair to take place (31,33).
However, mismatch repair of a similar mutation in MLV infection has been detected
(32). To resolve this conflict, one would need to test frequency of PBS reversion during
infection of CD4+ T cells that lacked mismatch repair mechanisms. While one could
employ transformed cell lines or CRISPR technology to generate these mismatch repairdeficient CD4+ T cells, there is a hereditary illness called Lynch Syndrome that is
associated with mutations in mismatch repair genes (34). Thus, one could compare the
relative rates of PBS (or POS) reversion in CD4+ T cells from either healthy donors or
donors with Lynch syndrome to determine the contribution of mismatch repair to this
phenomenon.
No matter how these mutations are incorporated, the process of one-off AUG
incorporation during overextension has implications for 5’ leader peptide vaccine
development. As presented in Chapter 2, viral escape from 5’ leader CTL responses
differs from that seen in the canonical proteome; we have observed mutations in one-off
AUGs, nonsense mutations, and even frameshift mutations. This observation raises an
obvious question – why would the 5’ leader encode any one-off AUGs? One possible
explanation is that the 5’ leader may require some one-off AUGs based on sequence
constraints of the underlying functional RNA elements (35,36). Another possibility is that
certain processes, like overextension, may restore these one-off AUGs as soon as they are
deleted. This second possibility is particularly relevant to the development 5’ leader
DRiP-based vaccine interventions – if the virus cannot eliminate a one-off AUG, then an
intervention targeting the downstream peptide may be effective. Future studies will need
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to investigate whether other processes maintain or incorporate one-off AUGs in the 5’
leader.
In summary, the results presented in Section 6.1 provide insight into HIV-1 5’
leader peptide expression and immune recognition. Using HIV-1 sequence evolution as
an indicator of underlying biology, I was able to identify peptide expression and immune
recognition of five 5’ leader peptides and understand why certain translation initiation
codons for these peptides are maintained in the 5’ leader. These findings have
implications for future interventions that could target this region of the genome and
deepen our understanding of retrovirus biology.

261

Section 6.2 – Env evolution during bnAb development

Env evolution in natural infection

The recent identification of over a hundred broadly neutralizing antibodies
(bnAbs) that can potently inhibit diverse HIV-1 strains has led to general interest in their
use in the prevention of HIV-1 infection (37-39). Eliciting these antibodies with a
vaccine, however, has been challenging (40). One approach to understanding bnAb
development has been the study of virus-antibody co-evolution in naturally infected
human subjects who develop these responses (37,41-46). In Chapter 4, I presented one
such study of a human subject called CH0848. By combining longitudinal plasma viral
single genome sequencing, monoclonal antibody isolation, binding ELISAs, and
neutralization assays, we were able to map the virus and antibody evolutionary pathways
during CH0848 infection, which ultimately resulted in the development of the potent V3glycan bnAb, DH270.
A major caveat to our interpretation of these data is that this report is a case study
of only one human subject. Moreover, we only characterized three CH0848 neutralizing
antibody lineages (DH270/DH272/DH475) out of a diverse, polyclonal response. This
shortcoming is exemplified by the discrepancy between neutralization breadth of
monoclonal DH270.6 and polyclonal CH0848 plasma – on the same 16 virus
neutralization panel, CH0848 polyclonal plasma neutralized ~88% of viruses whereas the
262

monoclonal bnAb DH270.6 only neutralized 69% (Haynes, B., unpublished). Thus,
understanding the complete development of heterologous neutralization breadth in
CH0848 will require future studies.
Despite this caveat, we were able to identify at least three major evolutionary
events along the path to DH270 development that may inform vaccine immunogen
design: a ten-amino acid (aa) V1 deletion in Env one year post-infection, a mutation
within an AID coldspot during DH270 affinity maturation, and diversification of V1
length and V3-glycan bnAb contact residues and signatures. We proposed a four-stage
vaccine regimen in Chapter 4 that could theoretically recapitulate these events and will be
tested in non-human primate trials in the near future.
Beyond the identification of candidate vaccine immunogens, analysis of CH0848
Env evolution revealed that the plasma virus population split into two persistent viral
lineages starting week 186 post-infection (also the first time point that DH270 was
detected). This finding, which was briefly covered in Chapter 4, is shown again in Figure
6.2. Analysis of the DH270 bnAb contact residues and neutralization phenotype of these
major (X, cross, and triangle) and minor (O) persistent lineages revealed differences.
Minor lineage Envs encoded a known V3-glycan bnAb resistance mutation at the base of
V3 that shifted a potential N-linked glycosylation (PNG) site from HXB2 position 332 to
334 and were resistant to DH270 neutralization. Major lineage Envs, however, retained
the PNG at N332 and exhibited a spectrum of DH270 binding and neutralization
phenotypes. Surprisingly, a subset of major lineage Envs (indicated with an X in Figure
6.2) remained neutralization sensitive to contemporaneous DH270 mAbs. I hypothesize
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that these DH270 neutralization-sensitive Envs were important for late stages of DH270
development – without sustained antigenic stimulation, DH270 may have been arrested at
an earlier stage of maturation and never developed into a cross-reactive bnAb.
Since the initial description of this pattern of lineage divergence in CH0848, we
have evaluated Env evolution in other subjects who do and do not develop broadly crossreactive plasma neutralization. We can detect multiple persistent viral lineages in all
subjects who develop bnAbs (N=4), but cannot in subjects who do not develop bnAbs
(N=2, Kreider, E., Learn, G., Li, Y., Hahn, B., unpublished). Thus, while these data are
preliminary, it appears that a viral correlate of neutralization breadth development may be
the establishment and persistence of multiple, genetically distinct viral lineages. Future
studies will be needed to increase the number of subjects evaluated for this quasispecies
structure and to test whether these distinct viral lineages have different phenotypic
properties as was observed in CH0848.
Finally, comparison of virus evolution among human subjects, as I have done
above, is confounded by many factors including genetic differences between transmitted
founder viruses, the number of transmitted founder virus, viral load setpoint, frequency of
sampling, and duration of follow up (41-47). To better understand the viral correlates of
bnAb development, a more controlled, reproducible experimental system for virusantibody co-evolution studies is needed. A recent advancement in simian/human
immunodeficiency virus (SHIV) design may be useful in controlling for some of these
differences. SHIVs are chimeric viruses that encode an HIV-1 env within a SIV backbone
and can cause persistent infection in rhesus macaques that recapitulates many of the
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pathogenic features of HIV-1 infection (48,49). Li and colleagues have recently
developed a method that has permitted the rapid cloning of SHIVs encoding primary,
unadapted HIV-1 envs (48), including transmitted founder envs like those from CH0848
and CH0505 (Li, H., Shaw, G., unpublished). Interestingly, preliminary studies have
shown that early virus and antibody evolution over the first year of SHIV.CH0505.TF
infection in rhesus macaques recapitulates events that occurred within the human subject
CH0505 (Li, H., Williams, W., Haynes, B., Shaw, G., unpublished). Thus, while this
experimental model is still being developed, it will likely be an invaluable tool for
understanding virus-antibody coevolution in the future.

Virus evolution during bnAb immunotherapy

In the last two years, multiple bnAbs have entered phase I human clinical trials
for both safety and efficacy testing (50-53). A recent trial using the CD4 binding site
(CD4bs) bnAb 3BNC117 found that viremic subjects experienced a 0.8-2.5 log drop in
viral load upon bnAb infusion that was sustained for ~1 month (50). Rebounding viruses
from these treated individuals demonstrated increased 3BNC117 neutralization resistance
after 1-6 months as compared to pre-treatment (50). In order to understand the potential
effects of bnAb therapy on viral populations and/or neutralizing antibody responses, we
performed a follow-up longitudinal study of these 3BNC117-treated subjects, which was
presented in Chapter 5. Subjects were followed for 6 months after infusion and assessed
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for both virus evolution and changes in plasma neutralization. Using a combination of
longitudinal single genome sequencing and neutralization assays, we demonstrated that
3BNC117-treated subjects exhibited an increase in heterologous neutralization breadth as
compared to untreated controls. Concomitantly, we observed measurable shifts within the
virus population using phylogenetic and pairwise sequence comparisons. Interestingly,
both increase in heterologous neutralization and virus population shifts were observed
regardless of initial 3BNC117 sensitivity.
While 3BNC117 infusion uniformly decreased viral loads, selected for increase
bnAb resistance, and boosted host immune responses, the associated changes within the
viral quasispecies were not consistent across subjects. As described in Chapter 5, certain
subjects exhibited a pattern of “clade shifting,” whereas others demonstrated mutational
selection within the 3BNC117 Env contact residues. In hindsight, this pattern may have
been expected based on a rhesus macaque trial in which SHIV-infected macaques were
treated with either 3BNC117 or a V3-glycan bnAb 10-1074 (54). When the rebound
viruses were sequenced in this macaque trial and assessed for changes in bnAb contact
residues, no mutations were observed in rebound viruses from the 3BNC117-treated
macaques. Viruses from 10-1074-treated macaques, however, all harbored deletions of
the potential N-linked glycosylation (PNG) site at HXB2 position 332, a known 10-1074
resistance mutation (54,55). 10-1074 has since been infused into viremic HIV-infected
human subjects in a Phase I human clinical trial. Similar to sequence evolution in the
macaques, nearly 100% of rebound viruses during this trial exhibited the deletion of the
PNG site at N332 (Schoofs, T., Kreider, E., Hahn, B., Nussenzweig, M., unpublished).
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This difference in virus escape patterns in treatment with a CD4 binding site
antibody and a V3-glycan dependent antibody may be due to the nature of the targeted
epitope. CD4 binding site antibodies engage the virus via the entry receptor contact
residues – if these residues were substantially mutated, the virus may no longer be able to
enter target cells (56). Shifts and deletions in the PNG site at HXB2 position 332,
however, are commonly seen during autologous neutralizing antibody escape (41,57,58).
Futher, because mutations that delete the PNG at N332 often abrogate 10-1074 binding, it
will be interesting to see if subjects treated with 10-1074 also exhibit a boost in
heterologous neutralization breadth.
Finally, while this study had an interesting and somewhat unexpected outcome, it
will require follow-up. Out of the 36 untreated and 15 treated viremic subjects within this
trial, we focused our virus sequence analysis on nine individuals who demonstrated a
range of 1) viral load setpoints, 2) years of HIV-infection, 3) initial 3BNC117
neutralization sensitivities, and 4) infusion doses (50). Controlling for all of these
variables while accounting for virus evolution would be impossible and precludes our
ability to make generalizable conclusions. Further, we did not have virus sequencing on
matched, untreated controls. Thus, while we interpreted that 3BNC117 infusion was
followed by shifts in the virus population, we cannot conclude whether these shifts are
larger than that seen in untreated controls.
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In Chapters 4 and 5, I evaluated virus evolution during the development of
heterologous neutralization breadth in two settings – natural infection and bnAb
immunotherapy. Although these two settings are quite different, common themes
emerged from our analysis. First, heterologous breadth correlated with the presence of
cooperating neutralizing antibody lineages (42). In CH0848, these lineages were DH272
and DH475. In the 3BNC117 trial, the cooperating antibody was the infused antibody,
3BNC117 itself. A second common theme was the evolution of viral diversity during
bnAb development. As discussed previously, we have observed multiple persistent viral
lineages in longitudinally followed subjects who develop bnAbs. Interestingly, the
subjects from the 3BNC117 trial with the broadest initial heterologous neutralization
(2A1, 2A3, and 2C4) all harbored viral quasispeices with complex clades structures.
Future studies will be needed to increase the number of subjects evaluated for this
phenomenon and understand what role antigenic diversity plays in bnAb development.

In conclusion, longitudinal single genome sequencing of plasma HIV-1 can be
used to discover novel aspects of virus biology and host-pathogen interactions. Future
studies should not only continue to build on these findings, hopefully revealing new
aspects of virus and host biology, but also translate these discoveries into novel HIV
vaccines and therapeutics.
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Section 6.4 – Figures

Figure 6-1 RhCMV68.1-5’L vaccination of five macaques
Reading frame +1, +2, and +3 of the SIVmac766 5’ leader were each incorporated into a
separate RhCMV68.1 vaccine vector. Macaques were immunized against RF+1, RF+2,
RF+3, or all three. PBMCs from vaccinated macaques were then incubated with
autologous T cells (taken prior to vaccination) that were either infected or not infected
with SIVmac766. T cell recognition of infected cells was assayed with interferon-γ and
TNF-α intracellular cytokine staining. SIV-specific T cell responses were elicited in
macaques immunized against RF+1, RF+2, RF+3, or all three.
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Figure 6-2 Multiple viral lineages persisted during bnAb development
1,223 Env protein sequences translated from single genome sequences were used to
generate a Maximum Likelihood phylogenetic tree rooted on the transmitted founder
sequence. Sequences sampled prior to the development of Tier 2 heterologous breadth
(week 186) are shaded in grey and sequences from after week 186 are highlighted. By
week 186, the quasispecies resolved into at least two distinct lineages with different
DH270 binding and neutralization profiles. Envs indicated with a circle simultaneously
lack the potential N-linked glycosylation (PNG) site (NXS/T) at HXB2 position 301 and
shift the PNG site at 332 to 334. Loss of critical V3 glycan bnAb-binding amino acids
conferred complete resistance to DH270 lineage Abs, and by week 246 this virus was
undetected. Binding and neutralization assays revealed that certain variants escape
DH270 lineage pressure by abrogating antibody binding (circle and triangle). Others
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maintain binding while disrupting neutralization (cross) or maintain both binding and
neutralization (X).
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